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Production of transgenic livestock animals by DNA microinjection has become a
routine procedure for research and commercial applications. However, this technique
is inefficient and only capable of adding transgenes by random integration. A cell
based system for the production of transgenic animals would offer significant
advantages, allowing in vitro analysis of transgenes before the production of whole
animals, precise placement of transgenes and the possibility of deletion, replacement
or mutation of endogenous genes. In mice embryonic stem cells provide a tool for such
precise genetic manipulation. However, despite considerable efforts, neither ES nor
EG cells capable of contributing to the germline of any livestock species have been
isolated.
This dissertation describes cell mediated transgenesis by in vitro transfection of
cultured cells followed by nuclear transfer. Several different cell cultures were
assessed for their suitability for nuclear transfer. Viable lambs were obtained from
embryonic, fetal and adult somatic cells. This demonstrated for the first time that
cellular totipotency is not irreversibly lost during differentiation. Some but not all of
these cell types could support cell mediated transgenesis. A genomic Factor IX
construct designed to express in the lactating mammary gland has been generated and
used to demonstrate nuclear transfer as a means of transgenesis. Viable Factor IX
transgenic female lambs were derived, and shown to express high concentration of the
recombinant protein in their milk. These now provide the prospect of recombinant
Factor IX as a safe alternative to human serum derived protein for the treatment of
Haemophilia B.
Also reported are preliminary experiments to assess gene targeting in farm animals. An
ovine HPRT targeting vector was constructed. Inactivation of the ovine HPRT locus
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Genetic manipulation of domestic animals could bring numerous agricultural and
medical benefits, including the introduction of desirable traits such as disease
resistance or enhanced performance into food animals, the production of high volume
biologically active human proteins for human therapy and donor tissues for human
xenotransplantation.
Since the technology was established 13 years ago (Hammer et al., 1985) the number
of transgenic farm animals and the range of commercial applications have grown
rapidly. These include sheep with improved wool production (Damak et al., 1996),
and pigs which carry the human regulatory genes for complement activation for use as
xeno-transplantation organs (Byrne et al., 1997; Cozzi et al., 1997). Currently the
greatest number of transgenic farm animals are produced for the production of
pharmaceutical proteins in their milk. These include complex mammalian proteins
which often require extensive post-translational modifications for their bioactivity. The
latter requirement excludes both E.coli and yeast as a production system and often
results in low levels of expression of functional protein in mammalian cell culture
systems. Production of exogenous proteins in the milk of transgenic animals was
established first in the mouse (Gordon et al., 1987) and later in rabbits (Buhler et al.,
1990), sheep (Wright et al., 1991), goat (Ebert and Schindler, 1991) cows
(Krimpenfort et al., 1991) and pigs (Wall et al., 1991).
However, the production of transgenic domestic animals, such as sheep, pigs and
cattle, by the current method of DNA microinjection into zygotes is inefficient
(transgenic rate: 1-5%), time consuming and costly. DNA integration occurs at random
and the quality and quantity of transgene expression as well as germline transmission
is uncertain.
In mice, embryonic stem (ES) cells provide an alternative to pronuclear microinjection
as a means of transferring exogenous DNA to the germ line of an animal and also
allow precise genetic modifications by gene targeting (Brandon, Idzerda and
McKnight, 1995). However, despite considerable efforts, there are still no ES cells
capable of contributing to the germ line of any livestock species.
Recently, it has been shown that viable sheep can be produced by transfer of nuclei
from in vitro cultured embryonic cells (Campbell et al., 1996a). The aim of this work
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was to demonstrate that nuclear transfer from stably transfected cells provides a means
of cell mediated transgenesis in livestock. The major advantages of such an approach
are:
1. All genetic manipulations and analysis are carried out in vitro.
2. All animals born are transgenic.
3. Germline transmission in 100% of animals.
4. Predetermination of the sex of the transgenic animal.
5. Reduction in the number of experimental animals.
6. Furthermore, if nuclear transfer competent cells support gene targeting by
homologous recombination, then this would provide the opportunity for precise
positioning of the transgene as well as deletion, replacement and mutation of an
endogenous gene.
The main requirement for this approach was the identification and/or isolation of cells
which can be genetically manipulated and still support development of fertile animals
after nuclear transfer.
The following chapters give an overview on methods for the production of transgenic
livestock, as well as production of nuclear transfer derived animals. The experimental
sections were aimed at identifying somatic cell types suitable for cell mediated
transgenesis. The work presented here established that cultured cells from different
developmental stages, including adult, are suitable for nuclear transfer. The latter
provided conclusive proof that differentiation is reversible.
Furthermore, the adult cell type, cultured ovine mammary epithelial cells, was chosen
to establish an in vitro model for the prediction of transgene expression in the
mammary gland of transgenic nuclear transfer derived animals (see Chapter 4).
The principle of cell mediated transgenesis in farm animals was exemplified by the
production of sheep transgenic for the human clotting Factor IX gene. Recombinant
Factor IX protein expressed in the mammary gland of these animals provides a safe
alternative to human blood derived products for the treatment of haemophilia B.
The possibility of gene targeting in large animals using cultured differentiated cells as
nuclear transfer donors is addressed in a review of somatic cell targeting and by an
attempt to inactivate the ovine HPRT locus in nuclear transfer competent cells.
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1.1. Approaches to transgenesis in farm animals
Transgenic animals have been defined as "animals that have integrated foreign DNA
into their germline as a consequence of experimental introduction of DNA" (Palmiter
and Brinster, 1985). For the purpose of this account the definition: "transgenic
animals" is taken to include animals in which endogenous genes have been mutated or
deleted by homologous recombination in gene targeting experiments.
Most methods of gene transfer and gene manipulation were first established in the
mouse and will therefore be discussed here. References to domestic livestock are given
where applicable. Progress in genetic manipulation of livestock species is often driven
by commercial aspects and publication of results is secondary to the protection of
intellectual property. Consequently this field of research is often shrouded in rumours.
This review will be restricted to data published in scientific journals.
1.1.1. Direct manipulation of zygotes and early embryos
1.1.1.1 Pronuclear microinjection
This method was first described in 1980 (Gordon et al., 1980), and since then has
been used extensively in many species. In short, naked DNA is microinjected into the
pronucleus of explanted zygotes which are then transferred to foster mothers to
complete gestation. Transgene integration into the host genome is random and in mice
typically occurs in 5-20% of offspring. This ratio can be increased to 40-56% by
consecutive introduction of DNA into both pronuclei (Kupriyanov, Zeh and Baribault,
1998). Although injections are carried out at the zygote stage, delayed integration of
exogenous DNA can lead to the production of mosaic founder animals with reduced
germline transmission.
Pronuclear microinjection is by far the most widely used method of gene transfer in
livestock (Ebert and Schindler, 1993). However, the proportion of offspring which are
transgenic (1-5%) is often significantly lower than in mice and the costs considerably
greater. It has been estimated that approximately 1200 microinjected bovine zygotes are
required to produce a single transgenic calf (Eyestone, 1994). This would require
approximately 300 super-ovulated cows as zygote donors and 600 cows as recipients
for microinjected embryos.
Although methods have been developed to reduce these numbers, there is still a
considerable incentive to use animals more efficiently. The use of donor animals for
zygote production can be avoided by in vitro maturation and fertilisation (IVM/IVF) of
oocytes obtained from slaughterhouse material. This technique was first developed in
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cattle and has been used to produce transgenic calves (Krimpenfort et al., 1991; Hill,
Curry and De Mayo, 1992; Bowen et ai, 1994). Although zygotes produced in vitro
are less viable then those derived in vivo, this is offset by the greater number available.
Further refinements of IVM/IVF and culture conditions can be expected to improve
zygote quality in the future.
Reduction in the numbers of recipients can be achieved by transgene analysis of
embryo biopsies prior to embryo transfer. Although there are several reports in the
literature (Bowen et al., 1994) where embryo biopsies were analysed by PCR, no
satisfactory method has yet evolved to distinguish between the integrated transgene and
the residual amounts of non integrated DNA (Krisher et al., 1994). Currently the most
promising method is selective production of transgenic animals using green fluorescent
protein (Ikawa et al., 1995, Takada et al., 1997). Alternatively, transgenic foetuses can
be identified in utero from samples obtained by amnio- or allantocentesis.
Improvements in the rate of transgene integration could be achieved by optimal timing
of zygote microinjection. Exogenous DNA is thought to integrate during DNA
replication and thus microinjection should ideally be performed before or during early
S-phase (Bishop and Smith, 1989). Attempts to synchronise bovine zygotes in S-
phase before microinjection have had limited success (Gagne, Pothier and Sirard,
1995).
1.1.1.2. Retrovirus mediated gene transfer
A retroviral vector is an infectious RNA virus that transduces a non-viral gene into
mitotic cells in vivo or in vitro (Weiss et al., 1985). Replication incompetent retrovirus
vectors do not encode structural genes (gag, pol, and env) and therefore cannot
produce viral particles, without the aid of a so called "packaging line". Such vectors
can infect high numbers of cells, resulting in the integration of a single copy of vector
DNA. (for Review on retroviral vectors see Miller 1992).
Transgenic mice have been produced by co-culture of early embryos with cells
producing either replication competent (Jaenisch, Fan and Croker, 1975), or defective
retroviruses (Soriano et al., 1986, Stewart et al., 1987). Retrovirus mediated gene
transfer also facilitated the production of transgenic chickens, which because of the
inaccessibility of the early avian embryos can not easily be achieved by other methods.
Although this approach is potentially more efficient than pronuclear injection, its use in
the derivation of transgenic large animals has been limited (Kim, Leibfried-Rutledge
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and First, 1993; Haskell and Bowen, 1995). Haskell and Bowen (1995) injected cells
producing replication defective virus into the perivitelline space of bovine zygotes and
achieved 7% mosaic transgenic foetuses at day 90. Retrovirus integration occurs in
dividing cells and requires the breakdown of the nuclear envelope in mitosis. In the
oocyte, during metaphase II of the second meiosis, the nuclear envelope is absent.
Therefore infection of metaphase II oocytes should lead to a high integration rate and
because integration occurs prior to fertilisation, a reduction in mosaicism. A recent
publication by Chan et al. (1998) showed that 56% of infected bovine oocytes showed
transgene expression at morula stage, while only 22% infected at zygote stage and
17% of microinjected zygotes were positive for the Lac-Z transgene. Furthermore,
four live calves infected at oocyte stage were all transgenic and carried the transgene in
their germline.
Retroviruses do, however, suffer several disadvantages which severely limit their
usefulness. The size of DNA transduced is limited and effectively restricts the use of
retroviral vectors to cDNAs, which are generally poorly expressed as transgenes.
Delayed retroviral integration and the possibility of several different independent
integrations leads to the frequent production of mosaic animals, which can fail to
transmit the transgene through the germ line. Insertion of retroviral long terminal
repeats (LTRs) into the host genome can also cause activation of adjacent genes with
possible deleterious effects. Perhaps the most serious problem with transgenic animals
carrying retroviral vectors is the risk of producing replication competent virus by
recombination. Uncertainty regarding this possibility excludes at present, the use of
animals containing retroviral transgenes for most human applications.
1.1.1.3. Sperm-mediated DNA transfer
DNA uptake by spermatozoa of mice, pig, sheep, cattle, poultry, carp, blowfly and sea
urchin has been demonstrated (Bachiller et al., 1991; Castro et al, 1990; Gavora et al.,
1991; Arezzo, 1989; Atkinson et al., 1991). DNA internalisation into the sperm head
has also been shown in mouse and cattle (Bachiller et al. , 1991; Atkinson et al.,
1991).
Lavitrano et al. (1989) have reported the production of transgenic mice by artificial
insemination using spermatozoa exposed to exogenous DNA. This could provide a
time and cost saving alternative for the production of transgenic animals and was
initially received with great interest. However despite considerable efforts from many
laboratories around the world, the results could not be repeated in mice (Brinster et al.,
1989). More optimistic results were reported for other species (Gandolfi, 1998).
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Transgenic fish have been generated with good efficiency (>20%) (Khoo et al:, 1992;
Tsai, Tseng and Liao, 1995). DNA uptake by fish sperm was further improved by the
use of electroporation (Patil and Khoo 1996).
Using sperm-mediated DNA transfer Lavitrano et al. (1997) claimed to have achieved
very high transgenic rate (54-60%) in pig. Although the structure of the integrated
transgene was not analysed, its integrity was assumed as 9 out of 12 piglets expressed
the transgene. This was in direct contrast with the reports by Schellander et al. (1995)
and Sperandio et al. (1996) who produced transgenic calves and pigs by this method,
but in both instances the transgenes were rearranged. Furthermore, recent experiments
by Zoraqi and Spadafora (1997) showed that DNA internalised into the mouse sperm
head became associated with the nuclear scaffold, was extensively rearranged and
underwent recombination with sperm genomic DNA. It therefore seems that sperm
mediated transgenesis may not be a realistic approach for livestock.
1.1.2. Cell mediated transgenesis
1.1.2.1. Embryonic stem cells (ES)
Mouse embryonic stem cells (ES) are pluripotent cells derived from early embryos
(Evans and Kaufmann, 1981; Martin 1981). These cells can be manipulated in vitro
and when reintroduced into the preimplantation embryo will contribute to all cell types
of a chimeric animal, including germ cells.
ES cells provided the first cell mediated method of transgenesis. DNA transfer into a
cell intermediate, rather than directly into the embryo, has the advantage that genetic
manipulation and analysis can be carried out in vitro before animals are produced.
Thus, ES cells are a direct alternative to microinjection into zygotes for the production
of transgenic animals and have been used where DNA microinjection is problematic,
e.g. in the production of mice containing yeast artificial chromosomes (Pearson and
Choi, 1993; Jakobovits et al., 1993). However, the most powerful application of ES
cell mediated transgenesis exploits the ability of ES cells to support homologous
recombination between exogenous DNA and chromosomal sequences. Gene targeting
by homologous recombination allows .precise modifications to be made at
predetermined sites in the genome and has been used extensively to effect a wide
variety of genetic manipulations (reviewed by Ramirez-Solis and Bradley, 1994 and by
Brandon et al., 1995).
Although great efforts have been made to derive ES lines from other species, definitive
ES cell lines remain elusive, with the possible exception of human ES cells (Thomson
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et al., 1998), where the ultimate test, the ability to contribute to the germline, is not
feasible due to ethical constrains. There are reports of ES or ES-like cell lines derived
from hamster (Doetschman, Williams and Maeda, 1988), mink (Sukoyan et al., 1992),
sheep (Piedrahita, Anderson and BonDurant, 1990; Tsuchiya et al., 1994), cattle
(Sims and First, 1993; Stice et al., 1994a; Stice et al., 1996; Strelchenko and Stice,
1994), pig (Piedrahita, Anderson and BonDurant, 1990; Notarianni et al., 1991;
Talbot etal., 1993, Gerfen and Wheeler, 1995) and rhesus monkey (Thomson et al.,
1995). In all of these cases, the limited definition of "cells which under the appropriate
in vitro conditions, can differentiate along at least three different lineages" was used to
underpin the "ES cell" claim. The production of pig (Wheeler, 1994) and rat chimeras
(Iannaccone et al., 1994) have also been reported, although in neither case has ES
contribution to the germ line been demonstrated.The experiment in the rat was later
proved to be erroneous (Iannaccone et al., 1994). An improved method of ES cell
derivation by drug selection may facilitate future ES cell derivation from other species
(McWhir et al., 1996). However, at present, ES cell technology remains restricted to
the mouse.
If and when large animal embryonic stem cells do become available, their use in the
production of chimeras in the same way as mouse ES cells will carry several
disadvantages. Farm animals have a long generation interval and the production and
breeding of chimeras can delay the analysis of transgene expression considerably.
Chimera production can be avoided in mice by deriving animals entirely from ES cells
e.g., by aggregation of ES cells with disadvantaged tetraploid embryos. However, this
method is exquisitely sensitive to the particular ES cells used (Nagy et al., 1993) and
the usefulness of this method for large animal ES cells is unknown.
1.1.2.2. Embryonic germ cells (EG)
Primordial germ cells (PGCs) are the progenitors of the gametes. Matsui, Zsebo and
Hogan (1992) and Resnick et al. (1992) first identified a combination of growth
factors (leukaemia inhibitory factor, steel factor and basic fibroblast growth factor)
which promote long term growth of mouse PGCs and their conversion to a cell type
termed embryonic germ (EG) cells. Morre recent experiments showed successful
derivation of pluripotent stem cells from cultured human primordial germ cells
(Shamblott et al., 1998). EG cells closely resemble ES cells and are functionally
equivalent for cell mediated transgenesis. EG cells can be manipulated in vitro, and
then contribute to somatic and germ cell lineages of chimeric animals (Stewart, Gadi
and Bhatt, 1994; Labosky, Barlow and Hogan, 1994).
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In contrast to the small number of cells available from early embryos, PGCs can be
isolated in relatively large numbers during their migration to the genital ridge. Thus,
isolation of EG cells from farm animals might be a viable alternative to ES cell
derivation.
Successful isolation and culture of chicken PG cells has led to the production of
germline chimeric chickens (Vick, Lee and Simkiss, 1993; Naito et al., 1994; Chang et
al.., 1997; Naito, Sakurai and Kuwana, 1998). Several attempts have been made to
isolate EG lines from PGCs in cattle (Cherny and Merei, 1994; Stokes, Cherny and
Brandon, 1994), pig (Shim et al., 1997; Piedrahita et al., 1998) and rat (Mitani et al.,
1994). Blastocyst injection of cultured EG cells led to production of mid-gestation
chimeric bovine embryos (Stokes, Cherny and Brandon, 1994). More recently
chimeric male piglets have been produced from both genetically manipulated
(Piedrahita et al., 1998) and normal EG cells (Shim et al., 1997). In both instances EG
cell contribution to the testes was detected. Unfortunately germline transmission could
not be established, as one of the animals was stillborn and the other failed to thrive and
was sacrificed.
1.1.2.3. Spermatogonial stem cells
There has been a recent demonstration that transplanted spermatogonia can repopulate
the testes of sterile, or sub-fertile recipients in mice (Brinster and Zimmermann, 1994;
Brinster and Avarbock, 1994), and rat (Avarbock, Brinster and Brinster, 1996) and
that rat spermatogonia transplanted into mice produce spermatozoa (Clouthier et al.,
1996). If a system can be developed which allows in vitro culture and genetic
manipulation of spermatogonia or spermatogonial precursors, this could provide a
future means of transgenesis (Loveil-Badge, 1996). Culture of immortalised
spermatogenic cell lines have been reported previously (Hofmann, Abramian and
Millan, 1995). More recently experiments have been published showing that primary
spermatogonial stem cells can be cultured for up to four months and, following
transplantation, produce spermatozoa (Nagano et al., 1998; Brinster and Nagano,
1998).
1.1.3. Conclusions
Due to the observed transgene rearrangements sperm mediated transgenesis might
never become a useful option for large animal transgenesis. The possible risk factors
associated with retroviral vectors deems this method unsuitable for the transgenic
production of proteins for human use.
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Most transgenic farm animals are currently produced by pronuclear injection of
zygotes. Multiple copies of the transgene are randomly inserted at a single locus.
Transgene expression is generally unpredictable and the proportion of transgenic
offspring is low. If integration occurs after the zygote stage, then animals may be
mosaic and germline transmission reduced or absent (Figure 1.1).
Gene targeting in ES or EG cells not only allows the addition of transgenes at a defined
chromosomal location but also the alteration of existing genetic information. Although
progress is being made in establishing ES or EG cultures from large animals, their
practical use so far is restricted to the mouse. Animals born are chimeric. Germline
transmission has to be tested by breeding, which is cost and time consuming in large
animals (Figure 1.1).

























Figure 1.1 Production of transgenic animals
Schematic diagram of three alternative methods for the production of transgenic animals:
DNA microinjection, ES cells, and nuclear transfer of genetically modified donor nuclei.
Expected germline transmission is also indicated.
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As will be discussed later, the lack of large animal ES cells may be circumvented by
recent developments in nuclear transfer technology. Cells genetically manipulated in
vitro could serve as nuclear transfer donors. All animals born would be transgenic and
germline transmission would be ensured (Figure 1.1). To guarantee expression of
transgenes, these could be inserted into a permissive locus by homologous
recombination. Alternatively, if nuclear transfer competent cells express the transgene
in a tissue specific manner, than quality and quantity of the recombinant protein could
be assessed in vitro prior to nuclear transplantation.
1.2. Nuclear Transfer
1.2.1. Historical perspective
The replacement of the nucleus from a one-cell animal egg with that of another cell was
first suggested by Spemann (1938) as a means of determining if nuclei of differentiated
and undifferentiated cells have equivalent developmental potential. Pioneering work by
Briggs and King (1952) showed that the nuclei from cells at the blastocyst stage,
following transplantation to enucleated eggs, were able to direct normal development
of the leopard frog Rana pipiens to feeding stage larvae, while nuclei from the
mesoderm or endoderm of the late gastrulation stage were unable to do so (King and
Briggs, 1955). This led to the conclusion that irreversible chromosomal changes occur
during development and that nuclear totipotency is lost.
In later experiments with eggs of Xenopus laevis, using either early embryonic cells or
larval intestinal cells as nuclear donors, not only normal larvae, but also some sexually
mature frogs were obtained (Fischberg, Gurdon and Elsdale, 1958; Gurdon, 1962;
Gurdon and Uehlinger, 1966; Di Berardino and Orr, 1992). The work was later
extended to the use of terminally differentiated, keratinised skin cells of adult foot web
as donor cells. Embryos derived did not survive much beyond metamorphosis
(Gurdon, Laskey and Reeves, 1975). These results could either be interpreted as the
loss of totipotency in somatic cells, or as failure of the technology employed to reveal
the full developmental potential of these nuclei. Nevertheless it could be concluded that
the developmental capacity of the transplanted nuclei decreased with age of the donor
cell, and that this might be due to accumulated chromosomal abnormalities.
1.2.2. Nuclear transfer procedure
The recipient cell or cytoplast can be an enucleated zygote, or a metaphase II (Mil)
arrested oocyte. The latter is more commonly used for farm animals. Enucleation can
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be achieved by a variety of methods, these include microsurgical removal (McGrath
and Solter, 1983; Willadsen, 1986; Sun, Laurie and Moor, 1991), chemical
enucleation (Fulka and Moor, 1993), or inactivation of the chromosomes by UV or
laser treatment (Gurdon, 1986; Moor, Sun and Galli, 1992). Physical enucleation, e.g.
by oocyte bisection, not only removes the chromosomes but also a proportion of the
cytoplasm which may contain components essential for embryo development. Normal
cytoplasmic volumes can be regained by fusing the donor nucleus with double
cytoplasts (Peura, Lewis and Trounson, 1998).
Any diploid cell can be employed as a karyoplast, although in mammals the majority of
studies have focused on the developmental capacity of early embryonic cells. Single
blastomeres can be obtained by disaggregation of the embryos (Willadsen, 1986) or by
aspiration (Prather et al., 1987). Individual cells from later stages of development or
from cells cultured in vitro are isolated by trypsinisation (Collas and Robl, 1990,
Campbell etal., 1996a).
The donor nucleus is introduced into the cytoplast either by microsurgical injection
(Gurdon, 1986; Collas and Barnes, 1994; Ritchie and Campbell, 1995; Wakayama et
al., 1998) or by cell fusion. The latter can be achieved by polyethylene glycol treatment
(Czolowska, Modlinski and Tarkowski, 1984), inactivated Sendai virus (McGrath and
Solter, 1983) or electrofusion (McGrath and Solter, 1983; Willadsen, 1986; Campbell
etal., 1996a).
If the cytoplasts are Mil oocytes, then the reconstituted embryo has to be activated to
induce development. Although a number of methods have been developed (treatment
with ionomycin, ethanol, electro-activation) (Loi et al., 1998), none are capable of
inducing the same range of activation responses as that initiated by sperm at
fertilisation. Artificial means of activation induce only a single transient influx of Ca2+
ions, while sperm entry induces multiple transients. In rabbits a series of electrical
pulses can significantly increase the efficiency of embryo development (Ozil, 1990).
Improvement in the development rate after ovine nuclear transfer has been reported
after ionomycin induced activation followed by a three hour incubation with 6-
dimethylaminopurine (Loi et al., 1998).
1.2.3. Cell cycle and nuclear transfer
Experiments in amphibians highlighted the influence of the recipient cytoplasm on the
cell cycle and transcriptional activity of the donor nucleus. These have later been
confirmed in mammalian species .
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Oocytes of most species pause twice during meiosis, before the first and then at the
second meiotic division, at which stage the mature oocyte can be fertilised. Metaphase
II oocytes have high levels of meiosis/mitosis promoting factor (MPF), which is a
heterodimer of p34cdc2 and cyclin. It is regulated by cytostatic factor (CSF/MAP
kinase) activity. During sperm activation CSF is destroyed and MPF activity falls
rapidly, due to proteolytic destruction of the cyclin subunit. The fertilised oocyte will
exit meiosis, and enter S-phase of the first mitotic division giving rise to the two cell
embryo (Whitaker, 1996; Figure 1.2).
Oocyte
Mil Gl G2 Mitosis
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Oocyte arrested at Decline ofMPF










Figure 1.2 Cell cycle and nuclear transfer:Schematic representation of MPF
levels in oocyte and zygote and its effect on nuclear transfer donor nuclei employed at
different stages of the cell cycle and transferred to a metaphase II oocyte.
This has profound implications for nuclear transfer (Campbell etal., 1996b). If a
nucleus is transferred to an oocyte with high MPF levels, nuclear envelope breakdown
and chromosome condensation occurs. This is followed by nuclear reformation and
DNA replication regardless of the cell cycle stage of the donor nucleus. Previously
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replicated DNA of the S and G2 phase nucleus will be re-replicated, which will lead to
incorrect ploidy of the reconstituted embryo or to irreversible chromosomal damage
(see Figure 1.2). Chromatin of S-phase nuclei show a typical pulverised appearance
and high incidence of abnormalities. Only G1 donor nuclei can support normal
development. In the mouse nuclear transfer efficiency and subsequent development to
blastocyst could therefore be improved by synchronising donor nuclei in G1 (Otaegui
et al., 1994; Ouhibi et al., 1994).
In contrast, if a donor nucleus is transferred to a fertilised oocyte/zygote in which MPF
levels have declined, then nuclear envelope breakdown does not occur and the cell
cycle of the incoming donor nucleus (Gl, S-phase, G2) will be completed, resulting in
normal development. As activation of the oocyte has the same effect as fertilisation
(i.e. decline ofMPF), nuclear transfer into preactivated oocytes can lead to live
offspring from S-phase or G2 nuclei (Campbell et al., 1994; Yong and Yuqiang,
1998).
1.2.4. Transcriptional activity in reconstituted embryos
The influence of the recipient cytoplasm on gene activity in amphibian embryos
produced by nuclear transfer has been extensively studied by Gurdon (1986). His
work established that the oocyte cytoplasm can reprogram differentiated nuclei. It will
activate genes which are normally expressed in the oocyte or early embryo and
inactivate inappropriate gene expression (Kono, 1997). These findings have later been
confirmed for sheep (Sun, Laurie and Moor, 1991) and cow (Kanka et al., 1991;
Smith et al., 1996). For example the bovine equivalent to the developmentally
regulated mouse antigen TEC-3 is expressed on bovine embryos from the 8-cell stage
onwards. Following nuclear transfer using TEC-3 positive blastomeres from the
morula and blastocyst as donors, TEC-3 antigen expression disappeared from the early
embryo and reappeared when embryos developed to morula or blastocyst stage (van
Stekelenburg-Hamers etal., 1994).
1.2.5. Nuclear transfer in livestock animals
Until recently, nuclear transplantation in livestock was only possible when using donor
nuclei from cells obtained directly from early embryos, or subjected to very short
periods in culture. Live animals have been produced by nuclear transfer from
embryonic blastomeres into enucleated oocytes in rabbit (Stice and Robl, 1988),
Rhesus monkeys (Meng et al., 1997), pigs (Prather, Sims and First, 1989), cattle
(Prather et al., 1987; Bondioli, Westhusin and Looney, 1990; Keefer, Stice and
Matthews, 1994; Sims and First, 1994), goat (Yong et al., 1991; Yong and Yuqiang,
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1998) and sheep (Willadsen, 1986; Smith and Wilmut, 1989). In spite of high rate of
development to the blastocyst stage, the percentage of embryos that lead to successful
pregnancy is generally low (20-25%; Westhusin, Pryor and Bondioli, 1991; Stice,
Keefer and Matthews, 1994).
Nuclear transfer from later stage embryos up to blastocyst stage has been achieved in
sheep (Smith and Wilmut, 1989) and cow (Collas and Barnes, 1994; Keefer, Stice and
Matthews, 1994). However, attempts to employ other cell types such as primordial
germ cells, somatic fibroblasts, or granulosa cells were less successful. Embryos
developed to blastocyst stage, but pregnancy either failed, or was only sustained for
the first trimester (Delhaise et al., 1995; Moens et al., 1996; Lavoir et al., 1994; Moor,
Sun and Galli, 1992; Collas and Barnes, 1994; Stice et al. 1994).
In spite of the progress achieved in livestock, nuclear transfer from late stage
blastomeres into oocytes proved to be difficult in mice. Live offspring have been
reported using 2-cell blastomeres (Robl et al., 1986; Tsunoda et al., 1989; Kono,
Kwon and Nakahara, 1991), and more recently using synchronised 4-8-cell
blastomere or synchronised cells of a compacted morula stage embryo in serial nuclear
transfer (Kwon and Kono, 1996; Tsunoda and Kato, 1997). It was thought that the
difficulties associated with mice may be related to the time at which the embryonic
genome becomes transcriptionally active. Mouse embryos show a marked increase in
transcription at the 2 cell stage, pigs at 4 cell, cows and sheep at the 8 cell stage, and
rabbits at 16 cell stage (Prather, 1993; De Sousa et al., 1998a; 1998b). It is
conceivable that a delay before genome activation, as seen in the cow and sheep,
allows the transplanted nucleus to be reprogrammed by its cytoplasmic environment
more efficiently. In addition mouse oocytes are very fragile and techniques have only
recently been developed, which achieve high survival rates of the manipulated oocyte
(Wakayama et al., 1998).
The small number of cells in the early embryo prohibits production of large numbers of
cloned animals, but also the genetic manipulation of cells prior to nuclear transfer. This
would require developmentally competent cells that proliferate in culture. Mid-gestation
bovine foetuses have been produced by nuclear transfer from cultured bovine embryo
explants (Stice et al., 1994; Stice et al., 1996). Live calves were obtained from
cultured inner cell mass cells (Sims and Lirst, 1994). The birth of sheep following
nuclear transfer from cells cultured for long periods has been reported by Campbell
(Campbell et al., 1996a). Cells originally derived from day 9 ovine embryonic discs
were passaged up to 13 times in culture and then used as nuclear donors. The authors
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propose that the key to successful nuclear transfer is the induction of a quiescent state
in the donor cell. In the quiescent state, termed G0, cell cycle activity is absent, protein
synthesis is reduced and changes occur to the chromatin (Whitfield et al., 1985). It has
been proposed that these alterations may render the nucleus more susceptible to
modification by the oocyte cytoplasm (Campbell et al., 1996a). Some cell types are
naturally in G0 (Sertoli cells, neuronal cells, cumulus cells), but quiescence can also be
induced in nuclear donor cells by culture in the presence of reduced amounts of serum,
termed serum starvation.
1.2.6. Conclusions
Ovine and bovine nuclear transfer are well established. Most recent experiments
successfully utilised quiescent karyoplasts derived from cultured differentiated
embryonic cells (Campbell et al., 1996a). If such nuclear transfer competent cell
cultures can be genetically manipulated in vitro, then they provide a means for cell
mediated transgenesis. If these cells support homologous recombination then they
might also provide a viable alternative to large animal ES cells. Furthermore
improvements in nuclear transfer should allow some of the fundamental questions of
genomic totipotency of advanced embryonic and somatic nuclei to be answered (Sun
and Moor, 1995).
1.3. Haemophilia B and Factor IX
The Factor IX gene was chosen to establish cell mediated transgenesis in livestock.
Production of recombinant Factor IX is of medical and commercial importance.
1.3.1. Haemophilia
The two main forms of haemophilia (haemophilia A and B) are inherited X-linked,
recessive bleeding disorders affecting mainly males. Haemophilia A affects one in
10,000 males and is caused by a mutation in the Factor VIII gene. Haemophilia B is
less common, affecting one in 30,000 males and is caused by a defect in the Factor IX
(FIX) gene. The severity of bleeding in both forms of haemophilia is linked to the
amount of the relevant clotting factor in the blood. Haemophiliacs with >5% of normal
level are classed as mild, 2-5% as moderate, and <2% as severe (Brownlee, 1987;
1995). Currently the treatment for haemophilia patients is human plasma derived FVIII
or FIX which is limited in supply, may be contaminated with other plasma proteins or
coagulation factors, and carries a risk of human infectious diseases. This has led to the
search for alternative treatments either in form of recombinant protein or gene therapy.
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1.3.2. Factor IX
Factor IX (FIX) is a vitamin K-dependent multi-domain glycoprotein and is
synthesised in the liver as a precursor molecule of 461 amino acids. It has to undergo
extensive post translational modifications to become biologically active (Tuddenham
and Cooper, 1994; Reiner and Davie, 1994). For protein domains please see Figure
1.3. Cleavage of the signal sequence occurs during vectorial transport into the ER. The
propeptide sequence is removed intracellular^ by a furin protease. The propeptide and
the gla-domain targets the vitamin K-dependent y-glutamyl carboxylase present in the
ER. y-carboxylation of the first 12 glutamic acid residues ensures correct protein
folding of FIX in the presence of calcium and allows binding to phospholipids. Other
modifications include partial (3-hydroxylation of aspartic acid residue 64, glycosylation
of serine 53 in the EGF-1 domain and asparagine residues 157 and 167 in the
activation peptide region.
The mature single chain protein (415aa, MW 56,000) circulates in the blood (5|_tg/ml).
It is an essential component of the clotting cascade and can be activated by FVIIa/tissue
factor or by FXIa. (see Figure 1.4). Activation occurs in two steps. First the Argl45-
Alal46 bond is cleaved, resulting in a two-chain inactive intermediate (FIXa),
containing the light chain (aa 1-145, Gla-domain and 2 EGF-domains) and a heavy
chain (aa 146-415). Next the heavy chain of FIXa is cleaved at Argl80-Vall81 to
yield a 35-residue activation peptide and an active serine protease (Fig. 1.3). FIXa then
activates FX to FXa leading to thrombin generation and fibrin clot formation (Fig. 1.4).
xu
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Figure 1.3 FIX protein domains
Schematic diagram of the FIX protein domains, also indicated are the amino acids
involved FIX activation. Gla, y-carboxyglutamic acid; AS, aromatic stack; EGF,
epidermal growth factor-like domain; AP activation peptide, TF tissue factor. The
diamond shapes represent potential N-linked carbohydrate side chains. Amino acids
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Figure 1.4: Coagulation cascade
Simplified version of the pathways of coagulation activation and inactivation (marked in
green). FIX (marked in red) is activated by FVIIa/tissue factor or by FXIa. FIXa then
activates FX to FXa leading to thrombin generation and fibrin clot formation.
Abbreviations: HK, high molecular weight kininogen; PL, phospholipid.
The gene structure of the vitamin-K dependent clotting factors (FVII, FIX, FX, and
protein C) is highly conserved (Furie and Furie, 1988). The human Factor IX gene is
about 34kb long and consists of eight exons and seven introns (Yoshitake
1985). The exons roughly correspond to specific functional domains. Exon I encodes
the majority of the signal peptide, exon II and III encode the propeptide and Gla
domain. Exon IV and V encode EGF domains, exon VI the activation peptide, VII and
VIII the catalytic domain. Mutations causing haemophilia B have been mapped. Most
of these are point mutations or small deletions (Giannelli et 1998).
The molecular cloning of the FIX coding sequence led to the development of
recombinant protein and gene therapy for the treatment of haemophilia B.
1.3.3. Factor IX gene therapy
Gene therapy is based on the fact that the replacement gene needs to be expressed at
only 5% of the normal FIX level to show a significant benefit.
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In animal models the FIX gene was administered either by receptor mediated transfer
(Perales et al., 1994), by retrovirus (Dai et al., 1992, Kay, Rothenberg and Landon,
1993), or by adenovirus vectors (Smith et al., 1993; Walter et al., 1996), in humans
by autologous implant of cells transfected ex vivo with a functional FIX gene (Palmer ,
Thompson and Miller, 1989, Dai et al., 1992). Common problems encountered with
these methods included the insufficient or transient nature of the FIX gene expression
and the host immune response to the vector. More encouraging results have been
reported by Snyder et al. (1997), who describe stable expression of human FIX in
mice transduced with adeno associated virus (AAV) vector encoding human FIX
cDNA. Because the vector contained no viral genes, the treatment caused no detectable
immune or inflammatory response. These experiments have now been extended to
correction of haemophilia in a dog model (Snyder et al., 1999; Herzog et al., 1999).
The AAV-FIX vector was either targeted to the liver or muscle, expression of rFIX (1-
1.4% of normal FIX plasma level) was detected for up to 16 months and a partial
correction of the coagulation defect was achieved. Several problems still have to be
overcome before this technology can be applicable to humans. The main hurdle is the
necessity to significantly increase the titer of the viral vector (Linden and Woo, 1999).
Loss of FIX function is often caused by single point mutations. Kren, Bandyopadhyay
and Steer (1998) developed a novel method which allows efficient site-directed
conversion of single nucleotides in vivo. The strategy is based on chimeric RNA/DNA
molecules complexed with a protecting polycation and a ligand (lactose) for the
hepatocyte asialoglycoprotein receptor. The complex was injected into the tail vein of
rats. The chimeric RNA/DNA molecules then induced site directed mutagenesis of the
FIX gene in the intact rat liver leading to a reduction in clotting activity. However,
there are some surprising aspects to the work as reported. Even if 50% of the liver
cells had been targeted, it is questionable whether this would lead to the reported
reduction in clotting activity. Clotting activity is generally only reduced if FIX levels
drop below 10% of normal. No other laboratory has been able to reproduce these
results (Strauss, 1998).
1.3.4. Production of recombinant Factor IX
Due to the extent of post-translational modifications, production of functional
recombinant human Factor IX (rFIX) is restricted to eukaryotic expression systems.
rFIX has been expressed in a variety of mammalian cells including human embryonic
kidney cells (Hamaguchi et al., 1991), human hepatoma and fibroblast cells (De La
Salle et al., 1985; Palmer, Thompson and Miller, 1989), canine kidney cells (Rees et
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al., 1988), Chinese hamster ovary cells (Balland et al., 1988), and baby hamster
kidney cells (Busby et aL, 1985). These studies showed that an increase in expression
led to a decrease in specific activity. Secretion of correctly processed material rarely
exceeded 5|lg/ml. Attempts to improve activity include, domain shuffling between
FVII and FIX (Berkner et al., 1987; Chang, J-Y. et al., 1997), over-expression of the
y-carboxylase or the propeptide processing enzyme in CHO cells (Rehemtulla et al.,
1993). These resulted in no more then a 3 fold increase in activity.
Due to the size of the FIX gene, expression vectors were all based on the FIX cDNA.
By producing a minigene containing a truncated first intron of the FIX gene expression
levels improved 7-9 fold (Kurachi et al., 1995).
To produce a large amount of biologically active recombinant human FIX, transgenic
mice and sheep were generated which expressed the recombinant protein in their milk
(Clark et al., 1989; 1992). In these experiments expression of functional protein was
low and was subsequently found to be a consequence of aberrant splicing of the cDNA
construct (Yull et al., 1995). Removal of the cryptic 3' splice site prevented the miss-
splicing and led to production of relatively high levels (60.9|lg/ml) of rFIX in the milk
of transgenic mice (Yull et al., 1995). Expression -although at low levels (13.7ng/ml)-
of rFIX in goat milk was achieved by in vivo transfection directly into the lactating
mammary gland (Zhang et al., 1997). The highest levels of fully active rFIX protein
(0.2mg/ml) were obtained in the milk of transgenic pigs (Lubon and Paleyanda,
1997). This proved that the mammary gland is capable of efficient post-translational
modification of the human FIX gene and could provide a safe and cost effective
alternative to human plasma derived FIX. Currently only a single recombinant FIX
product (BeneFix™) produced in CHO cells has been marketed in the U.S.A. and is
awaiting approval in Europe (White, Beebe and Nielsen, 1997).
1.4. Somatic cell targeting
Gene targeting is the use of homologous recombination to make defined alterations to
the genome. It is well established in the mouse (Brandon, Idzerbda and McKnight,
1995, Torres, 1998), where it relies on the high frequency of homologous
recombination between plasmids and cognate chromosomal sequences in murine ES
cells. Frequent homologous recombination, however, does not seem to apply to a large
number of other cell types. It is envisaged that first attempts towards gene targeting in
livestock will be based on nuclear transfer of differentiated somatic cells. The literature
reviewed will therefore be restricted to that describing gene targeting in somatic cells.
20
The driving force in this field is gene-therapy, the aim of which is the accurate
correction of genetic defects. The main handicap lies in the inefficiency of gene
targeting, which has been estimated to occur in 1 in 105 to 10~7 cells (Porter, 1989).
Targeting efficiency -as with mouse ES cells- varies greatly depending on cell type,
method by which DNA is introduced into the cell, targeted locus, targeting vector, and
length of homology.
1.4.1. Cell type targeted
The first gene targeting experiment was accomplished in transformed somatic cells
(bladder carcinoma cells), not in ES cells (Smithies et al., 1985). Most of the early
targeting constructs contained only small stretches of homology. More importantly,
these homologous regions consisted of DNA sequences, which were not derived from
the targeted cell line. The use of such non-isogenic DNA leads to mismatches between
vector sequence and targeted locus, reducing the effective size of the homologous
region. Most of the ES cell work now relies on use of isogenic DNA (te Riele,
Maandag and Berns, 1992) and/or long stretches of homology to achieve high
recombination efficiency. This led to the perception that ES cells are more proficient at
homologous recombination than primary or immortalised somatic cells.
Very few experiments attempted a direct comparison of targeting efficiency in somatic
cells versus ES cells. These include disruption of the N-myc gene in pre-B cell lines
(Charron et al., 1990), of the vincullin gene in F9 cells (Coll et al., 1995), and
inactivation of the interferon-gamma receptor in myoblasts (Arbones et al., 1994). In
all three instances absolute targeting efficiency in the ES or non-ES cells was
comparable. Targeting efficiency in myoblasts even exceeded that in ES cells.
Moreover the latter cells were primary cells, which supported homologous
recombination without obvious alteration to phenotype, karyotype and growth
characteristics.
Reproducibly high targeting efficiency was achieved using the chicken B cell tumour
line DT40 (Buerstedde and Takeda, 1991), with homologous recombinants accounting
for 6.5-100% of all transfectants (Buerstedde and Takeda, 1991; Takata et al., 1994).
As the absolute targeting frequency in these cells is not unusually high (3.1-8.4xl0"6),
it is presumed that transfectants obtained by non-homologous recombination are rare.
In most other mammalian cell lines the majority of stable transfectants are the result of
random integration and the ratio of homologous to non-homologous integration is in
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Table 1.1: Targeting efficiency in somatic cells
















Mouse pre-B cell N-MYC Not reported Charron et al.,
1990










inducable gene 1:6550 Promoter trap Itzhaki and
Porter, 1991
Myeloid
leukemia X-CGD 1:241 Zhen et al.,
1993




carcinoma Vinculin Coll et al.,
1995
Colon cancer p21 Not reported Promoter trap
Waldmann et
al., 1995









resecptor 1:100 Promoter trap Arbones et al.,
1994
Retinal epithelial (32 microglobulin Not reported Williams et al.,
1994
Foreskin
keratinocytes p2 microglobulin Not reported Williams et al.,
1994
Embryonic lung
fibroblasts p21 Not reported Promoter trap Brown et al.,
1997
All cells are of human origin unless otherwise indicated
HPRT Hypoxanthine Phosphoribosyltransferase
CFTR Cystic Fibrosis Transmembrane conductance regulator gene
X-CGD X linked Chronic granulomatous disease
the range of 1:30 to 1:40000 (Yanez and Porter, 1998). High numbers of random
integrants necessitate screening of large numbers of cell clones to detect a single
targeting event. Nevertheless targeting has been achieved in a wide variety of different
cell lines (see Table 1.1), most importantly in several primary cell types, such as
embryonic lung fibroblast (Brown, Wei, and Sedivy, 1997), retinal epithelial cells,
and foreskin keratinocytes (Williams et al., 1994). Targeting efficiency was between
4.3xl0"6 to 6xl0"8.
1.4.2. Targeting constructs
Gene targeting frequency can be improved by using isogenic DNA and increases
exponentially with length of homology up to 14kb (Deng and Capecchi, 1992), see
Table 1.2.








CHO cells APRT 1:250000 0.896kb
CHO cells APRT 1:39000 1.4239kb
CHO cells APRT 1:12600 2.159kb
CHO cells APRT 1:2100 3.237kb
Results shown in table 1.2 were taken from Scheerer et al. (1994)
CHO = Chinese Hamster ovary cells
APRT = Adenine Phosphoribosyltransferase
"Promoter trap" targeting vectors contain a promoterless selectable marker gene,
which relies on the promoter at the targeted locus for activation. This strategy reduces
the numbers of randomly integrated transfectants (see table 1.1). The same principle
applies to "Poly A trap" vectors.
Modification of the DNA ends such as single strand overhangs (Selden, Heartlein and
Treco, 1992) have been shown to improve targeting frequency, again by reducing the
number of non-homologous recombinants.
Recent publications showed very high homologous recombination efficiency when
using chimeric RNA/DNA oligonucleotides for targeting the P-globin gene in
lymphoblastoid cells (Cole-Strauss et al., 1996) and the Factor IX gene both in vitro
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and in vivo (Kren, Bandyopadhyay and Steer, 1998). Unfortunately the technology
does not seem to transfer easily and other researchers have failed to apply it to their
gene of choice (Strauss, 1998).
Only a short stretch of homology (491 bp) was sufficient, to correct a mutation in the
cystic fibrosis transmembrane conductance regulator gene. The high targeting
efficiency (1 in 100 cells) was achieved by denaturing the targeting DNA and
combining it with E.coli recA protein (Kunzelmann et al., 1996). The reason for the
success is unclear. The authors claim that their studies do not indicate an enhancement
of homologous replacement due to recA, and high targeting frequencies are not
generally obtained when small targeting constructs are used either single stranded or
double strand (Fujioka et al., 1993), see also Table 1.2 .
Retroviral vectors have been employed for gene targeting with limited success (Ellis
and Bernstein, 1989). More recently high targeting frequencies have been observed
with both the adenoviral and adeno-associated viral (AAV) vectors. 1:5 to 1:14
transfected CHO cells had a correctly targeted adenine phosphoribosyltransferase gene
(Wang and Taylor, 1993) and 11 out of 13 transfected primary human fibroblasts had
a correctly targeted hypoxanthine phosphoribosyltransferase gene (Russell and Hirata,
1998). Targeting did not rely on extensive sequence homology, 2.7 to 3.8kb was
sufficient. One critical factor is likely to be the delivery of large numbers of intact
vector genomes into the cell nucleus which persist as single-stranded, episomal copies.
1.4.3. DNA transfer
The most commonly used DNA delivery method is electroporation, but other methods
have been used. These include direct DNA microinjection (Zimmer and Gruss, 1989),
calcium phosphate precipitation (Nairn et al., 1993) and lipofection (Yanez and Porter,
1998). Many somatic cells have a significantly higher transfection efficiency when
using calcium phosphate precipitation or lipofection but electroporation seems to give a
higher overall targeting efficiency accompanied by fewer random integrations (Yanez
and Porter, 1998). Other parameters to be considered are growth conditions, and cell
cycle stage (Tempelton, Roberts and Safer, 1997).
1.4.4. Other factors influencing targeting efficiency
A variety of factors/conditions have been identified which influence targeting
efficiency. These include transcription of the targeted locus (Nickoloff, 1990;
Thyagarajan, Johnson and Campbell, 1995), introduction of double strand breaks at
the targeted locus (Smith et al., 1995), inactivation of the MSH2 gene (de Wind et al.,
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1995), which is involved in DNA mismatch repair, and proteins involved in the
homologous recombination pathway such as Rad 51 and Rad 54 (Shinohare and
Ogawa, 1995). Greater understanding of these factors could lead to a reduction of
undesirable random integration and an increase in homologous recombination.
1,4.5. Conclusion
Gene targeting can be performed in a variety of somatic cell lines. Overall targeting
efficiency (targeted events per transfectant) at least for transformed cells, appears
comparable to that in ES cells, but a much higher number of random integrants versus
integration by homologous recombination was observed. A ratio as low as one
correctly targeted event in a total of 10,000 transfectants is not uncommon. It therefore
necessitates extensive analysis of transfectants, which is both laborious and time-
consuming. Finally, gene targeting has been achieved in primary cells (Table 1.2), but
the frequency of homologous recombination in primary cells is lower than in
transformed cells (Thyagarajan et al., 1996).
1.5. Model for somatic gene targeting: HPRT
The literature shows that gene targeting can be achieved in somatic cells. However, the
ratio of random to targeted integrants is unfavourable. To shift this ratio many
investigators have taken advantage of targeting vectors which rely on promoter
trapping for the expression of the selectable marker gene (Table 1.1) or targeting of a
selectable endogenous gene such as HPRT (Zheng et al., 1991) or APRT (Scheerer
and Adair, 1994). Alternatively an inactivated marker-gene construct can be introduced
into cells and its function restored via homologous recombination (Russel and Hirata,
1998).
To assess gene targeting efficiency in somatic cells derived from livestock, in particular
sheep, I carried out a model gene targeting experiment, to inactivate the ovine HPRT
gene in cultured male cells.
1.5.1. HPRT function
The enzyme HPRT catalyses one of the first steps in the salvage pathway for the
purine bases hypoxanthine and guanine, which are converted to dATP for DNA
synthesis.
HPRT is located on the X-chromosome. It is ubiquitously expressed, with highest
enzyme levels in the brain (Krenitsky, 1969; Howard, Kerson and Appel, 1970),
particularly in the basal ganglia (Rosenbloom et al., 1967). This area of the brain is
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associated with low levels of de novo purine synthesis and is therefore sensitive to
HPRT deficiency, leading to the neurological disorder, Lesch-Nyhan syndrome.
Mouse models of the human disease were created by selection for spontaneous HPRT"
ES cells (Williamson, Hooper and Melton, 1992), by gene targeting of the murine
HPRT gene (Hwang et cil, 1996), and by retroviral insertion into the gene (Kuehn et
al., 1987).
HPRT expression is not required for cell growth in culture, which makes HPRT a
useful marker gene, which can be selected both for and against (Stacey et al., 1994).
The toxicity of 6-thioguanine in cells expressing HPRT allows for isolation of
spontaneous HPRT" mutants or for cells in which the HPRT locus was inactivated by
gene targeting.
1.5.2. HPRT gene
The coding sequence and gene structure of the HPRT gene is highly conserved
between human (Jolly et al., 1983), rat (Jansen et al., 1991), mouse (Konecki et al.,
1982), hamster (Konecki et al., 1982), and pig (Mansfield, 1996). It is divided into 9
exons, covering 30-40kb. The gene structure for both the mouse (Melton, Brennand
and Caskey, 1984) and human (Kim et al., 1986) genes are known and the entire
human HPRT gene has been sequenced (EMBL: HSHPRT8A).
Ovine and bovine HPRT genes have been mapped to the X-chromosome (Echard et
al., 1994) but have not been cloned. Isolation of isogenic ovine HPRT sequences is
therefore a prerequisite prior to targeted disruption of the ovine HPRT locus.
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Chapter 2
Construction and expression of a human Factor IX transgene in mice.
2.1. Background
This thesis describes the production of human FIX transgenic sheep by cell mediated
transgenesis. Due to the large size of the FIX gene, all previously published
experiments employed a FIX cDNA or mini-gene construct, which was expressed in
some but not all transgenic animals. In an attempt to optimise expression and
penetrance; e.g. increase the number of animals which express high levels of the
recombinant protein, the transgene used was a full-length genomic FIX gene under the
control of the ovine p-lactoglobulin promoter previously shown to provide high level
transgene expression in ovine mammary glands (Carver et al., 1993). This chapter
describes the cloning of the FIX construct (pMIXl) and its expression in transgenic
mice.
2.2. Transgene construct (pMIXl)
The nucleotide sequence of the human FIX gene (~33kb) has been determined
(Yoshitake, 1985). The gene is subdivided into 8 exons and 7 introns. It contains a
variety of repetitive elements including ALU repeats and members of the Kpnl (LINE)
element family. The transcribed mRNA is 2083 bases of which 1245 bases are
translated. 5' and 3' non-coding regions consists of 29 and 1390 bases respectively.
The pMIXl construct comprises 31.35kb of the genomic human FIX gene linked to
the ovine p-lactoglobulin (BLG) promoter and polyadenylation site.
Cloning of pMIXl: Human FIX DNA from a Nhel site at position 2982 (12bp
upstream of the AUG; positions refer to EMBL database file) to a BstBI site at position
33840 was derived from overlapping genomic plasmid and X clones (kindly provided
by Dr. G.G. Brownlee, University of Oxford).
A 3' fragment from the BstBI site to position 34346 (12bp downstream of the STOP
signal) was derived by PCR amplification which also introduced EcoRI, Xhol and
BamHI restriction sites. The amplified PCR product was digested with EcoRI/BamHI
and inserted between the EcoRI/BamHI sites of Bluescript, giving rise to FIX PCR 3'.
The integrity of the cloned fragment was confirmed by sequence analysis.
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Figure 2.1 shows a schematic outline of the pMIXl cloning strategy. Three subclones
(pFIX 5', pFIX M, and pFIX 3') were derived from a number of overlapping X and
plasmid clones (Anson, 1984).
pFIX 5' consists of 4 fragments:
1. the 3.98kb Nhel/Bglll fragment derived from clone 9-3.
2. the 8.19kb Bglll/PstI fragment derived from clone 8P-2.
3. the 2.07kb Pstl/Kpnl fragment derived from clone 7-4.
4. Bluescript KS- digested with Xbal and KpnI.
pFIXM (middle) consists of 4 fragments:
1. the 2.42kb Xbal/Kpnl fragment derived from clone 7-4.
2. the 6.88kb KpnI/Apal fragment derived from clone K-4.
3. the 5.81kb Apal/EcoRI fragment derived from clone /JHIX-1.
4. Bluescript KS- digested with Xbal and EcoRI.
pFIX 3' consists of 4 fragments:
1. the 5.36kb Smal/EcoRI fragment derived from clone A.HIX-1.
2. the 3.93kb EcoRI /BstBI fragment derived from clone 7JHIX-2.
3. the 0.49kb BstBI/XhoI fragment derived from FIXPCR3'
4. Bluescript KS- digested with Smal and Xhol.
The complete genomic FIX gene was assembled from the following four
fragments (Fig. 2.1):
1. the 13.82kb Notl/Nhel fragment derived from FIX5'.
2. the 11.89kb Nhel fragment derived from FIX M.
3. the 5.64kb Nhel/Xhol fragment derived from FIX3'.
4. Bluescript KS- digested with Not and Xhol
pMIXl: The 31.35kb Notl/Xhol fragment containing the entire FIX gene was
inserted into the ovine BLG expression vector pMADS-l- digested with Notl/Xhol
(Fig.2.1).
pMADS+ consists of 4.2kb of BLG promoter sequence, 30bp of 5' untranscribed
region, multicloning sites (EcoRV, NotI, Bglll, Nhel, Xhol, Clal), 170bp of 3'
untranscribed region including a poly A addition site and 2kb of 3' flanking region
cloned into pUC18 which has a modified polylinker to allow excision of the insert with
either Mlul or Pvul (PPL, unpublished). The Notl/Xhol fragment containing the
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genomic FIX gene was inserted into the Notl/Xhol site of pMADS+. Figure 2.2
shows a schematic map of the pMIX 1 construct.
A decrease in the growth rate was observed in bacteria containing FIX 5' sequences,
resulting in small colony size and reduced plasmid yield. The reason for this is
unknown.
The final cloning step required the efficient isolation and purification of intact large
DNA fragments, and the efficient transformation of bacteria with large plasmids.
Isolation of DNA fragments from agarose gels using commercially available matrixes
(Prep-A-Gene, Quiagen), led to some DNA degradation. After ligation and
transformation bacterial colonies often contained small plasmids which were either the
result of rearrangement or contamination with small DNA fragments/plasmids, which
transformed preferentially.
To avoid undesired recombination the bacterial substrain SURE was tested
unsuccessfully. To increase efficiency highly competent DH5a or XL-1 bacteria
commercially available (Stratagene) or prepared in house (see Material and Methods)
were used either for chemically induced transformation or electroporation.
Cloning was attempted into two BLG expression vectors (pMADS+ and pMAD6),
which differed in their 3' untranslated regions. pMAD6 contains parts of the
untranslated exon 6 and the entire intron 6 of the BLG gene, which is absent in
pMADS+. Cloning into pMAD6 proved repeatedly to be more difficult. The reason for
this is unknown.
Legend to Figure 2.1: Schematic representation of pMIXl cloning strategy. Factor
IX sequences are indicated in blue, ovine G-lactoglobulin (BLG) sequences in red, for
simplicity the plasmid vector sequences have been omitted from the diagram.
Overlapping plasmid and A clones obtained from Prof. Dr G.G. Brownlee are indicated
by single lines, intermediate constructs pFIX 5', pFIX M, and pFIX 3' and the final
construct pMIXl are indicated by solid boxes above which the individual fragments
contributing to the constructs are shown. Restriction enzymes marked are those used
during cloning, others have been omitted.
Legend to Figure 2.2: Schematic representation of construct pMIXl. pMIXl
comprises ~4.2kb of ovine B-lactoglobulin (BLG) promoter and 5' untranslated
sequence; ~31.35kb of the human Factor IX (FIX) gene from a Nhel site 12bp
upstream of the translational start site to an engineered Xhol site 12bp downstream of the
translational stop signal; ~2.2kb of BLG 3' non-coding sequence, polyadenylation signal
and 3' flanking sequence cloned into pUC18. Ovine BLG regions are indicated by red
boxes, Factor IX exons are indicated by black bars. The pUC18 vector is indicated at
































The cloning succeeded when the FIX fragment was separated on a sucrose velocity
gradient (see Material and Methods), large amounts of pure and intact fragment was
isolated, which ligated efficiently. After conventional transformation a small number of
bacterial colonies were obtained of which 75% contained the intact FIX gene cloned
into pMADS+.
pMIXl plasmid DNA preparations gave low yields, this was possibly the consequence
of large size and some unknown sequence element in the 5' portion of the FIX gene.
For micro-injection MIX insert was purified away from bacterial vector sequence by
digestion with Mlul and purification by sucrose velocity gradient. For cell-mediated
transgenesis either the isolated fragment or the linearised plasmid was used.
2.3. Factor IX transgenic mice
Transgenic mice were produced by microinjection of a 37.8kb pMIXl Mlul fragment
into the male pronucleus of fertilised mouse oocytes. Milk was collected from
transgenic founder females at day 10 post partum (This work was kindly carried out by
Small Animal Unit, PPL).
FIX protein content in milk was assayed by ELISA using a polyclonal rabbit anti-
human FIX antiserum (Dako) and quantified by comparison with purified human FIX
standard (Diagnostica Stago). Two different sets of data were obtained. Assays carried
out at time of milking, showed high levels of expression. Repeat experiments by a
second operator showed lower levels. The reason for this discrepancy remains
unresolved. Both results are given below (Table 3). (This work was kindly carried out
by the Protein Chemistry Lab, PPL).
Table 2.1: Expression of rFIX in the milk of
transgenic mice.
Assay 1 Assay 2
Mouse Copy FIX protein FIX protein
I.D. number pg/ml Rg/ml
4 2 376-400 123.3
9 10 46-80 30
95 10 100 83.3
97 10 94-98 35
99 10 512-524 125
104 5 n.t. 2.2
105 5 1 1
n.t. not tested
2.4. Conclusions
This is the first report in which a full length genomic human FIX gene was cloned and
expressed in transgenic animals. Due to the large size of the FIX gene all previous
publications used either cDNA or minigene constructs.
Analysis of pMIXl expression in transgenic mice showed that seven of seven female
founders expressed FIX in their milk. Even taking into account the conservative
expression level of 125|ig/ml, both penetrance and expression levels exceeded any
previous reports (Jallat etal., 1990; Yull et al., 1995), and indicated that pMIXl was
functional and suitable for introduction into sheep.
Efficient expression of the rFIX protein in the ovine mammary gland could lead to a
reliable, cost effective and most of all save source of the protein for the treatment of the
human disorder haemophilia B.
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Chapter 3
Genetic Manipulation of TNT4 cells
3.1. Background
In 1994 lambs were produced by transfer of nuclei from early passages (passage 1-3) of
cultured embryonic disc cells using preactivated recipient oocytes as reported by Campbell
et al. (1996a). Out of 4 animals born one male lamb (S1024) survived for ~6 months,
before it died of kidney failure. This was the first evidence that live offspring can be
obtained using cells maintained in culture through several passages. These ovine cells had
been derived by Jim McWhir and were assigned the functional name TNT (totipotent for
nuclear transfer). The male lamb was derived from the primary cell population TNT4.
To investigate if TNT4 cells remained totipotent for nuclear transfer after extended culture,
the experiment was repeated during the early part of the next breeding season (Oct.-Dec.
94) using cells from passage 6-11. No development to term was obtained from these later
passages (Campbell et al., 1996a).
Nuclear transfer experiments in the first quarter of 1995 tested serum starved (G0) TNT4
cells (passage 6-13) using three different methods which varied in the timing between
fusion of the karyoplast to the cytoplast and activation of the oocyte:
1. Nuclear fusion to preactivated cytoplasts.
2. Fusion of karyoplast and cytoplast at time of activation.
3. Fusion prior to activation.
The experiment led to the birth of two viable female nuclear transfer lambs (5LL2 "Megan"
and 5LL5 "Morag", in summer of 1995) (Campbell et al., 1996a). Both animals were
healthy and fertile.
The authors interpretations were, that no significant difference was observed when
comparing the 3 different fusion protocols, and that the success of the study was due to
quiescent state of the donor nucleus (G0). Not only did it provide a karyoplast at the right
stage of the cell cycle, it also provided a nucleus which was possibly more amenable to
reprogramming.
However the experiment as performed did not distinguish which factors were critical for
successful development of nuclear transfer lambs, i.e. improvements in the experimental
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manipulation, the type of cells used, the synchronisation of the cells in G0 or a
combination of method and cell type. It was therefore important to compare development
to term using different cell types as nuclear transfer donors, either derived from an embryo
or later stages of development (see Chapters 4 and 5).
Because TNT4 cells could be grown in culture for at least 13 passages without losing their
nuclear transfer potential, it became evident that if they could be transfected with
exogenous DNA, they could provide a novel method of producing transgenic animals.
Furthermore, if TNT cells were shown to support homologous recombination between
transfected DNA and chromosomal sequences, they might allow gene targeting in the same
way as mouse ES cells. These issues will be addressed in the following chapters.
Work on this thesis started in March 1995. At that time the results of the nuclear transfer
experiments using later passage TNT4 cells were still uncertain, birth of nuclear transfer
lambs was expected 3-4 month later. Throughout, the timing of experiments were dictated
by the sheep breeding season.
3.2. Characterisation of TNT4 cells and their potential for cell mediated
transgenesis.
The original aim of TNT4 cell isolation had been to establish an undifferentiated cell
population of ovine embryonic stem cells. Groups of 4-6 ovine embryonic discs
mechanically dissected from day 9 embryos were co-cultured on mitotically inactivated
mouse STO feeder cells. Cells derived from these explants were cultured under ES cell
conditions (Robertson, 1987; Magin, McWhir and Melton, 1992), TNT4 cells were
routinely grown on gelatinised plates in the presence of inactivated mouse STO feeder cells
(Ware and Axelrad, 1972) and ES cell culture medium supplemented with mouse leukemia
inhibitory factor (LIF) (Smith et al., 1988).
Little was known about the characteristics of this cell type. It was necessary to determine:
1. whether TNT4 cells represented ovine ES like cells.
2. if they were derived from single or multiple embryos.
3. if they had a limited lifespan or if, like mouse ES cells, they proliferated indefinitely.
4. which culture conditions were required for cell growth.
5. whether they were suitable for cell mediated transgenesis.
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3.2.1. Do TNT4 cells resemble ES cells.
The morphology of TNT4 cells was quite different from mouse ES cells (Evans and
Kaufmann, 1981). At passage 6 and later they appeared epithelioid (polygonal,
cobblestone appearance). However, the morphology of ovine ES cells is unknown and it
was therefore necessary to use available molecular criteria.
Initial characterisation by Campbell et al. (1996a) had shown that TNT4 cells expressed
lamin A and C. Both markers are absent in ES cells, but present in all other cell types (Van
Stekelenburg-Hamers et al., 1995). A finding suggesting that TNT4 cells do not share
characteristics with mouse ES cells.
There are a number of other markers characteristic for undifferentiated murine ES cells
(Pedersen, 1994). The expression of two of these markers was examined. In the mouse
alkaline phosphatase activity is a marker of undifferentiated cells of the embryo, ES cells
and primordial germ cells, and is strongly down regulated upon differentiation. Unlike in
the mouse expression in bovine fetuses is not strictly restricted to the inner cell mass (Van
Stekelenburg-Hamers et al., 1995). TNT4 cells were stained for alkaline phosphatase
activity, in parallel with the mouse ES line HM-1 (Magin, McWhir and Melton, 1992).
Strong staining for the developmental marker gene was observed in HM-1 cells, while
TNT4 cells were negative (data not shown).
Mouse Oct3/4 is a transcription factor expressed in the embryonic epiblast,
undifferentiated ES and EG cells and is strongly down regulated in differentiated cells
(Yeom et al., 1991). As the ovine equivalent to the mouse gene had not been
characterised, expression of a murine Oct3/4 reporter gene (pOct-LacZ) was used as a
convenient method to investigate if TNT4 cells expressed the gene. This reporter construct
had been shown previously to function in mouse ES cells (McWhir et al., 1996), and
more recently in pig and bovine embryos (PPL, unpublished data).
TNT4 cells were transfected with the Oct3/4-LacZ reporter construct and control
constructs (CMV-LacZ and PGK-LacZ). Details on constructs are outlined in Fig. 3.1, for
details on LipofectAMINE transfection, please refer to Chapter 3.2.4.1. 36-48 hours after
transfection cells were fixed, and incubated in the presence of X-gal, a histochemical
substrate for (3-galactosidase, which yields a blue precipitate upon hydrolysis. Promoter
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LacZ SV-40 BGH SV40 neo SV40
polyA polyA prom. poIyA
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Figure 3.1: Reporter gene constructs
Schematic diagram of reporter gene constructs for investigating of either promoter activity
in TNT4 cells or to establish transfection methods in cell types used for nuclear transfer.
Solid boxes indicate the promoters, reporter gene, selectable marker gene and polyA
signals, single lines indicate the plasmid vector sequences.
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Expression derived from the Oct3/4 promoter could only be detected in 30 cells per
2xl05 cells transfected, more than a 100 fold lower compared to p-galactosidase
expression directed by either the CMV or the mouse PGK promoter (see Figure 3.2).
<2 oo
Figure 3.2: Oct 3/4 directed expression in TNT4 cells
Expression of the reporter gene was directed by either the PGK, CMV, or Oct3/4
promoter (for details on constructs please see Figure 3.1). Shown is a comparison of the
number of cells staining positive for P-galactosidase.
The defining feature of ES cells is their ability to differentiate in vivo or vitro. ES cells
cultured in the absence of LIF and/or feeder cells will spontaneously differentiate into a
variety of cell types. Although TNT4 cell cultures were originally established in the
presence of feeder cells and mouse LIF, removal of these factors elicited no obvious
change in morphology, while differentiation was observed for the control HM-1 mouse
ES cells (data not shown).
3.2.2. Determining if TNT4 is of mixed origin
TNT cells were derived by co-culture of 4-6 ovine embryonic discs. When TNT4 cells
were used at passage 3 for nuclear transfer both male and female lambs were born,
indicating that at early passage the culture contained cells from at least two embryos.
Because only the male lamb was viable, it seemed important at the time to determine if
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both male and female populations were still present at a later passages and to be able to
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Figure 3.3: Sex determination
PCR amplification of ovine X and Y sequences analysed on 2% agarose gels.
A. PCR primers employed were bovine zfx and zfy primers, which in combination
successfully amplified both X and Y bovine sequences, but failed to amplify ovine Y
sequences.
B. PCR primers employed were bovine zfx and the "universal" Y primers Rg4 and Rg7,
which successfully amplified both X and Y ovine sequences.
C. Sex analysis of the lambs and abortuses produced by nuclear transfer during 1994
(S1024) and 1995 (5LL1 to 5LL5). Also included were samples from passage 6 and
passage 28 TNT4 cells and TNT4 single cell clones.
C/no DNA, Control PCR reaction in the absence of DNA.
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DNA was prepared from single cell clones at passage 12, and gender was determined by
PCR using X and Y specific primers and DNA from male and female sheep as control.
No protocol for gender determination by PCR in sheep was available at the time. The first
set of primers tested were designed to amplify portions of the bovine zfx and zfy genes
(Kirkpatrick and Monson, 1993). These bovine primers amplified ovine X but not Y
sequences (Fig. 3.3A). As an alternative the "universal" Y primers Rg4 and Rg7 (Griffiths
and Tiwari, 1993) were tested and successfully amplified ovine Y sequences. These
primers also worked in the presence of the bovine X primers, allowing simultaneous
detection ofX and Y sequences in a single reaction (Fig. 3.3B).
Figure 3.3 C shows sex analysis of the lambs and abortuses produced by nuclear transfer
during 1994 (S1024, male) and 1995 (5LL1 to 5LL5, females). Samples from passage 6
and passage 28 TNT4 cells showed that the amplified Y signal is weak at early passage
and more prominent at later passage, indicating that the male population might have
proliferated more readily. Of the three single cell clones analysed two were male (clone 3-1
and 3-3) and one female (clone 6-1), indicating that TNT4 was a mixed population at
passage 12.
3.2.3. Growth characteristics of TNT4 cells
As the aim was to employ TNT4 cells for cell mediated transgenesis two important factors
had to be established, whether the lifespan in culture was sufficiently long to allow for
genetic manipulation and whether the cells could withstand single cell cloning.
To determine the TNT4 lifespan, cells were split 1:8 every 3-4 days. Cells were counted at
every second or third passage. Doubling time of the cells up to passage 20 was 24-28hrs,
and increased significantly after passage 20. At this point cells were split 1:2 to 1:4.
Although some cells were cultured up to passage 30, many cells stopped dividing and a
change in cell morphology was observed. Cells became large and flattened, an appearance
consistent with replicative senescence (Goletz, Smith and Pereira-Smith, 1994). These
results showed, that TNT4 cells were primary cells with a limited lifespan, which
restricted the time available for genetic manipulation. Only a small number of
cryopreserved aliquots were available at passage 6, the main stock of TNT4 cells was
prepared at passage 9, which limited their usefulness.
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To determine if clones of TNT4 cells could be derived from single cells, 102 or 104 cells at
passage 9 were plated into 6 well dishes. The effect of different concentrations of serum
and the requirements for both LIF and feeder cells for cell growth was determined (Table
3.1 ).
Table 3.1: Serum, LIF and feeder cells requirements for
TNT4 cell proliferation and single cell cloning.
LIF Serum
(FBS)
No. of colonies per 10z
cells plated
104 cells plated.
Cell count after 5 days
- Feeders + Feeders - Feeders + Feeders
Mouse 5% 0 5 4.7xl03 8.6 xlO4
10% 3 o(NI! 6.7 xlO3 13.0 xlO3
20% 5 -20 6.7 xlO3 12.7 xlO3
Human 10% 12 >20 8.1 xlO3 16.6 xlO3
None 10% n.t. >20 n.t. 14.4 xlO3
FBS Fetal Bovine Serum
n.t. not tested
Results summarised in Table 3.1 show that single cell colonies could be obtained with
relatively high efficiency (1 colony per 50 cells plated). Cell proliferation and cloning
efficiency was optimal when cells were plated onto a feeder layer and medium was
supplemented with at least 10% FBS. Neither mouse nor human LIF was required for cell
growth. LIF has been shown to be species specific in its action (Robinson et al., 1994),
and the effect of human or mouse LIF on ovine cells is unknown. Therefore the inclusion
of mouse LIF during the derivation of TNT cultures might have been irrelevant.
3.2.4. Assessment of TNT4 cells for cell mediated transgenesis
Transfection and drug selection necessarily subject cells to potential metabolic insults and
extended periods in culture. The usefulness of TNT cells in this respect depended on their
ability to maintain totipotency throughout. A program of experiments to determine suitable
transfection conditions was carried out using either the Luciferase or LacZ reporter genes
under the control of constitutive promoters (e.g. PGK, CMV, SV40).
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Once transfection and selection conditions were established, cells were co-transfected with
a selectable marker gene and a FIX transgene. Stable integrants were obtained, their
nuclear transfer suitability assessed by determination of their chromosome number and
ability to survive serum starvation.
3.2.4.1. Transfection methods and optimisation
A wide variety of different methods to introduce DNA into mammalian cells are available.
These include:
1. Electroporation, which uses an electric field to open pores in the cell, through which
DNA diffuses into the cell (Neumann et al., 1982).
2. Polycationic liposome-mediated transfection: The positively charged liposomes and the
negatively charged DNA form a lipid/DNA complex, which is attracted by the negatively
charged sialic acid residues on the cell surface (Feigner et al., 1987). The precise
mechanism by which the DNA enters the cell has not been determined.
3. Calcium phosphate transfection (Graham and van der Eb, 1973) produces a co-
precipitate with the DNA. The particles adhere to the cell surface and enter the cytoplasm
by phagocytosis (Loyter, Scangos and Ruddle, 1982).
4. Receptor mediated DNA endocytosis uses polycation-ligand conjugates, such as
transferrin-polylysine (Wagner et al, 1990; Zenke et al., 1990). Ligand coated DNA
particles bind to receptors on the cell surface, and upon endocytosis, the DNA is
transported to the nucleus.
The method of choice based on previous experiments with other primary cell types was the
polycationic reagent LipofectAMINE. Reporter constructs used to optimise transfection
efficiency in TNT4 cells was the (3-galactosidase gene under the control of the PGK
promoter (Fig. 3.1).Transfection efficiency was estimated by the numbers of blue cells
obtained (Fig. 3.4). The amount of DNA (1.5pg) and number of cells plated (2xl05 per 6
well in the absence of feeder cells) was constant in all experiments. Preliminary
experiment had indicated, that the optimum amount of the liposome was in the region of
—7.5(0.1. Optimisation of the DNA/LipofectAMINE ratio and incubation time is shown in
Table 3.2.
The lipid/DNA complex was added to the cells in serum free medium. At the end of the
incubation time medium containing serum was added either directly to the cells or after the
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transfection mixture had been removed by washing cells with PBS. The latter resulted in
fewer transfectants. The presence of serum during transfection was investigated during a
16 hrs incubation and led to a 10 fold reduction in efficiency.
Figure 3.4: TNT4 transfectants stained for P-galactosidase activity
Phase-contrast photomicrograph of TNT4 transfectants stained for P-galactosidase
activity. Magnification: 100X.
Table 3.2: Optimisation of the DNA/LipofectAMINE ratio
and incubation time








1 hr 18-22 17 30
1 hr, PBS wash 8 5 7
2 hrs 40 70 65
2 hrs, PBS wash 30 22 35
3 hrs 45 >100 >150
3 hrs, PBS wash 45 80 130
16 hrs 120 >200 >250
16 hrs, serum 18 23 25
*average of 2 counts
The highest transfection efficiency was obtained after overnight incubation with the
lipid/DNA complex. An incubation time of 3 hrs was sufficient to obtain a reasonable
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number of transfectants. To minimise insult to the cells all further experiments were
carried out using lOpl of LipofectAMlNE and a 3-5hrs incubation time.
LipofectAMINE transfection was also compared with transfection by calcium phosphate
(CaP04) co-precipitation using the luciferase reporter gene. Conditions for an optimal
CaP04/DNA co-precipitation had previously been established.
Firefly luciferase catalyses the oxidation of beetle luciferin with concomitant production of
light. In nature the oxidation occurs from an enzyme intermediate, luciferyl-AMP which
can be substituted in the invitro assay by the substrate coenzyme A. Photon emission was
measured in light units using a luminometer.
The addition of chloroquine enhances transfection efficiency in some cell types.
Chloroquine is thought to increase the pH in the endosomal and lysosomal compartments
and thus reducing degradation of transfected DNA. Its effect on TNT4 transfection
efficiency was assessed (see Figure 3.5).
CaP04* LifectAMINE
Figure 3.5: Comparison of transfection methods
Comparison of two transfection methods: LipofectAMINE and calcium phosphate co-
precipitation. Transfection efficiency is measured indirectly (number of light units) using a
luciferase reporter gene. Effect of chloroquine on transfection efficiency was also
assessed. * Cells showed formation of syncytia (cell fusion)
Results in figure 3.5 show, that the greatest total number of transfectants was obtained by
CaP04 co-precipitation. However this was accompanied by a high number of cell fusions.
LipofectAMINE produced the greatest number of transfected cells per pg DNA without
cell fusion. Chloroquine did not improve transfection efficiency.
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Electroporation has been shown to be a convenient method for transfection of a variety of
cell types. One drawback is the requirement for large amounts of DNA (80-200flg per
experiment). A method had been published in which addition of DEAE-dextran to the
electroporation medium allowed reduction in the amount of DNA used (Gauss and Lieber,
1992). Following this protocol electroporation conditions were optimised using the PGK-
LacZ reporter gene and by varying the amount of DEAE-dextran (5- lOpg/ml), the voltage
(120-450V) and the capacitance (125-500fiFd). Cell number (lxlO6), amount of DNA
(l|Ug/ml) and electroporation medium (0.8ml serum free medium) was kept constant.
Transfection efficiency was determined by the numbers of cells staining positive for p-
galactosidase.
Results from two separate experiments are shown in Table 3.3. The highest number of
transfected cells was obtained when using lOjag/ml DEAE-dextran, 180V and 500(lFd. It
has to be noted that 10pg/ml DEAE-dextran alone might have contributed to 32% of all
transfectants (192/595, see Table 3.3).
Table 3.3: Optimisation of electroporation conditions
Experiment 1





0 0 0% 1
125 120 0% 27
125 250 50-70% 113
125 450 100% 0
250 120 0% 31
250 250 90% 34
250 450 100% 0
500 120 0% 41
500 250 90-95% 115
500 450 100% 0
* stained cells per 25cm2 flask
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Table 3.3 (continued): Optimisation of electroporation conditions
Experiment 2





500 140 0% 45
500 160 0% 120
500 180 5% 147
500 200 20% 345
500 220 50% >350
lOjig/ml DEAE-dextran
0 0 0% 192
500 140 0% All
500 180 20% 595
500 220 75% 147
* stained cells per 25cm2 flask
Electroporation was considerably less efficient then lipofection (59 transfectants compared
to >1000 per 2X105 cells plated), therefore all further transfections were carried out using
LipofectAMINE as described above.
3.2.4.2. Stable transfections of TNT4 cells with the FIX transgene.
In an attempt to use TNT4 cells for cell mediated transgenesis, cells were co-transfected
with the selectable marker gene PGKneo (a kind gift of D. Melton, ICMB, University of
Edinburgh) and the genomic FIX construct pMIXl (see Chapter 2.2, Fig. 2.2).
At the time of this experiment the transgenic pMIXl mouse study was still ongoing and
the function of the pMIXl construct unknown (see Chapter 2). TNT4 cells were therefore
also co-transfected with PGKneo, the genomic BLG gene (pUCXSRV) and the FIX
cDNA construct cFIXA3'SA (a kind gift of J. Clark, Roslin Inst.; Yull et al. 1995). The
latter construct was known to express in transgenic mice when co-integrated next to an
active BLG transgene.
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TNT4 cells were transfected in the absence of feeder cells, followed by culture in the
presence of feeder cells. Stable transfectants were selected in medium containing 0.2 or
0.4 mg/ml G418. Colonies were isolated and expanded for cryopreservation, DNA
analysis, chromosome count, and assessment of viability after culture in medium with
reduced serum (0.5% "serum starvation").
Table 3.4: Transfection timeline
Manipulation Day Passage No.
Thaw 0 9
Expand culture 3 10
Transfection 6 11
Selection 8 12
Pick colonies (24 well dishes) 21 13
Expand colonies (6 well dishes) 25-28 14
Cryopreservation 28-34 15
Expand for DNA analysis 31-43* 16-17
* experiment was terminated at day 43. At this stage a large number of cell clones had
stopped dividing.
During the course of the experiment (see Table 3.4) it was evident that the majority of
isolated cell clones were reaching the end of their lifespan. Out of 70 clones isolated, 19
could be expanded sufficiently for cryopreservation, and 16 to allow Southern blot
analysis (Table 3.5).



























3.2.4.3. DNA analysis of stably transfected TNT4 cells
DNA isolated from individual cell clones was analysed by Southern blotting. The results
are shown in Figure 3.6.
Figure 3.6: Southern analysis of stably transfected TNT4 cells
DNA was digested with BamHI and EcoRl and analysed on Southern blot using a 1.8kb
probe derived from the ovine BLG promoter. Detected fragment size: cFIXA3'SA, 3.9kb;
pUCXSRV, 2.9kb; pMIXl 7.4kb, endogenous BLG, 2.9kb. Please note that the amount
loaded was not constant, because of variation in numbers of cells harvested. The presence
of pUCSRV was determined by the intensity of the signal.
Four out of the eight clones transfected with the FIX cDNA contained both the BLG and
cFIXA3'SA transgenes (Clones 2, 5, 8, and 17), one clone contained only the BLG
transgene (Clone 9). The MIX 1 transgene was detected in 3 out of nine clones (Clones 45,
49, and 57).
The gender of the clones was analysed by PCR. 14 out of the 16 clones were male, two
were female. The latter 2 clones included cells of fibroblast morphology, indicating that
they were contaminated with growing feeder cells.
3.2.4.4. Assessment of TNT4 transfectants for nuclear transfer
To determine suitability of transfected TNT4 cell clones for nuclear transfer their
chromosome number and survival after serum starvation was determined. For the latter a
known number of cells were plated into 6 well dishes, after 24hrs cells were washed and
cultured for further 5 days with either 0.5% or 10% serum. At this point cells were
counted. It was expected that cells grown in high serum would undergo several cell
doublings, while those in low serum would only replicate once or twice. Results are
summarised in Table 3.6.
Table 3.6: Serum starvation of stably transfected TNT4 cells






Sex No. of cells
plated
0.5% serum 10% serum Comment addition of
10% serum
cFIXA3'SA and BLG
2 M 2.8x10" 2.5 xlO-" 3.8xl0J fib. morph. n.t.
5 M 1.25 xlO" 4.12 xlO" 15.2x10" n.t.
8 M 1.05x10" 0.87 xlO" 1.6 xlO" 1.12 xlO"
9 M 3.6 xlO" 4.75 xlO" 8.4 xlO" 7.5 xlO"
17 M 1.5 xlO" 1.37 xlO" 2.5 xlO" n.t.
pMIXl
45 F 3.88 xlO" 1.66 xlO" 1.68 xlO" fib. morph. n.t.
49 M 2.0 xlO" 3.2 xlO" 5.87 xlO" n.t.
57 M 2.7 xlO" 0.87 xlO" 2.12 xlO" 0.68 xlO"
2 of the 9 cultures had lost their epithelial morphology. These fibroblast like cells were
most likely escaped STO feeder cells, which showed continuous growth even in low
serum. Clone 5 achieved 1.65 cell doublings in the 0.5% serum and 3.5 doublings in the
10% medium. The remaining 5 cultures underwent <1 cell doublings in low serum
medium, and =1 in medium with 10% serum. Addition of full medium to serum starved
cells resulted in limited cell proliferation (0-0.9 cell doublings). This indicated that all 6
epithelial cell clones had probably reached the end of their lifespan, with the possible
exception of clone 5.
The chromosome number of stably transfected TNT4 cells was determined. To obtain
metaphase spreads, cells were synchronised using colcemid, which inhibits
polymerisation of spindle microtubules essential for chromosome movement during
mitosis. Spreads were stained with DAPI and visualised under UV fluorescence. As the
cells were dividing poorly, few metaphase spreads were obtained. None of the 69 spreads
analysed showed the euploid chromosome number of 54. Chromosome counts varied
between <40 to >100. These stably transfected TNT4 cells were unsuitable for nuclear
transfer.
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3.3. Conditional immortalisation of TNT4 cells
The above sections showed that TNT4 cells are differentiated, primary cells. Their limited
lifespan rendered the main cell stock (available at passage 9) unsuitable for cell mediated
transgenesis. One objective for further experiments was therefore to define other cell
types, which can be genetically manipulated and support embryonic development
following nuclear transfer (see Chapters 4 and 5). Should this fail, attempts could be made
to increase the TNT4 lifespan by conditionally immortalising the cells using the
thermolabile T-antigen mutant of SV40 (tsA58) (Jat et al., 1991). Although steps were
taken to minimise SV40 large T activity in future nuclear transfer derived animals by the
addition of loxP sites (see below), it was not possible to rule out an accumulation of
genetic aberrations during time spent in culture, which could lead to tumour formation. It
was therefore the least favoured option.
3.3.1. SV40 large T
SV40 is a small circular DNA virus whose natural host is primates. Its transforming ability
is attributed to the early gene products small and large tumour antigen (T-antigen).
Transforming ability of large T is mediated by its interaction with the tumour repressor
proteins p53 and pRb (Schreier and Gruber, 1990). Both proteins are involved in cell
cycle control and mutations in these genes are associated with cancer (Lane, 1992; Levine,
1990; Marshall, 1991; Hamel, Gallie and Philips, 1992; Hollingsworth, Hensey and Lee,
1993). Complexing of T-antigen with p53 and pRb renders the proteins non-functional,
resulting in cells which progress unchecked through the cell cycle, ultimately leading to
genetic instability and possibly tumour formation.
The temperature sensitive mutant of T-antigen tsA58 (substitution of alanine to valine at
position 438) has the same properties as wild type at the permissive temperature (33°C)
but at the restrictive temperature (39°C) T-antigen is inactive (Jat, 1991). It is not clear
whether inactivation is due to a conformational change in the protein or to instability of the
RNA (Deppert et al., 1991, Tegtmeyer, 1975). Using the temperature sensitive T-antigen
mutant for TNT4 immortalisation has the advantage that cells can be grown indefinitely in
culture and the immortalising agent can be rendered inactive prior to nuclear transfer by
culture at 39°C. Furthermore the immortalisation construct was flanked by loxP sites.
Addition of Cre recombinase either prior or during nuclear transfer could excise the tsA58
transgene (Baubonis and Sauer, 1993, Sunaga et al., 1997). Nuclear transfer derived
lambs would be T-antigen free.
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3.3.2. Generation of tsA58LOX construct
The SV40T construct "pUCtsA58" was obtained from C. Watson (Roslin Inst.). The
cloning of PGKtsA58LOX was achieved in three steps which are outlined in Fig. 3.7.
1. The 3kb KpnI/Sall fragment from pUC tsA58 and the XhoI/BamHI double stranded
oligonucleotide comprising the loxP site were cloned into Bluescript digested with
KpnI/BamHI (tsA58LOX).
2. The XhoI/BamHI double stranded oligonucleotide comprising the loxP site and the
0.5kb BamHI/Hindlll fragment containing the PGK promoter were cloned into Bluescript
digested with Sall/Hindlll (PGK-LOX).
3. The StuI/NotI fragment from tsA58LOX was cloned into PGK-LOX digested with
EcoRV and Notl.
The presence of the loxP sites in the final construct was confirmed by restriction enzyme
analysis and DNA sequencing.
Cloning ofSV40TtsA58
and LOX site SV40T tsA58
LOX
Cloning of PGK promoter
and LOX site












Figure 3.7: PGKtsA58LOX (Construct for conditional immortalisation)
Schematic diagram of cloning strategy. Indicated are the restriction enzyme recognition
sites in the poly linker of the plasmid vectors and those used for cloning.
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3.3.3. Immortalisation of TNT4 cells
TNT4 cells were transfected at passage seven with PGKtsA58LOX alone or co-transfected
with PGKtsA58LOX and PGK-neo. Cells were cultured at 37°C, as it was known for
rodent cells, that the tsA58 gene had some activity at this temperature, sufficient to
immortalise cells but minimising phenotypic transformation (Gordon, 1999).
Cell clones obtained after single cell plating (plated at 1:5000) or G418 selection were
analysed by PCR for the presence of the tsA58 gene and gender determination (see Fig.
3.8 and Table 3.7).
Clone Nr. 1 to 12 X13 to 24 X 25 to27
Figure 3.8: PCR detection of SV40 T in TNT4 transfectants
PCR amplification of SV40T sequences and analysis on agarose gel. X, DNA size marker;
No DNA, control PCR reaction lacking DNA.
Isolated cell clones had maintained epithelial morphology, but unlike the primary TNT4
cell clones, expanded rapidly even in the absence of feeder cells. 100% of picked cell
clones could be expanded and frozen compared to 23-27% of primary clones transfected
with a FIX transgene. Figure 3.8 shows that all clones contained the tsA58 gene,
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The sex ratio was also reversed when compared to the primary cell clones derived from the
FIX transfection. Only 2/40 clones were male. Whether this was due to the
immortalisation or due to the fact that cells were used at an earlier passage is
undetermined, although the latter is a more likely explanation.
3.4. Conclusions
The results in this chapter show that TNT4 cells do not share properties characteristic for
ES or EG cells, e.g. lack of ES cell markers such as alkaline phosphatase, lack of
expression of developmentally regulated genes such as Oct3/4. TNT4 cells represent a
differentiated cell type of epithelial morphology with a limited lifespan in culture.
Nevertheless, they are totipotent for nuclear transfer. At the time it still remained to be
determined whether this was due to some specific, yet undefined characteristics of the cells
or a result of improvements in the nuclear transfer technique.
A simple and reliable method for sexing of ovine cells has been established and applied to
determine the gender of TNT cells. Results indicated that the cell population was derived
from at least 2 individual embryos. Both male and female cells were present in the culture.
At early passage the majority of cells were female, at later passage the male cells
predominated, indicating a growth advantage of these cells. It should be noted that the
only fertile animals obtained from TNT4 cells were female.
Culture and transfection conditions were optimised to allow production of genetically
modified TNT4 cells. Clones which were stably transfected with either the cDNA or
genomic FIX expression construct were obtained. These cell clones had an extended cell
doubling time, or ceased to divide altogether. A change in morphology from epithelial
phenotype to one reminiscent of senescence was also observed. Serum starved cells could
not be induced to further cell divisions. All clones analysed were of male gender and had
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an aberrant chromosome count. None of these clones were suitable as nuclear transfer
donors. This led to the conclusion that the main cell stock (available at passage 9) was
unsuitable for cell mediated transgenesis.
Attempts were made to increase the TNT4 lifespan by conditionally immortalising the cells
using a temperature sensitive SV40T gene. As such a step could produce genetic
aberrations, possibly leading to tumour formation in nuclear transfer derived animals,
immortalised cells would have only been used if efforts to identify alternative cell types
had failed. Furthermore the immortalisation construct contained loxP recognition sites to
enable excision of the transgene prior to nuclear transfer.
Successful isolation of non-transformed nuclear transfer competent cell cultures suitable
for cell mediated transgenesis is described in Chapters 4 and 5. Therefore work on TNT4
cells was abandoned. Conditionally immortalised TNT4 cells might still provide a resource
to establish somatic gene targeting in ovine cells.
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Chapter 4
Identification and isolation of nuclear transfer competent
embryonic and adult cells
4.1. Background
The results in the previous chapter show that primary TNT4 cells were unsuitable in
practice for cell mediated transgenesis. It was therefore essential to investigate the use of
alternative cell cultures as donors for nuclear transfer. This would also establish if the
nuclear transfer method was generally applicable, or if the success was based on special
properties of the TNT4 cells.
If the nuclear transfer method was the enabling step (for example the use of quiescent
nuclei), then nuclei from a wide variety of differentiated cells should support development
after nuclear transfer, possibly even nuclei from adult cells. This therefore provided an
opportunity to address a major question in mammalian biology, is genomic totipotency lost
in somatic cells of the adult?
For the nuclear transfer season of winter '95/'96, I had the opportunity to test two
different cell types. One was a conservative choice, newly derived ovine embryonic cells
equivalent to TNT cells, and one was significantly more challenging, adult mammary cells
from a 6 year old ewe. The use of adult cells for nuclear transfer has received widespread
public attention and accounts of the experiment which ultimately gave rise to sheep 6LL3
"Dolly" have been published in popular books and magazines. I would like to make it clear
that the choice and inclusion of adult mammary cells in the nuclear transfer experiments
was entirely mine and that nuclear transfer procedures using these cells were carried out by
the group of Ian Wilmut at my instigation.
Adult ovine mammary epithelial (OME) cells were chosen for their possible practical
advantages for cell mediated transgenesis. An in vitro mammary culture may provide
predictive data on transgene expression in vivo (Figure 4.1). At present, practical
considerations make it necessary to use transgenic mice to assay constructs designed for
expression in large animals. However, the shortcomings of the mouse as a predictor of the
expression level in a large animal are widely recognised. For example, Carver (1993)
found a markedly different range of expression of human a-1 antitrypsin from the same
construct in the milk of transgenic mice and sheep. Velander et al. (1992) obtained lmg/ml
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Ovine mammary epithelial culture
(OME)
Genetic manipulation
Co-transfection ofOME cells with selectable marker gene and mammary specific transgene,





Addition of lactogenic hormones Cryopreservation
RNA and/or protein analysis
Identification of cell clones expressing





from favourable cell clones
Figure 4.1: Predictive model for in vivo transgene expression
The schematic diagram shows the isolation and culture of ovine mammary epithelial cells. At
first passage cells are transfected with selectable marker gene and a transgene under the
control of a milk specific promoter. Single cell clones are isolated and expression of
mammary specific genes is induced by addition of lactogenic hormones. Cell clones which
show high expression of the recombinant protein are identified prior to use as nuclear
transfer donors. Animals born are expected to express the transgene.
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human Protein C from transgenic pigs using a construct which expressed poorly in
transgenic mice. Similarly, post translational processing of a foreign protein by the mouse
mammary gland is a poor guide to large mammals (Drohan et 1994).
PPL in collaboration with Colin Wilde (Hannah Research Institute) tested the use of OME
cells for milk specific transgene expression invitro. Stably transfected OME cells, after
addition of lactogenic hormones, were analysed for expression of recombinant protein. If
the same cell clones could then be used as nuclear transfer donors, all animals born would
be transgenic and should express the recombinant protein in their milk (Figure 4.1). This
selection protocol would minimise the number of sheep which are normally required to
produce one high expressing animal. It is envisaged that such an approach is not restricted
to OME cells. Any nuclear transfer competent cell type, which mimics vivo transgene
expression, should be suitable.
4.2. Isolation of sheep embryonic cells
Figure 4.2. Phase-contrast photomicrographs of ovine embryonic cultures
A. and B. day 10 hatched blastocysts (magnifications: A. 300X; B. 200X), the arrow
indicates position of the embryonic disc; C. and D. disc explants at day 2-3 in culture,
indicated by the arrow (magnification: 500X), also visible are STO feeder cells; E. disc
explant after 9 days in culture (magnification: 200X); F. SEC1 embryonic cell culture at
passage 5 (magnification:200X).
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TNT4 cells had been isolated from cultures of several embryonic discs and were a mixed
population which was undesirable. An attempt was therefore made to newly derive sheep
embryo cultures (SEC) from single day 9-10 embryonic discs.
Day 9 to 10 ovine blastocyst stage embryos (Figure 4.2A and B) were derived from the
specific pathogen free Poll Dorset herd at PPL on 4 separate days (kindly provided by the
PPL Animal Husbandry Unit). The embryonic discs were mechanically dissected using
fine forceps and placed individually in 24 well dishes on mitotically inactivated STO feeder
cells (Figure 4.2 B). Culture conditions were essentially as for TNT and mouse ES cell
derivation. Medium was supplemented with bovine rather than murine LIF. A bovine LIF
expression vector had previously been cloned by the author and tested at PPL as part of a
different project. Explant details and cell lines derived are shown in Table 4.1.








explant Passage Sex I.D.
1 4 5
24.10.95
(d9 emb.) 43 22 4 2 1 1 M SEC1
27.10.95
(dlO emb.) 35 20 9 *
06.12.95




















culture lost due to bacterial contamination
culture lost due to incomplete inactivation of feeder cells
% corrected for loss of 9 primary explants
Four explants (SEC 1, 2, 3, 4) derived from single embryonic discs were cultured to
passage 4 and 5 and their gender determined by PCR (3 male and 1 female explant).
Although SEC cells were co-cultured with feeder cells, they attached directly to the culture
dish plastic. To test for feeder independence, SEC1 cells were grown in the absence of
feeders from passage 2 onwards, while SEC2 to 4 were cultured in the presence of feeder
cells. At passage 5 escaped STO feeder cells overgrew the embryonic cultures, which
were then discarded. All subsequent experiments were carried out using SEC1 cells
without feeders.
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Although culture conditions were based on those used for mouse ES cell derivation, none
of the SEC cultures resembled mouse ES cells, or TNT4 cells. When sub-confluent these
were large very flattened cells (Fig. 4.3) which became closely packed at confluence. It is
noteworthy that Gerfen and Wheeler (1995) describe the "ES like" pig cells used to
produce chimeras as follows: "Initially, embryonic cells of interest were translucent in
nature and difficult to locate". This was precisely the observation regarding SEC cells,
they were almost invisible as early colonies.
Figure 4.3: Embryo derived SEC1 cells
Phase-contrast photomicrograph of SEC-1 cells. Magnification: 750X.
4.2.1. Assessment of SEC1 cells for nuclear transfer
Prior to nuclear transfer, the chromosome number of SEC1 cells and their ability to
survive serum starvation was assessed.
iSubif *nip « -V
npm
w
Figure 4.4: Determination of SEC1 chromosome number
Fluorescent micrograph of DAPI stained metaphase spread. Magnification 1,500X.
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Metaphase spreads at passage 8 showed a modal chromosome number of 54 (Fig. 4.4).
Cells cultured for >12 passages showed signs of senescence and few cells gave metaphase
spreads, those which could be analysed were aneuploid.
Culture conditions necessary to arrest growth and the ability of cells to survive growth
arrest were assessed by monitoring cell number (Table 4.2).
Table 4.2: Serum starvation of SEC1 cells at passage 7
Day 0.5% serum,
cell count






Table 4.2 shows that cell growth was retarded in low serum after only 2 days. Addition of
10% serum allowed further cell growth even after 6 days of starvation
4.2.2. Nuclear Transfer using SEC1 donor nuclei
Cells which had undergone 5 days of serum starvation were provided for nuclear transfer,
which was carried out in Ian Wilmut's laboratory at the Roslin Institute as described
previously (Campbell etal., 1996a). A schematic outline of the nuclear transfer procedure
is shown in Figure 4.5. Animal care and veterinary procedures were carried out at the
Roslin Institute's large animal unit. Results of the nuclear transfer experiment and details
of veterinary examinations are included in this thesis for reasons of continuity and clarity.
Figure 4.5 (next page): Schematic outline of the nuclear transfer procedure. Oocytes
derived from Scottish Blackface (symbolised as a yellow sheep) are enucleated. The donor
cell derived from a different sheep breed (symbolised as a red sheep) is placed under the
zona pelucida into the perivitelline space. The cell nucleus is introduced into the cytoplast by
electrofusion, which also activates the oocyte. The reconstructed embryo is then either
cultured in vitro up to blastocyst stage or is transferred into a pseudopregnant intermediate
recipient ewe. At day 7 embryos are assessed for development. Late morulae and blastocysts
are transferred into final recipients. Pregnancies resulting from nuclear transfer are
determined by ultrasound scan at about 60 days after oestrus, and development is
subsequently monitored at regular intervals.
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Table 4.3: SEC1 nuclear transfer results
Donor cell: SEC-1
Derived from: day 9 embryo
Breed: Poll Dorset
Passage: 7-9




No. of reconstituted embryos 293 92
In vivo :





No. of morulae and blastocysts 90 36
No. of embryos transferred 72 15
No. of pregnancies /
No. of recipients
14/27 1/5
No. of live lambs 4 0
Nuclear transfer efficiency





* this percentage takes into account that only 80% of morula and blastocysts were
transferred to final recipients.
The result of the SEC1 nuclear transfer experiment is summarised in Table 4.3. Out of 14
pregnancies 4 were lost prior to day 90. For details of the remaining 10 pregnancies please
refer to table 4.4. The 4 liveborn nuclear transfer animals (6LL1, 6LL2, 6LL5, 6LL6),
two of which were born by caesarean section, are shown in Figure 4.6. Birth weight
varied from 4.2 to 6.5 kg (mean birth weight 5.55kg). Poll Dorset lambs in the PPL New-
Zealand derived flock have a mean birth weight of 5.1kg for single birth. No live animals
were obtained from the in vitro cultured embryos, indicating that further improvements to
the culture conditions are required. Two of the four males have fathered healthy lambs,
proving their fertility.
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5E337 <118 0.4 Mummified fetus
5E205 <118 1.7 Autolysis of organs, indications of liver
abnormalities
5E226 117 4.53 no gross abnormalities, kidney appeared
shrunken
1B44 116 0.35 Mummified fetus
5E550 twins 130 One fetus died, pregnancy terminated
5E1901 6LL1 149 6.5 Vaginal prolapse, induced
5E017 6LL2 152 6.0 Caesarean section, breached position
5E134 6LL4 149 5.8 Caesarean section, bom dead
5E524 6LL5 148 4.2 Normal birth
9M399 6LL6 152 Caesarean section, temporary facial paralysis
due to trapped nerve
Figure 4.6: SEC1 nuclear transfer sheep
Photo of four Poll Dorset sheep derived from cultured embryonic donor cells by nuclear
transfer.
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4.3. Nuclear transfer competent adult cell culture
OME cell preparation was carried out in Colin Wilde's laboratory at the Hannah Research
Institute as described by Finch et al. (1996). Ovine mammary tissue from a 6 year old
Finn Dorset ewe was dissected post mortem in the third trimester of pregnancy, digested
with collagenase and hyaluronidase, and fractionated by Percoll density gradient
centrifugation. Fractions which were 98% positive for the epithelial marker cytokeratin
were cryopreserved in multiple aliquots (OME (OP5)). Members of Wilde's group
attempted to optimise culture conditions of OME (OP5) and analysed expression of
endogenous milk genes. Frozen aliquots were shipped to PPL to investigate, if the cells
could be genetically modified, e.g. addition of transgenes under the control of a lactation
specific promoter.
Described here is the assessment ofOME (OP5) as nuclear transfer donors. Figure 4.7
shows the morphology of these cells.
Figure 4.7: Adult derived ovine mammary epithelium cells
Phase-contrast photomicrograph of OME (OP5) cells. Magnification: 300X.
4.3.1. Assessment of OME (OP5) cells for nuclear transfer
Both chromosome number and the ability to survive serum starvation was assessed prior
to nuclear transfer as described for TNT4 and SEC1 cells.
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Figure 4.8: Determination of OME (OP5) chromosome number
Fluorescent micrograph of DAPI stained metaphase spread, also shown is an interphase
nucleus. Magnification 1,500X.
OME (OP5) metaphase spreads at passage 3 showed a modal chromosome number of 54
(Fig. 4.8). Serum conditions necessary to arrest growth and the ability of cells to survive
growth arrest were assessed by monitoring cell number (Table 4.5). Cell growth was
retarded in low serum after 3-4 days. After addition of 10% serum further cell growth was
observed. 5 days of serum starvation was used to prepare cells for nuclear transfer.
Table 4.5: Serum starvation of OME (OP5) cells at passage 3
Day 0.5% serum,
cell count







4.3.2. Nuclear Transfer using OME donor nuclei
Cells which had undergone 5 days of serum starvation were provided to Ian Wilmut's
group at the Roslin Institute. Nuclear transfer was carried out as described in chapter
4.2.2. with the exception that reconstituted embryos were only cultured in vivo. The
results are summarised in Table 4.6.
Table 4.6: OME nuclear transfer results
Donor cell: OME (OP5)
Derived from: 6 year old adult
Breed: Finn Dorset
Passage: 3
Recipient oocyte: Scottish Blackface
In vivo
culture
No. of reconstituted embryos 277
In vivo :
No. recovered from oviduct
247
No. of morulae and blastocysts 29
No. of embryos transferred 29
No. of pregnancies /
No. of recipients
1/13
No. of live lambs 1
Nuclear transfer efficiency
(% of live lambs from reconstructed
embryos)
0.36%
Twenty nine embryos were transferred to final recipients, a single pregnancy was
established, and developed to term. Duration of pregnancy was 148 days and birth weight
6.6kg. The adult cell derived nuclear transfer sheep 6LL3 (better known as Dolly) is
shown in figure 4.9 together with her lamb 8LL5 (Bonny), which was produced by
natural mating and was bom in Spring 1998. Nuclear transfer efficiency for the adult cells
was lower than for the embryonic cells (0.36 live lambs per 100 reconstituted embryos
compared to 1.36).
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Figure 4.9: OME (OP5) derived nuclear transfer sheep
Photo of Dolly (6LL3) at 2 years of age together with her female offspring (Bonny, 8LL5),
which was derived by natural mating.
4.4. Microsatellite analysis of nuclear transfer derived lambs.
Sections 4.2 and 4.3 showed that healthy and fertile lambs were derived from both
embryonic and adult cells. In a separate experiment Keith Campbell and Patricia Ferrier in
Ian Wilmut's Group had isolated fetal fibroblasts from a day 25 Black Welsh Mountain
fetus (BLWF1). These too were nuclear transfer competent, and resulted in the birth of
two male lambs (Animal I.D. 6LL7, 6LL8) (Wilmut, 1997).
All nuclear transfer lambs displayed the morphological characteristics of the breed from
which the donor cell was derived (SEC-1, Poll Dorset; BLWF1, Black Welsh Mountain;
and OME, Finn Dorset). In addition, microsatellite analysis was carried out to confirm
genomic identity of donor cell and nuclear transfer derived sheep.
Microsatellites are repetitive elements containing simple sequence motifs, usually dimers
or trimers, e.g. (dG-dT).( dC-dA) dimers. Generally they are less then lOObp and are
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found embedded in unique DNA sequences (Tautz, 1989), allowing specific PCR
amplification of individual microsatellite loci. (Litt and Luty, 1989; Weber, 1990).
Differences in the size of alleles are due to variation in the number of repeats, which is
detected by gel electrophoresis.
Buchanan et al. (1993) have described a number of highly polymorphic ovine
microsatellite markers. Five of these (Table 4.7) were used to compare DNA from nuclear
transfer lambs, donor cells and recipient ewes.






MAF33 121-141 9 0.70
MAF209 109-135 8 0.79
OarFCB 11 121-143 9 0.79
OarFCB128 99-131 8 0.72
OarFCB304 150-188 9 0.54
PIC = polymorphic information content
Figure 4.10 shows the results obtained with four of these markers, as well as the gender
analysis of both cells and lambs using PCR. In each case donor cells and the lambs
derived from those cells had identical banding patterns, while the banding pattern for
individual recipient ewes varied.
Figure 4.11 shows that the microsatellite markers used are indeed polymorphic and can
distinguish between individual animals from the same breed. Four random Finn Dorset
sheep were compared with duplicate DNA samples from 6LL3 (Dolly) and the adult
derived donor cells OME (OP5). Each animal has its individual microsatellite banding
pattern (Fig. 4.11, sample 1-4). Again the nuclear transfer derived lamb and the donor cell
culture have an identical pattern (Fig. 4.11, OME and 5LL3). The latter samples were
analysed in duplicate.
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Figure 4.9: Microsatellite analysis of nuclear transfer sheep
Microsatellite analysis of recipient ewes, nuclear donor cells and lambs using four
polymorphic ovine markers. Cell populations are embryo derived (SEC1), fetal derived
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Figure 4.10: Microsatellite analysis of 6LL3 (Dolly), the adult derived
donor cells OME (OP5) and random Finn Dorset sheep
Microsatellite analysis of four random Finn Dorset sheep (1 to 4), and two samples each of
the mammary cell derived OME culture and nuclear transfer derived animal 6LL3 (Dolly).
The duplicated DNA sample had been prepared by independent investigators. M, DNA
prepared for microsatellite analysis; T, DNA prepared for telomere analysis by Paul Shiels;
H, DNA prepared at the Hannah Institute.
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4.5. Conclusions
The above results show that healthy and fertile nuclear transfer lambs were derived from
both cell cultures, embryonic SEC1 cells and, more significantly, from the fully
differentiated adult OME cells. From this it can be concluded that using the current nuclear
transfer method live animals can be derived from a variety of differentiated cell types and
that it is the practical aspects of the procedure, such as use of quiescent nuclei which lead
to successful birth of animals, rather than the characteristics of the euploid cell.
The nuclear transfer animal Dolly (6LL3) is the first animal cloned from an adult cell. It
provides ultimate proof that the process of differentiation at the level of the nucleus is not
irreversible. These findings are consistent with the view that differentiation is achieved by
systematic, sequential changes in gene expression and that the effects of epigenetic
changes are reversible. That the animal was indeed derived from the adult cells was
proven by microsatellite analysis using highly polymorphic ovine markers.
Nuclear transfer efficiency (% of live lambs per reconstructed oocyte) for the embryonic
cell line SEC1 (1.7%) was slightly higher than that obtained with TNT4 cells (1.07%),
while that for OME cells was lower (0.36%). The main difference in efficiency resulted
from the number of reconstituted embryos that developed to blastocyst (11.74% for OME
compared to 38.96% for SEC1). The percentage of transferred blastocysts that developed
to birth was only slightly lower (3.45% compared to 5.55%). The reduction of the
developmental capacity of the adult nucleus might reflect an accumulation of chromosomal
damage during ageing, such as telomere shortening and oxidative damage.
A major drawback of production of transgenic livestock by microinjection is the random
integration of the transgene, often resulting in wildly varying expression levels. This
requires the production of multiple transgenic animals which all have to be assessed for the
quality and quantity of the recombinant protein. This can both be cost and time
consuming, especially if the founder animal is male and the transgene is expressed in milk.
The use of mammary epithelial cells for nuclear transfer opens up the possibility to predict
expression of milk specific transgenes in vitro prior to the production of animals (Figure
4.1), therefore reducing time, cost and number of experimental animals. It is envisaged
that such an approach is not restricted to OME cells. Any nuclear transfer competent cell
type, which mimics in vivo transgene expression, should be suitable.
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The success of the experiments described here provide new research opportunities for
evaluation of the molecular mechanisms underlying differentiation, reprogramming, and
genomic imprinting. Production of animals without germline involvement may also
provide a new tool to investigate the mechanisms of ageing. Further beneficial aspects of
cloning from somatic cells could include easy preservation of genetically important strains
of laboratory and farm animals as well as endangered species (Wells et al., 1999). It might
also prove to be useful to humans as a means of providing autologous cells for
regenerative transplants (Smith, 1998; Trounson and Pera, 1998).
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Chapter 5
Human Factor IX transgenic sheep produced by transfer
of nuclei from transfected cells
5.1. Background
The proceeding chapters showed that normal sheep can be produced by transfer of nuclei
from adult mammary and embryonic cells cultured in vitro. In addition Wilmut et al.
(1997) described successful nuclear transfer from fetal fibroblast cells. The aim of work
described in this chapter is to determine if nuclear transfer from stably transfected somatic
cells could provide a means of producing transgenic livestock. Gene transfer into cultured
cells offers several important advantages over DNA microinjection into embryos, the most
significant of which is the ability to identify and analyse genetically manipulated nuclear
donor cells before producing whole animals. It also allows the sex of the animals to be
predetermined, which leads to a more efficient use of experimental animals.
The first objective was to identify a cell type most amenable for cell mediated transgenesis.
These cells would then be transfected with pMIXl, a vector designed to express human
rFIX protein in the milk of transgenic animals and which had been shown to be expressed
in the mouse mammary gland (see Chapter 2).
5.2. Assessment of cell types for cell mediated transgenesis
Embryonic, fetal and adult cell culture were each assessed for their potential use in cell
mediated transgenesis. The results are summarised in Table 5.1.
Table 5.1: Assessment of embryonic, fetal, and adult cells for cell
mediated transgenesis









1.07% 1.70% 1.35% 0.36%
Transfection
efficiency
1-5% n.d. n.d. 0.5%
Single cell
cloning
yes no n.d. yes
Euploidy after
cloning
no no* n.d. yes
n.d. not done
Cells aneuploid at passage >12
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In contrast, both fetal and adult cells can be isolated in essentially unlimited numbers with
no requirement for expansion. Large numbers of cells can be cryopreserved for
convenience and are available for genetic manipulation at first passage. Cell clones from
the adult OME (OP5) culture had been previously isolated (by A. Scott, Cell Biology,
PPL) as part of the aforementioned collaboration with Colin Wilde.
The euploidy of both cell clones and oligoclonal pools was tested as a basic requirement
for nuclear transfer. Table 5.2 shows the results of the chromosome counts, no adverse
effect on gross karyotype is indicated.
Table 5.2: Modal chromosome number of OME (OP5) transfectants





Pool 1 5 15 54
Pool 2 5 18 53
Clone 3 6 18 54
Clone 4 6 3 54 ? poor spreads
Clone 5 6 18 54
Total 5-6 99 54
No experiments were carried out with the fetal fibroblast cells BLWF1 as neither pathogen
status of the cell culture nor the animal, from which cells were derived, was known.
Previous experience by the author had shown that ovine fibroblast cells can be efficiently
transfected (data not shown) and, as shown for the adult cells,- the relatively short time in
culture should guarantee euploidy. The main advantage of fetal fibroblasts compared to
OME (OP5) cells, was the higher nuclear transfer efficiency and therefore the greater
likelihood of obtaining transgenic animals. For this reason it was decided to isolate both
male and female fetal fibroblast from PPL's specific pathogen free flock and assess those
for cell mediated transgenesis.
5.3. Isolation and manipulation of ovine fetal fibroblasts
Primary strains of ovine cells, termed PDFF1-7 (Poll Dorset Fetal Fibroblast), were
derived from seven day 35 fetuses kindly provided by PPL's Animal Husbandry Unit.
Sex analysis of each cell line by PCR revealed cell line PDFF5 to be male and the other six
female (Figure 5.1). As the immediate aim was to express recombinant FIX in the ovine
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mammary gland, a female cell line PDFF2 was chosen for transfection. Male PDFF5 cells
were also tested for their ability to support nuclear transfer because future experiments
such as gene targeting may benefit from the production of male animals (see Chapter 6).
PDFF £
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M F 12345 2
Figure 5.1: Sex determination of Poll Dorset fetal fibroblasts
PCR amplification of ovine X and Y sequences analysed on 2% agarose gels.
PCR primers employed were bovine zfx 5' and 3' and the "universal" Y primers Rg4 and
Rg7, which successfully amplified both X and Y ovine sequences. M, male control DNA; F,
female control DNA.
Trial transfections indicated that PDFF1, PDFF2 (both female) and PDFF5 (male) cells
could be readily transfected with a LacZ reporter gene using the cationic lipid reagent
LipofectAMINE (see also Chapter 3). pMIXl DNA and the selectable marker construct
PGKneo were cotransfected into PDFF2 cells at passage 1, after 3 days in culture, and
stable transfectants selected with G418. Because the possible effects of drug selection and
growth as single cell clones on the ability of cells to support nuclear transfer were
unknown, cells were treated in two ways after transfection. One group was grown at high
density under G418 selection, then cryopreserved as a pool for nuclear transfer. The other
group was plated at low density and cloned transfectants grown from isolated colonies.
Twenty four clones were isolated, of which 21 were expanded for analysis of genomic
DNA. Southern analysis similar to that in figure 5.4 showed that 10 clones contained
pMIXl DNA.
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5.3.1. Assessment of PDFF2 transfectants for nuclear transfer
The chromosome number of untransfected PDFF2 and 5 cells cultured up to passage 19
over a period of 80 days, was determined and showed a modal chromosome number of
54, the euploid ovine chromosomal complement. The chromosome number of pMIXl
transfected PDFF2 clones was determined at passage 6-7, after an average 40 days in
culture and the uncloned PDFF2 pool at passage 5, after only 19 days in culture.







PDFF2 7 7 71.4%
PDFF2 19 29 65.5%
PDFF5 4 32 83.3
Transfected
PDFF2 pool 5 37 75.7
PDFF2-7 - n/c -
PDFF2-12 6-7 26 92.3
PDFF2-13 6-7 33 75.8
PDFF2-14 - n/c -
PDFF2-15 - n/c -
PDFF2-31 6-7 46 70%
PDFF2-32 - n/c -
PDFF2-37 - n/c -
PDFF2-38 6-7 48 50%
PDFF2-42 - n/c "
n/c not counted, poor cell proliferation, few spreads.
Not all single cell clones could be readily expanded. The 4 clones which grew best in
culture showed a modal chromosome number of 54 indicating no gross chromosomal
instability after long term culture and drug selection (see Table 5.3). Clone PDFF2-12 and




Figure 5.2: Morphology of PDFF2 transfected cell clones
Phase-contrast photomicrograph of the two stably transfected PDFF2 cell clones (PDFF2-12
and PDFF2-13). Magnification: 250X.
The ability of PDFF2 cells to undergo and survive serum starvation was tested. After 5
days culture in medium containing reduced serum (0.5%), restoration of serum content to
10% reversed the effect and cell growth resumed (Table 5.4).
Table 5.4: Serum starvation of PDFF2 cells
Serum 0.5% 0.5% 0.5% 10% 10% 10%




1 2.8 3.4 8.6 22.2 n.t.
Cell number
(xlO4)




1 n.t. 2.2 n.t. n.t. 52
For nuclear transfer experiments cells were provided to Ian Wilmut (Roslin Institute) after
a 5 day culture in low serum.
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5.4. Nuclear transfer of transfected and non-transfected PDFF cells
Four cell types were used as nuclear donors: untransfected PDFF5, pooled PDFF2
transfectants, and two transfected clones, PDFF2-12 and PDFF2-13 confirmed as
containing >10 and ~5 copies of the pMIXl transgene respectively (see Fig. 5.4).
Transfer of nuclei from each cell type into enucleated oocytes derived from Scottish
Blackface ewes was carried out by members of Ian Wilmut's group at the Roslin Institute
as previously described (Campbell et al., 1996a, Chapter 4). Table 5.5 shows the results
of nuclear transfer.




PDFF2 pool PDFF2-12 PDFF2-13
No. of reconstructed embryos 82 224 89 112










No. of embryos transferred 5 22 19 21
No. of recipients 2 9 7 6
No. of pregnancies at day 60 2 4 4 1
No. of fetuses at day 60









No. of liveborn lambs










(% live lambs from
reconstructed embryos)
1.22% 1.34% 2.25% 0.89%
* Liveborn lambs were defined as those with a heart beat and able to breathe unassisted at
birth.
Live lambs were obtained from all four cell types. As expected, animals derived from
PDFF5 were male and those from PDFF2 were female. Figure 5.3 shows the four
transgenic lambs 7LL8, 7LL12, 7LL13 (Polly), and 7LL15 (Molly). All animals from
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PDFF2 cells had a slightly undershot jaw which did not interfere with the animal's well-
being. This is a genetic trait known to occur sporadically in the Poll Dorset breed and is
considered to be unrelated to nuclear transfer. The PDFF5 and SEC 1 lambs (also Poll
Dorset) did not show this feature.
Figure 5.3: Transgenic nuclear transfer derived lambs.
Lambs 7LL8, 7LL12, derived from PDFF2 pool, 7LL13 (Polly, derived from PDFF2-13),
and 7LL15 (Molly, derived from PDFF2-12).
Table 5.6 provides details of all 11 pregnancies established in surrogate mothers. Of the
original 14 fetuses, one was lost prior to day 80, 3 were lost at late stage pregnancy (130
days), 4 were lost perinatally and 7 were liveborn, as defined by heart beat and unassisted
breathing. One (7LL9) died shortly after birth due to meconium in the lung, and a second
(7LL16) was diagnosed with a heart defect and euthanised at 14 days old for animal
welfare reasons. Post mortem examination of abortuses and dead lambs did not indicate
any common factor as a cause of death.
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7LL9f 161 d 6.3kg yes no f
Induced, CS
52hrs later,
































































7LL13 155d 5.5kg yes yes f
Induced,
unassisted birth






All animals derived from PDFF cells exhibited a prolonged gestation (breed average =145
days) and with the exception of animals 7LL5-8, labour was induced artificially. Delayed
parturition was almost certainly the cause of death of lamb 7LL9. Subsequent to this, all
surrogate ewes were induced at day 153, and if necessary Cesarian section was carried
out. Three of 11 pregnancies were twin pregnancies. In two instances of twin pregnancies
(7LL6, 7LL7 and 7LL10, 7LL11) the death of one fetus in late pregnancy probably
resulted in the death of the sibling.
The birth weight of nuclear transfer derived lambs whose gestation exceeded 145 days
ranged from 3.0 to 8.7kg, with a mean value of 3.7kg for twin and 5.9kg for single
pregnancies. This is within the normal range for Poll Dorset lambs in PPL's New Zealand
derived flock (range 3 - 9kg for single pregnancies, mean weights 3.75kg for twins and
5.1kg for singles). It is not certain whether the apparently slightly higher mean birth
weight is significant given the small number of nuclear transfer lambs and increased
gestation time.
5.5. DNA analysis of nuclear transfer Iambs
DNA was prepared from blood samples from live lambs, or tongue biopsies of dead
animals and was analysed for the presence of the pMIXl and PGKneo transgenes. The
results are shown in Figure 5.4. A, B and C.
All fetuses and animals derived from the transfected PDFF2 cells were transgenic (Table
5.5). The three animals derived from the PDFF2 pool (7LL8, 9, 12) contained the
selectable marker gene PGKneo (Figure 5.4 A), but lacked the FIX transgene (Figure 5.4
B and C). This result was not unexpected as the transfection was carried out with a 3 fold
molar excess of PGK-neo, a consequence of the large size of the FIX transgene. Analysis
of single cell clones showed =50% of clones contained both transgenes.
Southern blots hybridised with a 1.8kb probe derived from the BLG promoter showed
that fetuses and lambs derived from the cell clones PDFF2-12 (7LL10, 14, 15, 16) and
PDFF2-13 (7LL13) contained the FIX transgene (Figure 5.4 B, 7.5kb). The additional
bands in animals derived from either PDFF2-12 (=5.5kb) or PDFF2-13 (=4.2kb) could
indicate an incomplete copy of the transgene. Also visible is a =3kb band which represents
the endogenous BLG gene.
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Figure 5.4: Southern analysis of nuclear transfer derived sheep
A. Southern analysis of the uncloned pool of cells (PDFF2 pool) and two lambs derived
from them (7LL8, and 7LL9) assayed for the presence of pMIXl and PGKneo transgenes
by hybridisation with BLG promoter and neo probes.
B. Assay for the presence of the pMIXl transgene in lambs derived from the pool (PDFF2
pool, lambs 7LL8, 7LL12) and the transfected clone (PDFF2-12, lambs 7LL10, 7LL14 to
7LL16. Lamb 7LL13 was derived from clone PDFF2-13. PDFF5 cells were non transfected.
The positions of the transgenes and the endogenous BLG gene are indicated.
C. Southern analysis to determine the integrity of the pMIXl transgene in lambs derived
from the transfected clones (PDFF2-12, lambs 7LL10, 7LL14 to 7LL16 and PDFF2-13,
lamb 7LL13) by hybridisation with BLG/FIX cDNA probe. Sizes of fragments containing
the 8 coding exons are indicated (see also Table 5.7). DNA was digested with BamHI and
EcoRI (for number and sizes of fragments please see Figure 5.5).
The integrity of the FIX transgene (pMIXl) was assessed after hybridisation with a FIX
cDNA probe, which detected all eight coding exons (Figure 5.4 C). The intensity of the
hybridisation signal is determined by the extend of homology, i.e. the size of the exonic
sequence contained within the fragment (see Table 5.7). Figure 5.5 shows a schematic
map of pMIXI, indicated are the locations of the eight exons and the BamHI and EcoRI
restriction enzyme recognition sites used for the Southern analysis.
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Figure 5.5: Schematic map of pMIXl
Schematic representation of construct pMIXl. pMIXl comprises ~4.2kb of ovine 13-
lactoglobulin (BLG) promoter and 5' untranslated sequence; ~31.4kb of the human Factor
IX (FIX) gene from a Nhel site 12bp upstream of the translational start site to an engineered
Xhol site 12bp downstream of the translational stop signal; ~2.2kb of BLG 3' non-coding
sequence, polyadenylation signal and 3' flanking sequence cloned into pUC18. Ovine BLG
regions are indicated by red boxes, Factor IX exons are indicated by black bars. The pUC18
vector is indicated at either end of the construct.
Table 5.7: pMIXl fragment sizes after digestion with BamHI and
EcoRI and detection with a BLG/FIX cDNA probe.
Fragment




7.47 Promoter and exon 1 1.9
4.91 Exons 2, 3, 4 0.3
4.76 Exon 5 0.13
3.22 Exons 7, 8 0.45
2.69 Exon 6 0.2
2.95 Endogenous BLG 1.8
5.6. Recombinant Factor IX expression in nuclear transfer sheep.
Transgenic nuclear transfer derived sheep could not be bred in winter 1997/98 as they
were still immature. rFIX expression was therefore analysed in milk obtained from
induced lactation of 7LL13 and 7LL15 at 11 months of age. Twenty one days after
application of lactogenic hormones, the two transgenic FIX animals were milked twice
daily for a period of 2 weeks. This work was carried out by Tim King at the Large
Animal Husbandry Unit, Roslin Institute.
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7LL13 yielded 3-10ml per milking over a period of 12 days. Milk from 7LL15 was only
obtained on day one (l-2ml). The concentration of rFIX in milk samples was estimated by
ELISA using human plasma derived FIX as a standard. Fig. 5.6 shows the standard curve
for human plasma derived FIX standard and table 5.8 shows the results for 7LL13 (milk
from day 1-3) and 7LL15 (day 1 only). The amount of rFIX in milk from 7LL15
(5mg/ml) at day one of lactation was more then twice that of 7LL13 (2mg/ml), possibly
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Figure 5.6: ELISA: Standard curve
The human FIX standard (ERL) was diluted in milk. Dilutions ranging from 1000 to
15.625gg/ml were assayed in triplicates using a Dynex microtiter plate reader. Results were
analysed using ORIGIN computer program.
Table 5.8: Concentration of rFIX in induced lactation milk
Sheep I.D. Copy Nr. Day of sample Mean (ig/ml
7LL13 (Polly) =5 Day 1 2442.93
7LL13 (Polly) =5 Day 2 1463.58
7LL13 (Polly) =5 Day 3 2123.52
7LL15 (Molly) >10 Day 1 5043.72
Sigmoidal Fit
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The high concentration of rFIX obtained by ELISA assay was confirmed by Western blot
analysis (Fig. 5.7). and comparison with purified human standard. It is noteworthy that
expression levels obtained on the first day of induced lactation can be an overestimate and
generally drop slightly during the first week of lactation.
O
6
Figure 5.7: Western analysis of induced lactation milk from FIX
transgenic sheep derived by nuclear transfer
Samples were analysed on a reducing SDS-PAGE gel (18% Tris/glycine gel). Milk samples
had been diluted 1:500, amounts loaded are indicated above the lanes. Amount of human
FIX standard (ERL) loaded: 45ng.
Figure 5.7 shows that rFIX migrates slightly faster then the human standard, possibly due
to a difference in glycosylation. The same migration pattern was also observed in
transgenic mice and in transgenic sheep obtained by microinjection of the FIX cDNA
construct cFIXA3'SA (PPL, unpublished data). FIX is secreted as a single chain protein
of about 56kDa, however it migrates slower under SDS-PAGE gel electrophoresis than
would be predicted on the basis of its molecular weight because it has a high net negative
charge. Both the human standard and the recombinant protein show the presence of lower
molecular species which represent activated FIX molecules.
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Although only two nuclear transfer derived MIX 1 transgenic animals were obtained, both
expressed high levels of rFIX protein, compared to only two out of nine transgenic sheep
obtained by microinjection of the FIX cDNA construct cFIXA3'SA (maximum expression
level 1.2mg/ml; PPL, unpublished data).
5.7. Production of transgenic animals by nuclear transfer compared with
pronuclear microinjection
It has long been recognised that the gestation of large numbers of non transgenic embryos
represents a major source of inefficiency in large animal transgenesis (Bowen et al.,
1994). Cell mediated transgenesis has the advantage that transgene analysis is carried out
in vitro. All animals born are transgenic. The number of animals required for the
production of a single transgenic founder animal should therefore be reduced.
Since 1989, PPL has carried out a number of studies to generate transgenic sheep by
pronuclear microinjection. Data collected from this work provided a realistic measure of
the overall efficiency of pronuclear microinjection and allowed comparison with cell
mediated transgenesis (see Table 5.9).






Oocyte donors 982 68
Intermediate recipients Not applicable 14
Final recipients 1895 22




Total no. of lambs born 1286 6
Total no. of viable transgenic
lambs borna
56 5
Percentage of offspring transgenic 4.35% 100%
No. of sheep required for
production of 1 transgenic lamb
51.4 20.8
a: Viable lambs were defined as those alive at 1 week of age
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Table 5.9 shows that a total of 51.4 animals were necessary to produce one transgenic
lamb by pronuclear microinjection compared to 20.8 animals using nuclear transfer, a
factor of approximately 2.5. The most significant difference being in the number of final
recipients used. The embryo transfer efficiency from both methods is similar.
Because nuclear transfer allows the sex of transgenic animals to be predetermined, cell
mediated transgenesis offers a further two fold increase in efficiency over pronuclear
microinjection when the sex of the transgenic founder animal is critical. The primary
interest of PPL is the expression of human proteins in milk, which requires transgene
analysis in female animals.
5.8. Conclusions
Cell mediated transgenesis is based on successful in vitro manipulation of cells without
diminishing their developmental potential after nuclear transplantation. Therefore a careful
assessment of all cell types previously used in nuclear transfer was carried out. The choice
of fetal fibroblasts for the production of transgenic animals was based on the following
criteria:
1. Large numbers of cells were available at early passage for genetic manipulation.
2. Cells were readily transfectable.
3. Cells remained euploid over prolonged time in culture.
4. Acceptable nuclear transfer efficiency.
Because no ovine fetal fibroblast cells were available from animals with the appropriate
pathogen free status, it was essential to establish new cultures. One of these (PDFF2) was
then co-transfected with PGK-neo and the human FIX construct pMIXl. Two cloned
transfectants and a population of neomycin resistant cells were used as donors for nuclear
transfer to enucleated oocytes. Six transgenic animals were live born. Three produced
from cloned cells contained the FIX and neo transgenes, whereas three produced from the
uncloned population contained the marker gene only. Animals transgenic for the FIX
transgene produced high concentrations of the recombinant protein in their milk (5mg/ml),
exceeding any previously reported expression data.
Further characterisation of the rFIX protein will be carried out on natural lactation milk and
will include an in vitro clotting assay to determine bioactivity. Other vitamin K dependent
proteins have been successfully expressed in the mammary gland of transgenic animals,
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including mice (FVII and Protein C; PPL unpublished data), sheep (FVII and Protein C
PPL unpublished data), and pigs (Protein C, Velander et al, 1992). High concentration of
recombinant protein can result in incomplete y-carboxylation and reduced bioactivity.
Recombinant FIX expressed at concentrations of up to 5g/l may exhaust the y-
carboxylation capacity of the mammary gland, therefore the rFIX protein expressed in
Polly and Molly might not be fully bioactive. Natural lactation milk is expected in late
spring 1999.
The efficiency of nuclear transfer, expressed as the number of liveborn lambs obtained per
100 reconstructed embryos, varied from 0.89% (PDFF2-13) to 2.25% (PDFF2-12) for
transfected cell clones. This rate is similar to that for non-manipulated embryonic cells
(1.70%, SEC1) and fetal fibroblasts (1.35%, BLWF1) (see Chapter 4). Although the
small sample size does not allow firm conclusions to be drawn about the relative efficiency
of each treatment, these data provide evidence that fetal cells which have undergone
transfection, drug selection and single cell cloning are capable of supporting nuclear
transfer.
The number of live lambs was reduced by the high mortality rate (46%) observed, which
was almost certainly exacerbated by two instances of twin pregnancies in which the death
of one lamb in late gestation led to loss of both. The mortality rate for non twin
pregnancies was 28.6%, higher than that occurring after normal breeding (-8%), but
similar to that observed after nuclear transfer from embryo blastomeres (5-40%) (Kruip
and den Daas, 1997). The data do not therefore suggest any correlation between lamb
mortality and extended culture or genetic manipulation of the donor cells.
These results represent the first example of cell mediated transgenesis in a mammalian
species other than mouse, and provide an unequivocal demonstration that differentiated
cells can undergo genetic manipulation in culture and produce viable animals by nuclear
transfer. Furthermore, comparison of the present data and that obtained from previous
microinjection studies at PPL indicates that production of a single transgenic founder by
cell mediated transgenesis requires approximately 2.5 fold fewer animals than pronuclear
microinjection, largely by reducing the size of the recipient flock.
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Chapter 6
Cloning and targeting of the HPRT gene in ovine fetal fibroblasts
6.1. Background
The success of gene targeting in mice relies on the high frequency of homologous
recombination between exogenous DNA and cognate chromosomal sequences in ES
cells. Current literature would indicate that the ratio of homologous to non¬
homologous integration events in most somatic cells is lower than in ES cells.
However, compared to ES cells, far less work has been done using somatic cells lines
and even less using primary cells. It was therefore essential to establish the frequency
of homologous recombination in primary fetal fibroblasts which were nuclear transfer
competent. Similar to early experiments which established targeting in mouse ES cells
(Thomas and Capecchi, 1987), a model gene targeting experiment was designed to
inactivate the selectable endogenous HPRT gene. The aim was not to produce HPRT"
sheep, because of possible deleterious effects. HPRT deficiency in human causes
Lesch-Nyhan syndrome, although HPRT negative mice show no such symptoms
(Kuehn et al., 1987; Williamson, Hooper and Melton, 1992).
6.2. Cloning of ovine HPRT sequences
The strategy for ovine HPRT targeting was to delete important exonic sequences and
replace these with a selectable marker gene. Details of the design of the targeting vector
are shown in Fig. 6.1. Although the ovine HPRT gene has been localised to the X-
chromosome (Echard et al., 1994), neither the gene nor cDNA had been cloned. The
first step therefore was to identify and clone portions of the ovine HPRT gene from
isogenic DNA derived from the male fibroblast cells PDFF5. This would provide 5'
and 3' homologous regions for the production of a replacement targeting vector.
Cloning of the HPRT gene could be achieved by generating a library of genomic
fragments in phage A,, then isolating ovine HPRT sequences using mouse or human
cDNA probes. However, it was considered that this approach could be complicated by
the presence of HPRT pseudogenes which have been demonstrated in mouse and
human. An alternative was long range PCR (Randolph et al., 1996) using primers
based on sequences conserved between HPRT genes from different species. This
strategy is supported by the fact that the gene structure of the human and mouse HPRT
genes are almost identical and that the coding sequence from mouse (Konecki et al.,
1982), rat (Jansen et al., 1991), pig (Mansfield, 1996), hamster (Konecki et al.,
1982), and human (Jolly et al., 1983) are known to be highly conserved.
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Figure 6.1: HPRT cloning strategy and PCR amplification of ovine
sequences
Schematic diagram of the human and mouse HPRT gene, indicated are the positions of
exons and sizes of introns. The two cloning strategies for the ovine HPRT gene are
outlined in correlation to the mouse HPRT gene. Also shown are the PCR amplification
products obtained from either mouse or ovine DNA and analysed on 1% agarose gel.
Primer sequences are given in Material and Methods,
u.d., undigested DNA; Spel, DNA digested with Spel.
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The original PCR and cloning strategy is shown in Fig. 6.1 (Strategy 1). The two
ovine PCR products were: an estimated 6-12kb fragment spanning from exon 3 to
exon 4, and a 4-5kb fragment spanning from exon 6 to exon 8. It was intended that
these two fragments should provide the 5' and 3' homologous regions for a targeting
vector. The function of the targeted gene would be interrupted by the deletion of the
5th and parts of the 4th and 6th exons and their replacement with a selectable neo
marker.
The sequence of the primer pairs used for amplification of ovine sequences was
deduced from regions of the HPRT coding sequence conserved between human, rat,
mouse and hamster. Long range PCR was performed on DNA from mouse embryos,
and DNA from the ovine fetus from which the PDFF5 culture was established. Using
mouse DNA as a template, the 6.5kb exon 3 to 4 fragment and the 4.3kb exon 6 to 8
fragment both amplified efficiently. Using sheep DNA exon 3/4 primers repeatedly
amplified a weak 8.5kb fragment (Figure 6.1, bottom right). Exon 6/8 primers failed
to amplify ovine HPRT sequences. A new set of primers was therefore designed to
amplify a region spanning from exon 2 to exon 3, which would then be used as the 5'
homologous region of the targeting vector while exon 3 to 4 sequences would provide
3' homology (Figure 6.1, Strategy 2). Figure 6.1 (bottom left) shows successful
amplification of a =1.6kb fragment in sheep and 2.9kb in control mouse DNA
comprising of exon 2 to 3 sequences.
Cloning exon 2 to 3: The PCR primers contained EcoRI and BamHI restriction
sites. The amplified 1.6kb PCR fragment contained an additional internal EcoRI site
(see Fig. 6.4). After partial digestion with EcoRI and complete digestion with BamHI
it was cloned into the EcoRI and BamHI sites of Bluescript. Sequence analysis
confirmed that it was HPRT (Fig. 6.3 and Table 6.1).
Cloning exon 3 to 4: The PCR primers contained BamHI restriction sites. The
attempt to clone the 8.5kb PCR fragment either as a BamHI fragment or directly into
the PCR cloning vector pGEM-T failed repeatedly. Restriction enzyme mapping of the
PCR product indicated that this fragment contained two internal Spel sites releasing a
7.5kb fragment which was cloned into the Spel site of Bluescript (see Fig. 6.2).
Orientation of the Spel insert was determined by restriction enzyme analysis and DNA
sequencing.
Although the subcloned fragment contained no exon, sequence analysis showed a
stretch of homology (91.8%) with sequences from the 3rd intron of the human HPRT
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gene located about 900bp 5' of exon 4. Search of the entire EMBL data base produced
only a single match, again intron 3 of the human HPRT gene. This ruled out the
possibility that sequence homology was due to a repetitive element. To confirm this
result, PCR primer pairs were designed to amplify sequences spanning from exon 3
into intron 3 and from intron 3 into exon 4 (Fig. 6.2). Sequence analysis of the
subcloned PCR fragments, (designated as Exon 3 and Exon 4), confirmed that
sequences were derived from exon 3 and 4 of the HPRT gene (Fig. 6.3 and Table
6.1).
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Figure 6.2: Ovine HPRT exon 3 to 4
Shown is the amplified PCR product spanning from exon 3 to exon 4 of the ovine HPRT
gene. Because efforts to clone the 8.5kb BamHI fragment failed, the 7.5kb Spel
fragment was subcloned into the plasmid vector Bluescript and partial DNA sequence was
obtained using "universal" and "reverse" primers. From this sequence PCR primers
were deduced for amplification of the "exon 3" and "exon 4" fragments. Their
analysis on a 1% agarose gel is also shown. Both fragments were subcloned into the
plasmid vector Bluescript and partial DNA sequence was obtained.
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Ovine ttatgctgaggatttggaaagggtgttcattcctcatggactaattatggacaggtiagtatgatctcaagttgg
111111111111111111111111111 1111111111111111111111111111 1111 11111 II II
Human ttatgctgaggatttggaaagggtgtttattcctcatggactaattatggacaggtaagtaagatcttaaaatga
*
14840 "14850 "14860 "14870 "14880 "14890 "14900
Exon 2 Intron 2
Ovine aataatataatttaatttttattaaataattgattttaatttntgtaggaccgaacgactggctcgagatgtgatgaaggagatgg
1111 II I III 11111111 11111111 III 11111111 11111 II 11111111111111II11111111
Human tttaatgtatgaaactttctattaaattcctgatttta-tttctgtaggactgaacgtcttgctcgagatgtgatgaaggagatgg












Exon 3 111 N 1111111111111111111II11111M II111111111 1111111 it 11111111111111111111
cttgctcgagatgtgatgaaggagatgggaggccatcacattgtagccctctgtgtgctcaaggggggctataaa
"16620 "16630 "16640 "16650 "16660 "16670 "16680
ttctttgccgacctgttggattacatcaaagcactgaacagaaatagtgacagatccattcctatgactgtagattttatcanactgaan





*16700 *16710 *16720 *16730 *16740 *16750 *16760 *16770
AGCTACTGTGTAAGTGTATTTCATACATGTTTAAAATAAACATGGCATTTTTATGATATGCATCCTATATGTATCAGCTTCAACTGATTG
I I I I I I I I I I III I I I I I III III II I I I III I I I II III
AGCTATTGTGTGAGTATATTTAATATATGATTCTTTTTAGTGGCAACAGTAGGTTTTCTTATATTTTCTTTGAATCTCTGCAAACCATAC








i i i i i i i i i i i i i i i i i i i i i i i ii i i i i ii i i i i i i i i i i i i i i i i i i i i i i i i i i i i iii iii i i i i i i i i i i ii i
tacaatttgcttgactcatgggaatcgtacagggccagaaccagacacctgtcatgctaataacttccctcacaattcagaaatcactgt
"27470 "27480 "27490 "27500 "27510 "27520 "27530 "27540 "27550
gactgaagatgggtggctgctgtaatattgcccattcaaaaatgcgtgtgccccattttt-aggactcttcagagcatcaaatcagtagt
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
gattgaagatgggtggctgttataatactacccacttaaaaatggatgtaacccattttttaggactcttaaaaacatcaaatcagtaat
"27560 "27570 "27580 "27590 "27600 "27610 "27620 "27630 "27640
Ovine ggccaattagaacttcttaatttt
1111 11111 1111 11111111 Intron 3
Human ggccgattaggactttttaatttt
Ovine ttttttttttaaattagaacgaccagtcaacaggtgacataaaagtaattggtggagatgatctctcaactttaactgga
I I I I I 11 I I I ii 11111 11111111111111 111111111111111111111111111111111111111111111
Human tttttttttttaactagaatgaccagtcaacaggggacataaaagtaattggtggagatgatctctcaactttaactgga
"27880 "27890 "27900 "27910 "27920 "27930 "27940 "27950
Intron 3 Exon 4
Figure 6.3: Sequence comparison of ovine and human HPRT
Comparison of ovine and human HPRT sequences was carried out using the DNASTAR
Align program. Bases in red indicate mismatches, shadowed areas the exon sequences,
and the arrows indicate positions of primers used for PCR amplification of the ovine
HPRT gene.
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14822-14888 66 92.5 0
16575-16640 65 86.8 1
16613-16788 175 94.9 0
27467-27670 203 84.4 1
27910-27954 44 100 0




6.3. Construction of ovine HPRT targeting vector
The cloning strategy is outlined in Figure 6.4, the individual cloning steps are outlined
below.
1. The 1.5kb EcoRI fragment containing parts of the ovine HPRT exon 2 and intron 2
was cloned into the EcoRI site of PGK-neo (Bluescript). Orientation of the insert was
determined by restriction enzyme analysis.
2. The 3.2kb Xhol/Clal fragment containing the ovine HPRT exon 2/intron 2
sequence and PGK-neo gene was then cloned into the Xhol/Clal site of o.HPRTint.3
giving rise to PFOHN (Poll Dorset fibroblast, ovine HPRT, neo). This targeting
vector was designed to inactivate the ovine HPRT gene by deleting exon 3 and
replacing it with PGK-neo.
Figure 6.4 (next page): Schematic diagram of the construction of the ovine HPRT
targeting vector PFOHN. Restriction sites indicated are those used for cloning or present
in the polylinker of the plasmid vectors. Ovine HPRT sequences are marked in blue:
exon sequences in dark blue; PGKneo in pink.







































6.4. Targeting of the endogenous HPRT gene in PDFF5 cells.
The male PDFF5 cells have been shown to be nuclear transfer competent (Chapter 5).
The frequency of homologous recombination in these primary fetal fibroblasts was to
be determined by targeted inactivation of the HPRT gene. Cells transfected with the
PFOHN targeting vector were first selected for PGK-neo expression for 5-7 days to
allow elimination of non transfected cells and for the HPRT protein in correctly
targeted cells to decay. Loss of HPRT was then determined by 6-TG selection.
Because little is known about the influence the DNA delivery method has on gene
targeting efficiency both electroporation and LipofectAMINE were used. For no clearly
defined reason, most gene targeting experiments in mouse ES cells employ
electroporation as a method of DNA transfer, but LipofectAMINE gives higher
transfection efficiencies in somatic cells. In a preliminary experiment the optimal
transfection conditions for both methods were determined.
A range of electroporation parameters for transfection of PDFF5 cells, similar to those
applied for determination of electroporation efficiency of TNT4 cells (Chapter 3), were
examined by transient transfections with the SV40 LacZ reporter gene. It was
established that PDFF5 cells are readily transferable ( 5%) at 350V, 500pF, 150pg
DNA/107 cells.
Incubation time for DNA-LipofectAMINE complex
6hrs 16hrs 24hrs
Added at: a.m. p.m. a.m.
Figure 6.5: (3-galactosidase staining of PDFF5 transfectants
2xl05 cells per well were transfected with 1.5pg of CMV-LacZ using lOpl
LipofectAMINE and incubated for the times indicated above the wells. After 48hrs ceils
were stained for P-galactosidase activity.
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LipofectAMINE transfection had so far been the most efficient method to introduce
DNA into both embryonic and fetal ovine cells. Under optimised conditions >75% of
PDFF5 cells could be transfected. This is visualised in Figure 6.5 (middle panel) in a
transient experiment using the CMV-LacZ reporter gene. During this experiment the
exposure time of cells to the DNA-LipofectAMINE complex varied from 6 to 24 hrs.
Transfection efficiency was measured by the number of stained cells. The 16hr
exposure gave by far the greatest number of positive cells (>75%). It is not assumed
that the result is purely a function of exposure time, as repeat experiments gave lower
transfection rates. It is more likely that the cell-cycle stage was optimal for efficient
uptake of DNA. A more systematic analysis is part of future experiments.
Targeting was attempted both by introduction of DNA via electroporation and by
lipofection. 2xl07 PDFF5 cells were electroporated with 150|lg of linearised PFOHN
DNA. After selection in 0.6 mg/ml ofG418 for 5 to 7 days selection was switched to
35|ig/ml 6-TG for 2 weeks. No 6-TG resistant colonies were obtained from a total of
1000 transfected neor clones. The delay of 5-7 days prior to 6-TG selection was to
allown degradation of the ovine HPRT protein, based on the assumption that its half
life was similar to the mouse HPRT protein.
Using LipofectAMINE no 6-TG resistant colonies were obtained from a total of 3500
transfected neor clones.
6.5. Conclusions
4500 neor transfectants were analysed for inactivation of the endogenous HPRT gene
using 6-TG selection. No resistant colonies were obtained. These results may indicate
that homologous recombination events in ovine primary fibroblasts, in particular in
PDFF5 cells, are rare and hence gene targeting events, especially for non-selectable
loci might be difficult to identify. The ratio of homologous to non-homologous
integration for other somatic cell types range from 1 in 50 to 1 in 10,000 (see Table 1,
chapter 1). It is therefore possible that the number of transfectants analysed was not
sufficient to detect a targeting event, and further experiments are required.
Other formal possibilities for the low targeting efficiency are:
1. By far the largest number of colonies screened were obtained by lipofection, and it
is unknown what influence the DNA delivery method has on targeting efficiency.
2. The regions of homology present in the targeting vector were obtained by PCR
amplification and could therefore contain single base differences to the target locus,
thus reducing targeting efficiency.
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3. Different loci have markedly different targeting efficiencies and it is therefore
possible that homologous recombination frequency at the ovine HPRT locus is low.
Most significant though were results obtained from David Melton's group (ICMB,
Edinburgh University), which questioned the suitability of HPRT as a model for gene
targeting in sheep. His aim was to isolate spontaneous HPRT mutants from the ovine
PDFF5 cells. 1.09 x 108 cells were plated in 6-TG and no colonies were obtained.
This was a unique result, as all previously tested cell types showed spontaneous
HPRT deficiency in about 1 in 105 cells (David Melton, personal communication). His
findings indicated uncertainty regarding the purine metabolism/HPRT pathway in
sheep. As 6-TG has never been used for selection of ovine cells it was also
conceivable that it has a non specific toxic effect in sheep fibroblast. Until these
questions are resolved, targeting of the HPRT locus was discontinued.
Ongoing and future experiments include production of an isogenic X library, restoring
activity of a mutated selectable marker gene (Gfp-neo fusion gene), which was stably
integrated into ovine fetal fibroblast cells and targeting of endogenous genes including




Work presented here showed that nuclear transfer animals can be derived from a
number of differentiated cell types, including embryonic, fetal and adult cells and that
some, but not all of these cells can be employed for cell mediated transgenesis.
The lamb 6LL3 (Dolly) is the first mammal to be derived from an adult cell. Not only
did it prove that chromosomal changes occurring during differentiation are reversible,
it also offers a unique possibility to study the possible persistence of epigenetic
changes, in particular ageing related changes such as oxidative damage and telomere
shortening. Analysis of telomere length has recently been carried out (Shiels et al.,
1999).
As Dolly was the only example of a cloned animal derived from an adult cell, questions
were raised both about the significance and veracity of the result. That these doubts
were unfounded, was proven both by extensive microsatellite (Ashworth et al., 1998)
and DNA fingerprint analysis (Signer et al, 1998). More significantly a report by
Wakayama et al. (1998) has now shown, that fertile mice can be obtained by nuclear
transplantation using cumulus donor nuclei derived from adult animals. The
importance of this report also lies in the improvement of the nuclear transfer technique,
overcoming for the first time the difficulties associated with cloning in the mouse, for
example the fragility of the oocyte. Mice -having a short generation time- provide an
ideal model system to investigate factors influencing nuclear transfer efficiency. The
experiments in mice and sheep have now also been repeated in the cow, where cloned
calves were obtained from oviduct or cumulus cells (Kato et al., 1998), from
granulosa cells (Wells et al., 1999), from ear cells (Vignon et al., 1999), and
mammary gland cells (Zakhartchenko et al., 1999). Furthermore birth of nuclear
transfer calves is expected for April 1999 derived from mammary cells present in early
bovine milk (Nature Biotechnology 1998, Business and Regulatory News Brief).
Nuclear transfer technology is clearly still in the early stages of development and
several problems remain to be addressed. In particular the incidence of perinatal
mortality and the lack of spontaneous parturition (Chapter 5; Wells et al., 1997; Wells,
Misica and Tervit, 1998; Kato et al., 1998). Many types of manipulation of
preimplantation embryos other than nuclear transfer have been reported to increase fetal
morbidity and mortality e.g., in vitro culture, IVM/IVF, asynchronous embryo transfer
and progesterone treatment of the mother (Kruip and en Dass, 1997; Walker,
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Hartwich and Seamark, 1996). An increased understanding of the interaction between
the transplanted nucleus and the host cytoplasm, the relationship between the early
embryo and the maternal environment and improved culture systems will increase the
success of embryo production and manipulation in vitro. Factors already known to
affect late fetal development include the presence of serum in embryo culture medium
(Kruip, and en Dass, 1997; Walker, Hartwich and Seamark, 1996), and imprinting of
the early embryonic genome (Reik et al., 1993; Jaenisch, 1997; Romer et al., 1997).
This report is also the first example of cell mediated transgenesis in a mammalian
species other than mouse, and provides an unequivocal demonstration that
differentiated cells can undergo genetic manipulation in culture and produce viable
animals following nuclear transfer. This work has now been repeated by Cibelli et al.
(1998), producing 3 cloned transgenic calves from non-quiescent fetal fibroblasts,
while the work reported here and by others (Wakayama et al., 1998; Kato et al., 1998;
Wells et al., 1999; Vignon et al., 1999; Zakhartchenko et al., 1999) employed nuclei in
G0. Although first indications confirm that nuclei at the G0 stage produce nuclear
transfer embryos that are more developmentaly competent (Galat et al., 1999; Hill et
al., 1999), further experiments are required to determine the importance of quiescence
to the success of nuclear transfer.
Although still in its infancy, the use of somatic cell donors for nuclear transfer in
livestock offers many advantages over pronuclear microinjection as a means of
generating transgenic animals. Perhaps the most significant of these is a large reduction
in the number of experimental animals required, which is desirable for both ethical and
commercial reasons.
It has long been recognised that the gestation of large numbers of non transgenic
embryos represents a major source of inefficiency in large animal transgenesis (Wall,
1992). Several schemes have been devised to address this problem by identifying
transgenic embryos before embryo transfer, either by detection of the transgene in
embryo biopsies by PCR (Bowen et al., 1994), or by coexpression of a marker gene
(Takada et al., 1997; Thompson et al., 1995). However these methods, with the
possible exception of that of Takada et al. (1997), are restricted by the persistence of
unintegrated DNA during the short time embryos can be cultured in vitro before
embryo transfer. Cell mediated transgenesis circumvents this problem altogether. Cells
transfected in vitro can be analysed extensively in the laboratory before any effort is
devoted to large animals. This will be especially useful when producing transgenic
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animals with very large transgenes such as YACs, where microinjection often fails to
produce animals with a complete transgene.
Delayed integration of microinjected DNA into the embryo genome often results in
mosaic founder animals. The reduced rate of transgene transmission resulting from
germ line mosaicism can hinder or prevent the establishment of transgenic lines from
potentially valuable founder animals. In contrast, animals produced by nuclear transfer
from an in vitro manipulated donor cell are entirely transgenic.
Because nuclear transfer allows the sex of transgenic animals to be predetermined, cell
mediated transgenesis offers a further two fold increase in efficiency over pronuclear
microinjection when the sex of the transgenic founder animal is critical, for example if
the primary interest is the expression of human proteins in milk, which requires
transgene analysis in female animals. However expansion of a flock is far easier from
males. These conflicting requirements result in a delay in flock expansion where the
founder is female, and breeding of animals in which transgene expression is unknown
where the founder is male. Transgene expression in vitro, in nuclear transfer
competent cells, might even allow prediction of transgene expression in vivo and
remove a further uncertainty in transgenic production.
In principle, cell mediated transgenesis allows the process of founder analysis and
flock expansion to be significantly streamlined. The founder generation can be entirely
female. Sheep carrying different random integrations of the transgene can be produced
by nuclear transfer from independently transfected cell clones and milk analysed at an
early stage. Once a suitable clone has been identified, the corresponding stock of cells
can be used to generate an "instant flock" by further nuclear transfer. Animals within
such a flock could be superior to those produced by conventional breeding as a source
of proteins for human therapy, because genetic identity would contribute to the
consistency of the medicinal product. Although only two animals were generated from
two independent clones, these serve to illustrate the scheme. Animals 7LL13 and
7LL15 were induced to lactate at ~11 months of age, at which time the FIX levels in
milk were determined. Both animals expressed rFIX at levels up to 100 fold higher
than any previously reported (Yule et ai, 1995; Kurachi et al., 1995) with a total
amount of recombinant protein of up to 5g/l. It is presumed that this result is a
consequence of using a large genomic FIX construct, while all previous investigators
employed cDNA based vectors.
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It is anticipated that cell mediated transgenesis will be widely applicable. The
procedures of transfection, drug selection and growth from single cell clones are
essentially the same as those required for gene targeting. The results presented here,
coupled with previous demonstrations of homologous recombination in several
somatic cell types (please see Chapter 1, Table 1), now provide the first realistic
prospect of targeted genetic manipulation in a livestock species. The power of gene
targeting has been amply demonstrated in mice. Extension of this technique to large




8.1. Nucleic acid methods
8.1.1. Isolation of DNA
8.1.1.1. From blood
DNA was extracted using the Nucleon biosciences kit as recommended by the supplier.
1. 4.5ml of lOmM Tris pH 8, 0.32M sucrose, 5mM MgCl2, 1% Triton X-100 was
added to 1.5ml of blood collected in an EDTA coated vial, and centrifuged for 5 min,
at 3,000rpm.
2. Cell pellet was resuspended in 350p,l 0.4M Tris pH 8, 60mM EDTA, 150mM NaCl,
1% SDS and incubated at 65°C for 30 min, after which a lOOpil of sodium perchlorate
was added for deproteinisation.
3. The sample was extracted with 600(il of ice cold chloroform, 150|il of "Nucleon"
silica resin was added, followed by centrifugation for 5min. at 4000rpm.
4. Supernatant was collected, DNA was ethanol precipitated and resuspended in 50fil of
TE.
8.1.1.2. From tissue culture cells or tissue samples
1. Cells or small pieces of tissue samples were incubated in lOmM NaCl, 25mM EDTA
pH 8, 1% SDS, 100-200|lg/ml of proteinase K, at 65°C for l-16hrs (depending on
tissue type and sample size).
2. After 2 phenol extractions DNA was ethanol precipitated and resuspended in TE.
8.1.1.3. From small numbers of cells for use in PCR reactions
1. Cells were collected by centrifugation, resuspended in 50-100|il of 50mM
KC1, 1.5mM MgCl2, lOmM Tris pH 8.0, 0.5% NP40, 0.5% Tween, 100|ig/ml
proteinase K.
2. Incubated for 20-60 min. at 65°C.
3. Proteinase K was heat inactivated by incubation for 10 min, at 95°C.
4. Typically 4-10(ll was used for PCR reactions.
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8.1.1.4. From bacteria: mini prep
1. l-2ml of Luria broth or 2YT (50- lOOpg/ml ampicillin) was inoculated with bacteria
and incubated overnight at 37°C.
2. After centrifugation the pellet was resuspended in 100)il 50mM glucose, 25mM Tris
PH 8, lOmM EDTA, 5mg/ml lysozyme, incubated for 5min, at r.t..
3. 150(ll 1% SDS, 0.2M NaOH was added.
4. After 5 min of incubation at r.t. 200|il of cold 3M potassium acetate pH 4.9 (pH
adjusted with acetic acid) was added, incubated for 5 min on ice and centrifuged for 5
min, 16,000rpm.
5. Supernatant was extracted once with phenol, DNA was ethanol precipitated and
resuspended in 20-100p.l TE.
8.1.1.5. From bacteria transformed with pMIXl
This method was employed for isolation of pMIXl DNA. Due to the large size of the
plasmid >40kb plasmid yields were generally low and multiple small cultures gave
generally the best yields.
1. 6x100ml of terrific broth, 200|_tg/ml ampicillin was inoculated with a single bacterial
colony and grown for 16-24hrs, at 37°C.
2. After centrifugation each pellet was resuspended in 2ml 50mM glucose, 25mM Tris
PH 8, lOmM EDTA, 5mg/ml lysozyme, and incubated for 5min, r.t..
3. 4ml 1% SDS, 0.2M NaOH was added.
4. After 5min of incubation 3ml of cold 3M potassium acetate pH 4.9 (pH adjusted with
acetic acid) was added, incubated for 5min on ice and centrifuged for 20 min,
3,500rpm.
5. Supernatant was extracted once with phenol, DNA was ethanol precipitated and
resuspended in 500p.l TE.
6. Quantity and quality of the six plasmid preparations were analysed by restriction
enzyme digestion (see Figure 8.1). Due to the large size of the pMIXl construct
(41.5kb) plasmid yields were often low. Only samples which contained a reasonable
amount of DNA were pooled for further purification (see Fig. 8.1, sample 3, 4, 5).
7. 1.7g CsCl and 120j_l1 EtBr was added to 1.5ml of DNA solution and transferred into
11x32mm quick-seal tubes (TLA-100.2 Beckmann rotor)
8. Centrifuged for 16hrs, 80,000rpm, at r.t..
9. Plasmid band was withdrawn with the help of a syringe.
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10. DNA was dialysed against TE for 2hrs, at 4°C, then phenol extracted, ethanol









Figure 8.1: Isolation of pMIXl plasmid DNA
BamHI digest of pMIXl DNA. DNA was isolated as described above and a 100th of each
sample was analysed on a 1% agarose gel.
8.1.1.6. From bacteria: Maxi prep
1. Bacterial colony was transferred to 200-500ml of terrific broth, lOOpg/ml ampicillin
and grown for 16-24hrs, at 37°C.
2. After centrifugation cell pellet was resuspended in 3ml 15% sucrose, 50mM EDTA,
50mM Tris pH 8.0, 5mg/ml lysozyme, and incubated for 15min on ice.
3. 6ml 62.5mM EDTA, 50mM Tris pH 8.0, 0.1% Trition was added, mixed gently and
incubated on ice for 30min.
4. Centrifuged 45min, 18000rpm.
5. Supernatant was decanted, its volume adjusted to 10ml. 9.5g CsCl and 1ml EtBr
was added and transferred to quickseal tube (NVT 65 rotor, Beckmann)
6. Centrifuged at 55,000rpm for 16hrs, at r.t..
7. Plasmid band was withdrawn using a syringe.
8. DNA was dialysed against TE for 2hrs, at 4°C, then phenol extracted, ethanol
precipitated and resuspended in TE.
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8.1.1.7. From phage lambda.
1. Single phage plaques were isolated and incubated in phage buffer (lOmM Tris pH
7.4, 20mM NaCl, 20mM MgCl2), resulting in =Txl09 pfu/ml.
2. For the plate lysate = 1 (),000pfu were absorbed to 1ml of LE392 bacteria (these had
been resuspended in lOmM magnesium sulphate, O.D.600 = 0.5) for 20min, 37°C.
3. 7ml 0.8% agarose in L broth, ImM MgCl2, lOmM MgS04 was added and spread
onto fresh L agarose plates, and incubated overnight.
4. Plates were cooled, 12-15ml of phage buffer and 1-2 drops of chloroform was added,
followed by incubation for 2-16hrs, 4°C.
5. Phage buffer was collected, l|lg/ml of RNase and DNase was added and incubated
for 30min, at 37°C.
6. Centrifuged for 25min, 7000rpm.
7. Supernatant was collected and centrifuged at 30,000rpm for 2hrs, at 4°C in a swing-
out rotor (SW41, Beckmann).
8. Pellet was resuspended in 0.5ml of phage buffer, insoluble particles removed by
centrifugation and DNA extracted by addition of EDTA (final concentration 20mM),
SDS (final concentration 0.5%), proteinase K (final concentration 50|lg/ml) and
incubation for lhr, at 65°C, followed by phenol extraction.
9. DNA was then dialysed against TE, for 16-24hrs, at 4°C.
10. Collected phage DNA could either be used directly or was concentrated following
ethanol precipitation.
8.1.2. Preparation and transformation of competent E-coli (DH5a, XL1)
The methods listed below achieved transformation efficiencies of >107cfu/pg of input
plasmid DNA.
8.1.2.1. Chemical method
1. Overnight culture was diluted 1:100 in L broth, and grown to O.D.600 = 0.4-0.6.
2. Chilled, centrifuged and resuspended in 1/4 volume lOOmM RbCl, 50mM MnCl2,
30mM K Acetate, lOmM CaCl2, 15% Glycerol, and incubated for l-2hrs on ice.
3. Centrifuged and resuspended in 1/40 of original volume lOmM MOPS pH 7.0,
lOmM RbCl, 75mM CaCl2, 15% Glycerol.
4. 200|il aliquots were frozen in liquid nitrogen and then stored at -70°C.
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5. For bacterial transformation 20- 100|ll of competent and l-5|il of DNA or ligation
mix was added.
6. After incubation for 30min on ice, cells were heat shocked 45sec, at 42°C, and then
placed on ice for 2min.
7. l-2ml of L Broth was added and cells were incubated for 20min, at 37°C before
plating on LB plates containing 100|ig/ml ampicillin and if required X-Gal and IPTG
(see buffers below).
8.1.2.2. Electroporation method
The method used is essentialy as described by Wu, 1993.
1. 500ml of 2YT medium was inoculated with 2.5ml of an overnight culture of DH5a
bacteria. These were grown to O.D.600 of 0.6, and then cooled on ice for 10-15min.
2. Cells were pelleted and resuspended in 250ml of ice cold 1M HEPES pH 7 and
harvested by centrifugation.
3. Cells were resuspended in 20ml of ice cold 10% (V/V) glycerol and harvested again
by centrifugation.
4. Cells were resuspended in an equal volume of ice cold 10% (V/V) glycerol and lOOpl
aliquots were stored frozen.
5. Cells were thawed on ice, DNA added to 50|ll of competent cells and transferred to
a chilled cuvette (0.1cm).
6. Cuvette was placed into the chilled electroporation chamber and pulsed once (2000V,
200D, 25|EF).
7. 1ml of SOC medium was added, cells were transferred to 15ml tube and incubated for
30min-lhr, 37°C before plating on LB plates containing 100|ig/ml ampicillin and if
required X-Gal and IPTG (see buffers below).
8.1.3. Recombinant DNA manipulation
Enzymes were supplied by Bohringer or New England Biolabs and used as recommended
by the supplier. Bacterial vectors had previously been purchased from Promega (pGEM-
T), Stratagene (Bluescript) and New England Biolabs (pUC18).
8.1.3.1. Polymerase chain reaction (PCR)
Primers were designed using the OLIGO 4 computer program. PCR reactions were carried
out essentially as recommended by the supplier of the thermostable Taq and Expand™
DNA polymerases (Bohringer). The latter was used for long range PCR and is composed
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of both thermostable Taq and Pwo DNA polymerases. Reaction conditions were optimised
by varying either annealing temperature, buffer composition (e.g. MgCl2 concentration) or
cycle conditions. Genomic DNA was diluted to ~50ng/pl either in H20 or in 50mM KC1,
1.5mM MgCl2, lOmM Tris pH 8.0, 0.5% NP40, 0.5% Tween, the latter often facilitated a
more efficient PCR reaction. Primer sequences and optimised PCR conditions are given in
the relevant sections (see below).
8.1.3.1.1. PCR based method for ovine sex determination
Primers employed had previously been described for amplification of SRY and bovine zfx
sequences (Griffiths, 1993; Kirkpatrick, 1993) and are shown below. PCR conditions





1. PCR reactions were carried out in a total volume of 50pl, containing 5(0.1 lOx PCR
reaction buffer (Bohringer, 1.5mM MgCI2), 2.5pi of each primer Rg4 and 7 (Primer
stock: 20pMolar), 0.8pi of each primer zfx5' and 3' (Primer stock: 20pMolar) and
~0. lpg of DNA or 5-10pl of cell lysate (see isolation of DNA from small numbers of
cells for use in PCR reactions).
2. After incubation at 95°C, for 5min, reaction was cooled to 80°C and 8pl dNTP
(final concentration 0.2mM), 0.5pl Taq DNA polymerase (Bohringer) were added,
followed by 35 cycles of 94°C, 30sec; 55°C, 30sec and 72°C, 45sec, extension was
completed by final incubation at 72°C, 5min.
3. A 5pl aliquot of the PCR reaction was analysed on a 2% agarose gel (1:1 mix of
agarose and Nusieve agarose).
8.1.3.1.2. PCR conditions for microsatellite analysis
Microsatellite analysis was carried out as described by Buchanan et al. (1993). The
primers and PCR conditions used are listed below.
Primer FCB 11 (5') GCA AGC AGG TTC TTT ACC ACT AGC ACC
Primer FCB 11 (3') GGC CTG AAC TCA CAA GTT GAT ATA TCT ATC AC
Primer FCB 128 (5') ATT AAA GCA TCT TCT CTT TAT TTC CTC GC
Primer FCB 128 (3') CAG CTG AGC AAC TAA GAC ATA CAT GCG
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Primer FCB 304 (5') CCC TAG GAG CTT TCA ATA AAG AAT CGGP
Primer FCB 304 (3') CGC TGC TGT CAA CTG GGT CAG GG
Primer MAF 33 (5') GAT CTT TGT TTC AAT CTA TTC CAA TTT C
Primer MAF 33 (3') GAT CAT CTG AGT GTG AGT ATA TAC AG
Primer MAF 209 (5') TCA TGC ACT TAA GTA TGT AGG ATG CTG
Primer MAF 209 (3') GAT CAC AAA AAG TTG GAT ACA ACC GTG G
PCR reactions were carried out in a total volume of 20pl, containing 2pl lOxPCR reaction
buffer (lOOmM Tris pH 8.3, 15mM MgCl2, 500mM KC1), 2pl of both 5' and 3' primer
(Primer stock: 3.33pMolar) and ~0.1|ig of DNA. After incubation at 95°C, 5min, reaction
was cooled to 80°C and 2pl dNTP (final concentration 0.125mM), 0.25pl Taq (Bohringer)
were added, followed by 10 cycles of 94°C, 30sec; 63°C, 45sec and 23 cycles of 90°C,
30sec; 63°c, 45sec. For primer pair MAF33 the annealing/extension temperature was
lowered from 63°C to 59°C. The PCR products were analysed on 4% Metaphor agarose
gels.
8.1.3.1.3. PCR detection of SV40T in TNT4 transfectants
Primers designed to amplify a 516bp fragment of the SV40T are shown below.
Primer SV40T 5' GGGGAGTCCAGAGTTGCCTTCA
SV40T 3' CTCCCCACCATCTTCATTTTTATC
1. PCR reactions were carried out in a total volume of 50pl, containing 5pl lOx PCR
reaction buffer (lOOmM Tris pH 8.3, 15mM MgCl2, 500mM KC1), 2.5pl of each
primer (primer stock: 20pMolar) and 5-10|ll of cell lysate (see isolation ofDNA from
small numbers of cells for use in PCR reactions).
2. After incubation at 95°C, 5min, reaction was cooled to 80°C and 8pl dNTP (final
concentration 0.2mM), 0.5pl Taq DNA polymerase (Bohringer) were added,
followed by 35 cycles of 94°C, 30sec; 58°C, 30sec and 72°C, 60sec, extension was
completed by final incubation at 72°C, lOmin.
3. 5-10|il aliquot of the PCR reaction was analysed on a 1.5% agarose gel.
8.1.3.1.4. Isolation of ovine HPRT sequences by long range PCR
Cloning of portions of the ovine HPRT gene by long range PCR is described in Chapter
6. Listed below are the PCR primer pairs and conditions employed for the amplification of
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ovine HPRT sequences. Cloning of the amplified product was either attempted directly























Amplification of ovine sequences spanning from exon 2 to 3 and 6 to 8
1. PCR reactions were carried out in a total volume of 50pl, containing 5pl lOx PCR
reaction buffer (22.5mM MgCI2, 500mM Tris pH 9.2, 160mM (NH4)2S04,;
Bohringer), lpl of each primer (Primer stock: 20pMolar) and 0. lpg of genomic
DNA.
2. After incubation at 95°C, 5min, reaction was cooled to 80°C and 14pl dNTP (final
concentration 0.35mM), 0.75pl Expand™ DNA polymerase (Bohringer) were added,
followed by:
1 cycle: 94°C, 30sec; 55°C, 45sec and 68°C, 2min;
10 cycles: 94°C, 30sec; 60°C, 45sec and 68°C, 2min;
25 cycles: 94°C, 30sec; 65°C, 45sec and 68°C, 2min plus 20sec extension per cycle
1 cycle: 68°C, 15min
Amplification of ovine sequences spanning from exon 3 to 4
PCR reaction was carried out as described for amplification of sequences spanning from
exon 2-3, with the following modifications to the cycle conditions:
1 cycle: 94°C, 30sec; 60°C, 45sec and 68°C, 8min;
10 cycles: 94°C, 30sec; 66°C, 45sec and 68°C, 8min;
25 cycles: 94°C, 30sec; 65°C, 45sec and 68°C, 8min plus 20sec extension per cycle
1 cycle: 68°C, 25min
Amplification of ovine sequences spanning from exon 3 to intron 3 and
from intron 3 to exon 4
PCR reaction was carried out as described for amplification of SV40T sequences, with the
following modifications to the cycle conditions: 35 cycles of 94°C, 30sec; 65°C, 30sec
and 72°C, 50sec, final extension 72°C, lOmin. The PCR reactions contained 0. l|lg of
ovine genomic DNA.
8.1.3.2. Restriction digest
Restriction digests were carried out as recommended by the supplier of the restriction
enzyme. Reactions were stopped by addition of 1/10 volume of gel loading buffer. DNA
was analysed on 0.8-1.0% agarose, 0.5|ig/ml EtBr gels in TBE unless otherwise stated.
8.1.3.3. Purification of DNA fragments
8.1.3.3.1. Fragments up to =20kb: "Prep-A-Gene" (Bio-Rad) method
1. DNA band was excised from the agarose gel and incubated with 3 volumes of
Prep-A-gene binding buffer (50mM Tris pH 7.4, ImM EDTA, 6M NaClOJ for
5min, at 55°C.
2. 5fll/|lg of DNA of Prep-A-gene matrix was added and incubated for 5-1Omin at room
temperature.
3. Spun in Eppendorf centrifuge for 30sec, pellet was washed 3 times in 50x volume of
binding buffer, followed by three washes in 20mM Tris pH 7.4, 2mM EDTA, 0.4M
NaCl, 50% Ethanol.
4. After a final spin, DNA was eluted from the matrix in either H20 or TE, 5min, at
55°C.
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8.1.3.3.2. Fragments over 20kb: Sucrose density gradient
This method was used for fragment isolation during pMIX 1 cloning and for purification of
the MIX1 micro-injection fragment.
1. For a 20-40% sucrose gradient 0.5ml of 40% sucrose was overlaid first with 0.5ml
of 30% then 20% sucrose and left to equilibrate at 4°C for 2hrs.
2. This was then overlaid with 100|ll of restriction enzyme digested DNA and
centrifuged for 20hrs, at 15°C, 26,000rpm (TLS 55 rotor, Beckmann ultracentrifuge
TL-100).
3. After centrifugation fractions were collected in 96 well microtiter plates, a 3-10p.l
aliquot of each fraction was analysed on a 1% agarose gel.
4. Fractions containing the purified DNA fragment were pooled, ethanol precipitated and
resuspended in TE
8.1.3.4. Ligation
Ligations were carried out as recommended by the supplier of the T4 DNA ligase
(Bohringer). Amounts of DNA in a typical 20(0.1 reaction would vary depending on the
number of fragments to be ligated (2, 3, or 4 part ligations) and on the size of vector and
insert DNA (e.g. 10-50ng of plasmid vector DNA, 50-250ng of insert DNA). Reactions
were stopped by heat inactivation at 70°C for lOmin.
8.1.3.5. DNA sequence analysis
Double stranded DNA sequencing was carried out using the "ABI PRISM™" dye
terminator cycle sequencing ready reaction kit with AmpliTaq® as recommended by the
supplier (Perkin Elmer).
1. Each 20|ll reaction contained 0.4|ig of DNA template, 8ul Terminator Ready Reaction
Mix, 4pmole primer.
2. The PCR reaction was incubated for 1 min at 94°C followed by 25 cycles: 95°C,
30sec; 55°C, 15sec; 60°C, 2min.
3. The sample was transferred to 1.5ml microcentrifuge tube and 2fll of 3M sodium
acetate pH 5.2 and 50|ll 95% ethanol was added, incubated on ice for lOmin and
centrifuged for 20min.
4. Pellet was washed with 70% ethanol, pellet was dried and then resuspended in 5(0.1
formamide/25mM EDTA pH 8, 50mg/ml blue dextran (5:1 ration), heated at 90°C for
2min to denature, and placed on ice until loading.
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5. 2.5|ll was loaded onto a 4.75% acrylamide/bis acrylamide (19:1), 6M urea gel in lx
TBE. Sequencing gel was run and analysed with the help of ABI PRISM™ 377
automated sequencer. DNA sequences were analysed using either Factura or
DNASTAR computer programs.
Sequencing primer: Reverse AACAGCTATGACCATG
Forward GTAAAACGACGGCCAGT
8.1.3.6. Southern Analysis
Southern blot: After electrophoresis the agarose gel was exposed to U.V. light to nick
the DNA, which facilitates transfer of larger fragments. After incubation in 0.5M NaOH to
denature the DNA the gel was neutralised in 0.5M Tris, pH 7.2, 1.5M NaCl). DNA was
transferred to Duralon UV membrane by capillary action (transfer buffer: 20x SSPE) and
DNA was crosslinked to the membrane using an ultra violet "Stratalink" machine
(Stratagene) at 1200pJ.
32P DNA labelling: The "Random Primed DNA Fabelling Kit" from Bohringer was
employed for incorporation of 32P into the randomly primed, and newly synthesised
complementary DNA strand. The reaction was carried out as recommended by the
supplier. A typical 20p,l reaction contained 25-100ng of DNA, ljil of each dATP, dCTP,
dGTP, and dTTP (Stock: 0.5mM), 5)0.1 32P-dCTP, lp.1 Klenow. After incubation for 30-
60min at 37°C, 80|ol of TE was added to the reaction and the unincorporated 32P
nucleotides were separated from the DNA using a Sephadex G-50 column according to the
manufactures recommendations (Nick Column, Pharmacia).
Southern blot hybridisation
1. Filter membrane was wetted in 2x SSPE and placed in hybridisation bottle.
2. After addition of 30ml 0.5M NaP04 pH 7.2, 7% SDS, ImM EDTA the filter was
pre-hybridised for l-4hrs at 65°C.
3. The pre-hybridisation solution was discarded and replaced with 20ml 0.5M NaP04
pH7.2, 7% SDS, ImM EDTA, 106-107cpm/ml of denatured 32P labelled DNA probe
and hybridised over night at 65°C.
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4. Filter was rinsed in 2x SSPE and then washed three times in 40mM NaP04 pH7.2,
1 % SDS, ImM EDTA at 60°C for 15min.
5. Signal was detected by exposure to X-OMAT AR5 film.
8.1.4. Construction of the FIX expression vector pMIXl
Construction of pMIXl was carried out as described in the Chapter 2 using standard
methods as described above. All fragments required for cloning were isolated from mini
plasmid or X prep. DNA, using gel electrophoresis and Prep-A-Gene purification. The
final cloning step required manipulation of DNA fragments >30kb, these were separated
and purified on sucrose gradients (see 8.1.3.3.2.).
Cloning of FIX3'PCR required amplification of the 3' end of the human FIX gene by PCR.
The PCR primers used are listed below, also indicated are the restriction enzyme
recognition sites contained within the primer sequence.
Primer FIXl: 5' GC GAATTC AGATCT TTA ACA TTG CCA ATT AGG 3'
EcoRI Bglll
Primer FIX2: 5' GC GGATCCTCGAG ATC CAT CTT TCA TTA AGT GAG C 3'
BamHI Xhol STOP
1. PCR reactions were carried out in a total volume of 50pl, containing 5pl lOx PCR
reaction buffer (lOOmM Tris pH 8.3, 15mM MgCl2, 500mM KC1), 2.5gl of both
primer FIXl and 2 (primer stock: 20pMolar) and =10ng of X HIX2 DNA.
2. After incubation at 95°C, 5min, reaction was cooled to 80°C and 8pi dNTP (primer
stock 1.25mM; final concentration 0.2mM), 0.5pl TAQ DNA polymerase (Bohringer)
were added, followed by 35 cycles of 94°C, 30sec; 65°C, 30sec and 72°C, 45sec,
extension was completed by final incubation at 72°C, 5min.
3. An aliquot of the PCR reaction was analysed on a 1% agarose gel.
4. The PCR product was purified away from unincorporated nucleotides, primers and
the thermostable polymerase using the Bohringer "PCR Clean Up Kit" as
recommended by the supplier.
5. After digestion with the restriction enzymes EcoRI and BamHI the PCR product was
cloned into the EcoRI/BamHI site of the plasmid vector Bluescript.
6. The integrity of the cloned PCR fragment was confirmed by DNA sequence analysis.
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8.1.5. Construction of the immortalisation vector PGKtsA58LOX
Construction of PGKtsA58LOX was carried out as described in the Chapter 3 using
standard methods as described above.
For the loxP site two complementary oligonucleotides were synthesised (see sequence
below), the 5' and 3' overhangs were designed to facilitate cloning to vector DNA




1. The two complementary DNA strands were annealed at a concentration of l(ig/|0i.
2. Four |ig of annealed oligonucleotides were then phosphorylated using 4|il of T4
Polynucleotide Kinase in 20|0.1, 76mM Tris pH 7.6, lOmM MgCl2, ImM ATP, 15mM
DTT, 1mM spermidine.
3. After incubation at 37°C for 30min the reaction product was stored frozen at -20°C
until required.
8.2. Protein Analysis
8.2.1. Western Blot analysis (Factor IX)
Reducing SDS PAGE
1. Samples were loaded in 5-15|ll 0.5M Tris pH 6.8, 2% Glycerol. 10% SDS, 0.1%
bromophenol blue, 5% (3-mercaptoethanol onto a 18% 10 well Tris-glycine gel
(Novex).
2. After electrophoresis the Tris-glycine gel was washed once in transfer buffer (25mM
Tris, 129mM glycine), 15min at room temperature.
3. The nitrocellulose membrane (Immulon P, Millipore)was cut to size, rinsed first in
methanol then in transfer buffer.
4. The protein was transferred to the nitrocellulose membrane using an Electroblotter
(100mA, 25Volts, 30min).
5. The membrane was then incubated in 50ml blocking buffer (PBS, 2% BSA, 0.1%
Tween 20) for lhr.
6. Followed by a lhr incubation in 50ml of 1:2000 rabbit anti-FIX antibody (Dako
P0300) in blocking buffer.
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7. Followed by a lhr incubation in 50ml of 1:5000 anti-rabbit horseradish peroxidase
antibody (Sigma) in blocking buffer.
8. Followed by 4 washes in PBS, lOmin. each.
9. 2.5ml of the two developing chemicals (Supersignal chemiluminescent substrate
peroxide and Luminol/enhancer solution; Pierce) was added for -lmin, then rinsed in
PBS.
10. The signal was visualised using Hyber film.
8.2.2. ELISA (Factor IX)
1. 96 well microtiter plates were coated with 1:1200 dilution of anti-FIX polyclonal
antibody (Dako P0300) in PBS pH 7.2, 0.02% Na azide, lOOpl per well, and
incubated over night at room temperature.
2. Plates were washed 3 times with wash buffer (PBS pH 7.2, 0.5M NaCl, 0.2%
Tween)
3. 130jll1 of Blocking buffer (PBS pH 7.2, 3% w/v gelatin) was added per well and
incubated for lhr at r.t., followed by 3 rinses with wash buffer.
4. Milk samples were used in a dilution series from 1: 500 to 1:16000 and the human
FIX standard (ERL) was used in a dilution series from 1 OOOpg/ml to 15.625|ig/ml.
Both were diluted in PBS pH 7.2, 0.5M NaCl, 0.2% Tween.
5. 50|il of each dilution was loaded per well in triplicates and incubated for lhr at r.t.,
followed by 3 rinses with wash buffer.
6. The anti-FIX polyclonal antibody horseradish peroxidase conjugate (Dako) was
diluted 1:1000 in PBS pH 7.2, 0.5M NaCl, 0.2% Tween, 50jil was added to each
well and incubated for lhr at r.t., followed by 3 rinses with wash buffer.
7. 100|ll of TMB Colour Reagent (KPL single component peroxidase substrate) was
added to each well and incubated for =15min.
8. The reaction was stopped by addition of lOOpl 0.2M H2S04 and signal analysed
using a Dynex automated microtiter plate reader.
8.3. Cell culture
Cells were grown on standard tissue culture plastic pre-coated with 0.1% gelatin, and
incubated at 37°C in a 5% C02 humidified atmosphere. For routine passage cells were
washed twice with PBS, disaggregated enzymatically using trypsin, which was inactivated
by addition of medium containing serum. Cells were then pelleted, resuspended in growth
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medium and transferred at appropriate dilution to culture dishes/flask. Isolation of single
cell colonies was performed with the help of cloning rings.
8.3.1. Calcium phosphate transfection
Transfection was carried out as described by Chen and Okayama (1987).
1. 2xI05 cells were seeded per 3.5cm diameter well on the day before transfection.
2. Day 1: 5pg DNA was added to 0.25ml of 50mM HEPES, 280mM NaCl, 1.5mM
Na2HP04 pH 7.0> mixed, and dropwise 0.25ml of 250mM CaCl2was added.
3. After 30 min at r.t. the precipitate was added to the medium and incubated overnight
4. Day 2: Cells were washed with PBS, and medium replaced.
5. Day 3: Cells were lysed for Luciferase assay.
8.3.2. Polycationic liposome-mediated transfection
LipofectAMINE transfection was carried out as recommended by the supplier (GIBCO
BRL)
1. 2xl05 cells were seeded per 3.5cm diameter well on the day before transfection.
2. Day 1: 1.5-2pg DNA was added to 0.1ml OptiMEM, mixed, and dropwise 0.1ml of
OptiMEM containing lOpl of LipofectAMINE was added.
3. After 30-45 min at r.t. 0.8ml OptiMEM was added to the precipitate, and this was
then added to the cells which had been washed twice with OptiMEM.
4. After l-24hrs 2ml of culture medium plus 10% serum was added.
5. Day 3: Cells were either fixed for p-galactosidase assay, lysed for Luciferase assay,
or plated at a 1:10 dilution into medium containing G418 for selection of single cell
colonies.
8.3.3. Electroporation
The method used is described below.
1. 0.8ml of serum free medium containing lxlO6 cells, lpg/ml DNA, and 5-10pg/ml
DEAE-dextran was transferred to an electroporation cuvette.
2. Electroporation parameters varied for the voltage from 120-450V and for the
capacitance from 125-500|lFd.
3. After the cells were subjected to the electroporation they remained for a further lOmin,
room temperature in the cuvette and were then transferred in 5ml of culture medium
plus 10% serum to a 25cm2 flask and incubated at 37°C for 48hrs.
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4. Cells were either fixed for p-galactosidase assay or plated at a 1:10 dilution into
medium containing G418 for selection of single cell colonies
8.3.4. Luciferase assay
The assay was carried out essentially as described by the supplier of the reagents
(Promega).
1. Cells were rinsed twice with PBS.
2. Cell lysis buffer was added and incubated for 10-15min at room temperature.
3. Cell lysate was transferred to Eppendorf microcentrifuge tubes and centrifuged for 5-
lOsec to pellet debris. At this point cell lysate was frozen for future analysis.
4. Cell lysate was diluted 1:100 in lysis buffer.
5. 20|il of cell lysate was mixed with lOOjll of Luciferase assay reagent and reaction was
placed in luminometer to measure light emission.
Lysis buffer: 25mM Tris pH 7.8
2mM DTT
2mM 1,2 diaminocyclohexane-N, N, N\ N'-tetraacetic acid
10% glycerol
1% Triton X-100








8.3.5. li-galactosidase assay (Histochemical reaction)
1. The medium was aspirated and cells were washed with PBS.
2. Cells were fixed with 2% Formaldehyde, 0.2% Glutaraldehyde
in PBS for 5 min at room temperature.
3. Fixative was aspirated off, and cells washed with PBS.
4. Overlay solution including lmg/ml X-Gal was added and incubated for 30 min-4hrs at
37°C. Reaction was stopped by washing with PBS.
5. Cells were dried with methanol for 10 min before assessment.




8.3.6. Alkaline phosphatase staining
Alkaline phosphatase staining was carried out as described by Wassarman (1993) with
some minor modifications.
1. Cells were fixed with 4% (w/v) paraformaldehyde for 20min.
2. Washed 3x in Tris-maleate buffer pH 9, for lOmin.
3. Staining solution (Tris-maleate pH 9, 0.4mM MgCl2, 0.4mg/ml Naphthol- AS-MX
phosphate, lmg/ml Fast Red TR salt) was added and staining reaction was allowed to
develop for 15-20min (control cells became bright pink).
4. Reaction was stopped by addition of PBS.
8.3.7. Freezing of cells
1. Cells were trypsinised, spun, and resuspended in 0.5 ml of medium.
2. One volume freezing medium (growth medium +20% DMSO +20% serum) was
added.
3. Cells were frozen at -80°C and after 24hrs transferred to liquid nitrogen.
8.3.8. Production of mitotically inactivated feeder cells
Medium containing 10|lg/ml mitomycin C was added to STO cells and cells were
incubated for 2-4 hours, after which cells could be used directly or were stored in liquid
nitrogen until required.
8.3.9. Determination of chromosome number (metaphase spreads)
1. Typically cells (25cm2 flask)were grown until about 75% confluent, 0.2|ig/ml
colcemid was added to the culture medium and cells were incubated for 30min-6hr.
2. Cells were trypsinised, pelleted and resuspended in 4ml 75mM KC1, incubated for 8-
lOmin at room temperature before centrifugation.
3. Pellet was resuspended in 5ml methanol/acetic acid (3:1) added dropwise while
vortexing and incubated for lhr at room temperature.
4. Step 3 was repeated twice and then stored at -20°C.
5. Metaphase spreads were prepared by dropping fixed cell nuclei onto cold slides.
These were allowed to dry for a few minutes at room temperature.
6. 40(il of mounting solution, 10|ig/ml DAPI was added to the slide, viewed under
fluorescence microscope using appropriate filter.
7. Photographs were taken and chromosome number determined.
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8.3.10. Serum starvation
l-2xl04 cells were plated into 12 well dishes. After 18-24hrs cells were washed twice
with either PBS or serum free medium, medium containing 0.5% serum was added and
cells were incubated at 37°C for 5 day. Cells were disaggregated enzymatically l-2hrs
prior to nuclear transfer.
8.3.11. Derivation of ovine embryonic cell culture
Embryos were collected at day 9-10 and rinsed 3 times in ES isolation medium, 2x
pen/strep (see 8.4 for medium and buffers). The embryonic disc was dissected with the
help of watchmaker forceps #5. Once -60-90% of the trophectoderm had been removed,
the individual discs were rinsed 6 times in ES isolation medium, 2x pen/strep, transferred
to gelatinised 24 well dishes and cultured in the presence of STO feeder cells, ES isolation
medium and bovine LIF. Embryonic cultures were observed at 1-2 day intervals, if
required growing trophectoderm cells were removed mechanically. After 8-14 days the
explant was trypsinised and transferred onto fresh feeder cells. Cell growth after the first
trypsinisation was a good indication that embryonic cultures had been established, these
where then passed regularly at 1:4 to 1:10 dilutions.
8.3.12. Fetal fibroblast derivation, culture and transfection with pMIXl.
Fetuses were collected at day 35 and rinsed 3x in PBS. Head, hooves, heart, liver and
kidneys were dissected. The remaining fetus was finely chopped with a scalpel and then
transferred to a 125ml flasks containing 15ml trypsin, incubated with magnetic stirrer for
20-40min at 37°C. 35ml fibroblast medium, 2x pen/strep was added, cells were pelleted,
washed twice in fibroblast medium, 2x pen/strep and then plated onto gelatinised plates.
At first passage, 2xl05 PDFF2 cells were plated into a 3.5cm diameter well and
cotransfected with 0.5|ig PGKneo (kindly provided by David Melton, University of
Edinburgh), 1.5|lgMluI digested pMIXl DNA using "LipofectAMINE" (GIBCO) under
conditions recommended by the supplier. 48hrs after transfection cells were split 1:10 and
G418 added to 0.6mg/ml. Transfected PDFF2 cells reached subconfluence after 6 days
selection. At third passage a portion of the cells were split 1:10, subjected to a further 5
days selection and cryopreserved as an uncloned population. Other portions were split
1:1000 and 1:5000 and subjected to G418 selection for a further 7 days. Individual
colonies were isolated, expanded for cryopreservation at passage 5 and a portion of each
clone grown further for chromosome counting and Southern analysis.
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20mM EDTA, pH 7.4
lOxTBE 0.9M Tris pH8.3
0.9M boric acid
20mM EDTA
lOx running buffer: for 1Litre




Gel loading buffer: 50% glycerol
0.2M EDTA pH 8.2
0.1% dye (bromophenol blue, bromocresol green)
lOxTBE 0.9M Tris pH8.3
0.9M boric acid
20mM EDTA
TE lOmM Tris, pH7.4
ImM EDTA













5g Bacto yeast extract
20g Bacto Tryptone
10ml 250mM KCL
Autoclave, then add 5ml 2M MgCl2, 20ml 1M glucose
24g Bacto yeast extract
12g Bacto Tryptone
4ml glycerol




lOg yeast extract (Difco)
16g Tryptone
X Gal plates 50|il 20mg/ml X-Gal
5|il 0.2M IPTG spread on 10cm plate
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8.4.3. Tissue culture media and solutions
100 X pen/strep stock
5000 units penicillin (Glaxo)
50mg streptomycin (Glaxo) in 100ml PBS.
Gelatin 0. l%w/vinH20





Trypsin EGTA 2.5g Trypsin (porcine Difco)






3.0g Tris pH 7.6
1,0ml Phenol red (Difco)
0.1ml Polyvinyl alcohol
ES cell medium Glasgow MEM (BHK-21) 500ml
Fetal calf serum 56ml
lOOmM Sodium pyruvate 5.6ml
lOOx Non-Essential Amino Acids 5.6ml
500mM (3-mercaptoethanol 1.1 ml
200mM L-Glutamine 5.6ml
ES isolation medium: As ES cell medium,
5% New born calf serum
lx pen/strep
OME cell meduim F12:DMEM 500ml






Fibroblast medium Glasgow MEM (BHK-21) 500ml
Fetal calf serum 56ml
1OOmM Sodium pyruvate 5.6ml
Non-Essential Amino Acids 5.6ml
200mM L-Glutamine 5.6ml
STO medium F12:DMEM 500ml
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Fertilization of mammalian eggs is followed by successive cell
divisions and progressive differentiation, first into the early
embryo and subsequently into all of the cell types that make up
the adult animal. Transfer of a single nucleus at a specific stage of
development, to an enucleated unfertilized egg, provided an
opportunity to investigate whether cellular differentiation to
that stage involved irreversible genetic modification. The first
offspring to develop from a differentiated cell were born after
nuclear transfer from an embryo-derived cell line that had been
induced to become quiescent1. Using the same procedure, we now
report the birth of live lambs from three new cell populations
established from adult mammary gland, fetus and embryo. The
fact that a lamb was derived from an adult cell confirms that
differentiation of that cell did not involve the irreversible mod¬
ification of genetic material required for development to term.
The birth of lambs from differentiated fetal and adult cells also
reinforces previous speculation1,2 that by inducing donor cells to
become quiescent it will be possible to obtain normal develop¬
ment from a wide variety of differentiated cells.
It has long been known that in amphibians, nuclei transferred
from adult keratinocytes established in culture support develop¬
ment to the juvenile, tadpole stage3. Although this involves differ¬
entiation into complex tissues and organs, no development to the
adult stage was reported, leaving open the question of whether a
differentiated adult nucleus can be fully reprogrammed. Previously
we reported the birth of live lambs after nuclear transfer from
cultured embryonic cells that had been induced into quiescence. We
suggested that inducing the donor cell to exit the growth phase
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Figure 1 Phase-contrast photomicrograph of donor-cell populations: a. Embryo-
derived cells (SEC1); b, fetal fibroblasts (BLWF1); c, mammary-derived cells
(OME).d, Microsatellite analysis of recipient ewes, nuclear donor cells and lambs
using four polymorphic ovine markers22. The ewes are arranged from left to right
in the same order as the lambs. Cell populations are embryo-derived (SEC1), fetal-
derived (BLW1), and mammary-derived (OME), respectively. Lambs have the
same genotype as the donor cells and differ from their recipient mothers.
causes changes in chromatin structure that facilitate reprogram-
ming of gene expression and that development would be normal if
nuclei are used from a variety of differentiated donor cells in similar
regimes. Here we investigate whether normal development to term
is possible when donor cells derived from fetal or adult tissue are
induced to exit the growth cycle and enter the GO phase of the cell
cycle before nuclear transfer.
Three new populations of cells were derived from (1) a day-9
embryo, (2) a day-26 fetus and (3) mammary gland of a 6-year-old
ewe in the last trimester of pregnancy. Morphology of the embryo-
derived cells (Fig. 1) is unlike both mouse embryonic stem (ES) cells
and the embryo-derived cells used in our previous study. Nuclear
transfer was carried out according to one of our established
protocols1 and reconstructed embryos transferred into recipient
ewes. Ultrasound scanning detected 21 single fetuses on day 50-60
after oestrus (Table 1). On subsequent scanning at ~ 14-day inter¬
vals, fewer fetuses were observed, suggesting either mis-diagnosis or
fetal loss. In total, 62% of fetuses were lost, a significantly greater
proportion than the estimate of 6% after natural mating4. Increased
prenatal loss has been reported after embryo manipulation or
culture of unreconstructed embryos2. At about day 110 of preg¬
nancy, four fetuses were dead, all from embryo-derived cells, and
post-mortem analysis was possible after killing the ewes. Two fetuses
had abnormal liver development, but no other abnormalities were
detected and there was no evidence of infection.
Eight ewes gave birth to live lambs (Table 1, Fig. 2). All three cell
populations were represented. One weak lamb, derived from the
fetal fibroblasts, weighed 3.1 kg and died within a few minutes of
birth, although post-mortem analysis failed to find any abnormality
or infection. At 12.5%, perinatal loss was not dissimilar to that
occurring in a large study of commercial sheep, when 8% of lambs
died within 24 h of birth6. In all cases the lambs displayed the
morphological characteristics of the breed used to derive the
nucleus donors and not that of the oocyte donor (Table 2). This
Table 1 Development of embryos reconstructed with three different cell types
No. of fused No. recovered No. of morula/ No. of morula No. of pregnancies/ No. of
couplets from oviduct blastocyst or blastocysts no. of recipients live lambs
Cell type (%)» (%) No. cultured (%) transferredt (%) (%>*
Mammary epithelium 277 (63.8)a 247 (89.2) - 29 (11.7)a 29 1 /13 (7.7) 1 (3.4%)
Fetal fibroblast 172 (84.7)b 124(86.7) - 34 (27.4)b 34 4/10(40.0) 2 (5.9%)
24 13 (54.2)b 6 1/6(16.6) 1 (16.6%)§
Embryo-derived 385 (82.8)b 231 (85.3) - 90 (39.0)° 72 14/27 (51.8) 4 (5.6%)
92 36 (39.0)b 15 1 /5 (20.0) 0
* As assessed 1 h after fusion by examination on a dissecting microscope. Superscripts a or b within a column indicate a significant difference between donor cell types in the efficiency of
fusion (P < 0.001) or the proportion of embryos that developed to morula or blastocyst (P < 0.001).
t It was not practicable to transfer all morulae/blastocysts.
t As a proportion of morulae or blastocysts transferred. Not all recipients were perfectly synchronized.
§This lamb died within a few minutes of birth.
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Figure 2 Lamb number 6LL3 derived from the mammary gland of a Finn Dorset
ewe with the Scottish Blackface ewe which was the recipient.
Table 2 Delivery of lambs developing from embryos derived by nuclear
transfer from three different donor cells types, showing gestation length
and birth weight
Duration of Birth
Breed of Lamb pregnancy weight
Cell type lamb identity (days)* (kg)
Mammary Finn Dorset 6LL3 148 6.6
epithelium
Fetal Black Welsh 6LL7 152 5.6
fibroblast Black Welsh 6LL8 149 2.8
Black Welsh 6LL9t 156 3.1
Embryo- Poll Dorset 6LL1 149 6.5
derived Poll Dorset 6LL2t 152 6.2
Poll Dorset 6LL5 148 4.2
Poll Dorset 6LL64 152 5.3
* Breed averages are 143,147 and 145 days, respectively for the three genotypes Finn Dorset,
Black Welsh Mountain and Poll Dorset.
tThis lamb died within a few minutes of birth.
tThese lambs were delivered by caesarian section. Overall the nature of the assistance
provided by the veterinary surgeon was similar to that expected in a commercial flock.
alone indicates that the lambs could not have been born after
inadvertent mating of either the oocyte donor or recipient ewes.
In addition, DNA microsatellite analysis of the cell populations and
the lambs at four polymorphic loci confirmed that each lamb was
derived from the cell population used as nuclear donor (Fig. 1).
Duration of gestation is determined by fetal genotype7, and in all
cases gestation was longer than the breed mean (Table 2). By
contrast, birth weight is influenced by both maternal and fetal
genotype8. The birth weight of all lambs was within the range for
single lambs born to Blackface ewes on our farm (up to 6.6 kg) and
in most cases was within the range for the breed of the nuclear
donor. There are no strict control observations for birth weight after
embryo transfer between breeds, but the range in weight of lambs
born to their own breed on our farms is 1.2-5.0 kg, 2-4.9 kg and
3-9 kg for the Finn Dorset, Welsh Mountain and Poll Dorset
genotypes, respectively. The attainment of sexual maturity in the
lambs is being monitored.
Development of embryos produced by nuclear transfer depends
upon the maintenance ofnormal ploidy and creating the conditions
for developmental regulation of gene expression. These responses
are both influenced by the cell-cycle stage of donor and recipient
cells and the interaction between them (reviewed in ref. 9). A
comparison of development ofmouse and cattle embryos produced
by nuclear transfer to oocytes10'11 or enucleated zygotes12,13 suggests
that a greater proportion develop if the recipient is an oocyte. This
may be because factors that bring about reprogramming of gene
expression in a transferred nucleus are required for early develop¬
ment and are taken up by the pronuclei during development of the
zygote.
If the recipient cytoplasm is prepared by enucleation of an oocyte
at metaphase II, it is only possible to avoid chromosomal damage
and maintain normal ploidy by transfer of diploid nuclei14'15, but
further experiments are required to define the optimum cell-cycle
stage. Our studies with cultured cells suggest that there is an
advantage if cells are quiescent (ref. 1, and this work). In earlier
studies, donor cells were embryonic blastomeres that had not been
induced into quiescence. Comparisons of the phases of the growth
cycle showed that development was greater if donor cells were in
mitosis16 or in the G1 (ref. 10) phase of the cycle, rather than in S or
G2 phases. Increased development using donor cells in GO, G1 or
mitosis may reflect greater access for reprogramming factors present
in the oocyte cycoplasm, but a direct comparison of these phases in
the same cell population is required for a clearer understanding of
the underlying mechanisms.
Together these results indicate that nuclei from a wide range of
cell types should prove to be totipotent after enhancing opportu¬
nities for reprogramming by using appropriate combinations of
these cell-cycle stages. In turn, the dissemination of the genetic
improvement obtained within elite selection herds will be enhanced
by limited replication of animals with proven performance by
nuclear transfer from cells derived from adult animals. In addition,
gene targeting in livestock should now be feasible by nuclear transfer
from modified cell populations and will offer new opportunities in
biotechnology. The techniques described also offer an opportunity
to study the possible persistence and impact of epigenetic changes,
such as imprinting and telomere shortening, which are known to
occur in somatic cells during development and senescence, respec¬
tively.
The lamb born after nuclear transfer from a mammary gland cell
is, to our knowledge, the first mammal to develop from a cell
derived from an adult tissue. The phenotype of the donor cell is
unknown. The primary culture contains mainly mammary epi¬
thelial (over 90%) as well as other differentiated cell types, including
myoepithelial cells and fibroblasts. We cannot exclude the possi¬
bility that there is a small proportion of relatively undifferentiated
stem cells able to support regeneration of the mammary gland
during pregnancy. Birth of the lamb shows that during the develop¬
ment of that mammary cell there was no irreversible modification of
genetic information required for development to term. This is
consistent with the generally accepted view that mammalian differ¬
entiation is almost all achieved by systematic, sequential changes in
gene expression brought about by interactions between the nucleus
and the changing cytoplasmic environment17. □
Methods
Embryo-derived cells were obtained from embryonic disc of a day-9 embryo
from a Poll Dorset ewe cultured as described1,with the following modifications.
Stem-cell medium was supplemented with bovine DIA/LIF. After 8 days, the
explanted disc was disaggregated by enzymatic digestion and cells replated onto
fresh feeders. After a further 7 days, a single colony of large flattened cells was
isolated and grown further in the absence of feeder cells. At passage 8, the modal
chromosome number was 54. These cells were used as nuclear donors at
passages 7-9. Fetal-derived cells were obtained from an eviscerated Black Welsh
Mountain fetus recovered at autopsy on day 26 of pregnancy. The head was
removed before tissues were cut into small pieces and the cells dispersed by
exposure to trypsin. Culture was in BHK 21 (Glasgow MEM; Gibco Life
Sciences) supplemented with L-glutamine (2mM), sodium pyruvate (1 mM)
and 10% fetal calf serum. At 90% confluency, the cells were passaged with a 1 :2
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i division. At passage 4, these fibroblast-like cells (Fig. 1) had modal chromo-
j some number of 54. Fetal cells were used as nuclear donors at passages 4-6.
I Cells from mammary gland were obtained from a 6-year-old Finn Dorset ewe
in the last trimester ofpregnancy18. At passages 3 and 6, the modal chromosome
number was 54 and these cells were used as nuclear donors at passage numbers
3-6.
Nuclear transfer was done according to a previous protocol1. Oocytes were
recovered from Scottish Blackface ewes between 28 and 33 h after injection of
j gonadotropin-releasing hormone (GnRH), and enucleated as soon as possible.
They were recovered in calcium- and magnesium-free PBS containing 1% FCS
I and transferred to calcium-free M2 medium19 containing 10% FCS at 37 °C.
Quiescent, diploid donor cells were produced by reducing the concentration of
serum in the medium from 10 to 0.5% for 5 days, causing the cells to exit the
growth cycle and arrest in GO. Confirmation that cells had left the cycle was
obtained by staining with antiPCNA/cyclin antibody (Immuno Concepts),
revealed by a second antibody conjugated with rhodamine (Dakopatts).
Fusion ofthe donor cell to the enucleated oocyte and activation of the oocyte
were induced by the same electrical pulses, between 34 and 36 h after GnRH
injection to donor ewes. The majority of reconstructed embryos were cultured
| in ligated oviducts of sheep as before, but some embryos produced by transfer'
from embryo-derived cells or fetal fibroblasts were cultured in a chemically
| defined medium20. Most embryos that developed to morula or blastocyst after 6
days of culture were transferred to recipients and allowed to develop to term
(Table 1). One, two or three embryos were transferred to each ewe depending
! upon the availability of embryos. The effect of cell type upon fusion and
I development to morula or blastocyst was analysed using the marginal model of! Breslow and Clayton21. No comparison was possible of development to term as
it was not practicable to transfer all embryos developing to a suitable stage for
transfer. When too many embryos were available, those having better mor¬
phology were selected.
Ultrasound scan was used for pregnancy diagnosis at around day 60 after
; oestrus and to monitor fetal development thereafter at 2-week intervals,
j Pregnant recipient ewes were monitored for nutritional status, body condition
j and signs of EAE, Q fever, border disease, louping ill and toxoplasmosis. As
lambing approached, they were under constant observation and a veterinary
surgeon called at the onset of parturition. Microsatellite analysis was carried
out on DNA from the lambs and recipient ewes using four polymorphic ovine
markers22.
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Ovine primary fetal fibroblasts were cotransfected with a neomycin resistance marker
gene (neo) and a human coagulation factor IX genomic construct designed for expression
of the encoded protein in sheep milk. Two cloned transfectants and a population of
neomycin (G418)-resistant cells were used as donors for nuclear transfer to enucleated
oocytes. Six transgenic lambs were liveborn: Three produced from cloned cells con¬
tained factor IX and neo transgenes, whereas three produced from the uncloned pop¬
ulation contained the marker gene only. Somatic cells can therefore be subjected to
genetic manipulation in vitro and produce viable animals by nuclear transfer. Production
of transgenic sheep by nuclear transfer requires fewer than half the animals needed for
pronuclear microinjection.
Microinjection of DNA into the pronuclei
of fertilized oocytes has been the only prac¬
tical means of producing transgenic live¬
stock since the method was established in
1985 (1). However, only a small proportion
(~5%) of animals integrate the transgene
DNA into their genome (2, 3). In addition,
because the timing and site of integration
are random, many transgenic lines do not
provide sufficiently high levels of transgene
expression or germline transmission. The
consequent inefficient use of animals and
associated high costs are a major drawback
to pronuclear microinjection.
In mice, embryonic stem cells provide an
alternative to pronuclear microinjection as
a means of transferring exogenous DNA to
the germline of an animal and allow precise
genetic modifications by gene targeting (4,
5). However, despite considerable efforts,
embryonic stem cells capable of contribut¬
ing to the germline of any livestock species
have not been isolated (6-11).
Recently, viable sheep have been pro¬
duced by transfer of nuclei from a variety of
somatic cell types cultured in vitro (12-14).
We now demonstrate that nuclear transfer
from stably transfected somatic cells pro-
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vides a cell-mediated method for producing
transgenic livestock.
We have used a transgene designed to
express human clotting factor IX (FIX) pro¬
tein in the milk of sheep. FIX plays an
essential role in blood coagulation, and its
deficiency results in hemophilia B (15).
This disease is currently treated with FIX
derived mainly from human plasma. Re¬
combinant FIX produced in milk would
provide an alternative source at lower cost
and free of the potential infectious risks
associated with products derived from hu¬
man blood.
The transgene construct, pMIXl (16),
comprises the human FIX gene, containing
the entire coding region (17), linked to the
ovine p-lactoglobulin (BLG) gene promot¬
er, which has been previously shown to
provide a high level of transgene expression
in ovine mammary glands (18). Analysis of
pMIXl expression in transgenic mice
showed that seven of seven female founders
expressed FIX in their milk (19). The level
of expression in two animals (125 |Xg/ml)
exceeded that achieved in previous studies
(20, 21), indicating that pMIXl is func¬
tional and suitable for introduction into
sheep.
Primary strains of ovine cells, termed
PDFF (Poll Dorset fetal fibroblast) 1 to 7,
were derived from seven day-35 fetuses from
the specific pathogen-free flock at PPL
Therapeutics (22). Sex analysis of each cell
strain by the polymerase chain reaction
(PCR) (23) revealed PDFF5 to be male and
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Table 1. Results of nuclear transfer. Nuclear transfer was performed as described previously (72, 73).
All cells were exposed to a reduced serum concentration (0.5%) for 5 days before use as nuclear donors.
PDFF5 cells were used for nuclear transfer at passage 2 or 3, PDFF2 transfected pools at passage 5 to
7, and transfected clones PDFF2-12 and PDFF-13 at passage 7 to 9. Liveborn lambs were defined as








Reconstructed embryos 82 224 89 112
No. developed to morulae 5(6.1%) 22 (9.8%) 19(21.4%) 23 (20.5%)
or blastocysts
Embryos transferred 5 22 19 21
Recipients 2 9 7 6
Pregnancies at day 60 2 4 4 1
Fetuses at day 60 (% of 3 (60%) 4(18.2%) 6 (31.6%) 1 (4.8%)
embryos transferred)
Liveborn lambs (% of 1 (20%) 3 (13.6%) 2 (10.5%) 1 (4.8%)
embryos transferred)
Nuclear transfer efficiency 1.22% 1.34% 2.25% 0.89%
(% live lambs from
reconstructed embryos)
the other six to be female.
Trial experiments indicated that both
PDFF2 and PDFF5 cells could be readily
transfected with a lacZ reporter gene with
the use of the cationic lipid reagent Lipo-
fectamine. PDFF2 cells at passage 1, after
3 days in culture, were cotransfected with
pMIXl DNA and the selectable marker
construct PGKneo, and stable transfec-
tants were selected with G418. Because
the effects of drug selection and growth as
single-cell clones on the ability of cells to
support nuclear transfer were unknown,
cells were then treated in two ways: One
group was grown at high density under
G418 selection and then cryopreserved as
a pool for nuclear transfer. The other
group was plated at low density under
G418 selection, and cloned transfectants
were grown from isolated colonies (22). A
total of 24 clones was isolated, of which 21
were expanded for analysis of genomic
DNA. Ten clones were found to contain
pMlXl by DNA hybridization analysis
(24).
Untransfected PDFF2 cells cultured to
passage 19 over a period of 80 days exhib¬
ited a modal chromosome number of 54,
the euploid ovine chromosomal comple¬
ment. The chromosome number of the
four most rapidly growing pMlXl-trans¬
fected clones (PDFF2-12, -13, -31, -38)
was determined at passage 6 or 7, after an
average of 40 days in culture, and that of
the uncloned PDFF2 pool was determined
at passage 5, after 19 days in culture. Each
clone and the pool showed a modal chro¬
mosome number of 54, indicating the ab¬
sence of gross chromosomal instability
during culture and drug selection.
We have proposed that induction of qui¬
escence in nuclear donor cells by serum
deprivation is necessary for successful nu¬
clear transfer (12). After 5 days of culture in
medium with a reduced serum content
(0.5%), immunofluorescence detection of
proliferating-cell nuclear antigen (PCNA),
which is an indicator of active DNA repli¬
cation, showed that none of the cells ana¬
lyzed was in S phase, consistent with cell
cycle arrest (25). Restoration of serum con¬
tent to 10% reversed this effect and cell
growth resumed.
Four cell types were used as nuclear do¬
nors: untransfected male PDFF5 cells,
pooled female PDFF2 transfectants, and two
transfected clones, PDFF2-12 and PDFF2-
13, which contained >10 and ~5 copies of
the pMIXl transgene, respectively. Transfer
of nuclei from each cell type into enucleat¬
ed oocytes derived from Scottish Blackface
ewes was performed as previously described
(12, 13).
Live lambs were obtained from all four
cell types (Table 1). As expected, animals
derived from PDFF5 cells were male and
those from PDFF2 cells were female. The
efficiency of nuclear transfer, expressed as
the number of liveborn lambs obtained per
100 reconstructed embryos, varied from
0.89% for PDFF2-13 to 2.25% for PDFF2-
12. This efficiency is similar to the value
(1.35%) that we obtained previously for
nonmanipulated fetal fibroblasts from an¬
other breed of sheep (BLWF1) (13).
Pregnancies resulting from embryo trans-
Table 2. Characteristics of nuclear transfer-derived lambs. Outcomes of 11 153 of gestation; when required, cesarean section (CS) was performed 24 to
pregnancies resulting from nuclear transfer of PDFF donor cells. When 52 hours later. The average duration of gestation for the Poll Dorset flock at











neo FIX Sex Comments
1 PDFF5 7LL5 147 3.8 M Unassisted birth








Stillbirth, one fetus dead for <1 week
3 PDFF2 pool <80 Regressed
4 PDFF2 pool 7LL8 155 7.6 (+) (-) F Assisted birth because of position of
lamb
5 PDFF2 pool 7LL9* 161 6.3 (+) (-) F Induced, CS 52 hours later, died 90 min
postpartum, meconium in lung
6 PDFF2 pool 7LL12 155 8.7 (+) (-) F Induced, CS 52 hours later
7 PDFF2-12 7LL3* 130 F Spontaneous abortion
8 (twins) PDFF2-12 7LL10* 132 3.6 (+) (+) F Loss of fetal heartbeat, induced, CS,
7LL11* 132 4.5 (+) (+) F stillbirth, one fetus abnormal
9 PDFF2-12 7LL14* 148 3.6 (+) (+) F Induced, CS 24 hours later, heartbeat,
no breathing
10 (twins) PDFF2-12 7LL15 155 4.6 (+) (+) F Induced, unassisted birth, 7LL16
7LL16* 155 3.0 (+) (+) r euthanized at 14 days, heart defect
11 PDFF2-13 7LL13 155 5.5 (+) (+) F Induced, unassisted birth
*Lamb died or was euthanized for animal welfare reasons.
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fer were determined by ultrasound scan at
about 60 days after estrus, and development
was subsequently monitored at regular inter¬
vals. Of the original 14 fetuses, 7 were live-
born, as defined by heartbeat and unassisted
breathing (Table 2). Postmortem examina¬
tion of aborted fetuses and dead lambs did
not reveal any common factor as a cause of
death.
All animals derived from PDFF cells ex¬
hibited a prolonged gestation, and, with the
exception of animals 7LL5 to 7LL8, labor
was induced artificially. Delayed delivery
was likely the cause of death of lamb 7LL9.
Subsequently, all surrogate ewes were in¬
duced at day 153, and, if necessary, cesarean
section was performed. Three of 11 preg¬
nancies were twin pregnancies. In two in¬

















Fig. 1. DNA analysis of transfected clones and
transgenic sheep. Genomic DNA was isolated
from the blood of live animals or tongue samples
from dead animals, digested with Bam HI and Eco
Rl, and subjected to Southern hybridization with
either a 1,8-kb fragment of the BLG promoter or
the neo gene. (A) Southern analysis of the un-
cloned pool of cells (PDFF2 pool), and two lambs
(7LL8 and 7LL9) derived from them, for the pres¬
ence of pMIX1 and PGKneo. (B) Assay for the
presence of the pMIX1 transgene in lambs derived
from the PDFF2 pool (7LL8 and 7LL12) and from
the transfected clones PDFF2-12 (7LL10, 7LL14
to 7LL16) and PDFF2-13 (7LL13). PDFF5 cells
were not transfected. The positions and sizes of
fragments corresponding to the transgenes and
the endogenous BLG gene are indicated. The lane
marked X is a 1 -kb ladder of phage X fragments
from 3 to 12 kb.
7LL11), the death of one fetus in late preg¬
nancy probably resulted in the death of the
sibling.
The birth weight of nuclear transfer-
derived lambs whose gestation exceeded
145 days ranged from 3.0 to 8.7 kg, with a
mean of 3.7 kg for twins and 5.9 kg for
single pregnancies. Poll Dorset lambs in the
PPL Therapeutics New Zealand-derived
flock have mean weights of 3.75 kg for
twins and 5.1 kg for single pregnancies.
Flowever, comparison is complicated by the
fact that nuclear transfer-derived lambs
were gestated in Scottish Blackface surro¬
gate mothers. All animals from PDFF2 cells
had an undershot lower jaw that did not
interfere with their well-being. This char¬
acteristic is a genetic trait that occurs spo¬
radically in the Poll Dorset breed and is
considered to be unrelated to nuclear trans¬
fer. The PDFF5 lambs did not show this
feature.
DNA from nuclear transfer-derived
lambs was analyzed for the presence of
pMIXl and PGKneo transgenes (Fig. 1).
All fetuses and animals derived from the
transfected PDFF2 cells were transgenic.
The three animals derived from the PDFF2
pool (7LL8, -9, -12) contained the select¬
able marker gene but lacked the FIX trans-
gene (Fig. 1, A and B). Fetuses and lambs
derived from the cell clones PDFF2-12
(7LL10, -14, -15, -16) and PDFF2-13
(7LL13) contained both the FIX transgene
(Fig. IB) and PGKneo.
Our approach has shown that cell-me¬
diated transgenesis is possible in a mam¬
mal other than the mouse. The technique
is still in the early stages of development
and problems remain to be addressed—in
particular, the lack of spontaneous partu¬
rition and the incidence of perinatal mor¬
tality. However, the mortality rate we ob¬
served (46%) was exacerbated by two twin
pregnancies in which the death of one
lamb in late gestation may have resulted in
the loss of the other. The mortality rate for
nontwin pregnancies was 28.6%, higher
than that occurring after normal breeding
(—8%) but similar to that observed after
nuclear transfer with embryonic blastomeres
(5 to 40%) (26). Our data therefore do not
suggest any correlation between lamb mor¬
tality and extended culture or genetic ma¬
nipulation of the donor cell. Many types of
manipulation of preimplantation embryos—
for example, in vitro oocyte maturation and
fertilization, in vitro culture, asynchronous
embryo transfer, and progesterone treatment
of the mother—have been shown to in¬
crease fetal morbidity and mortality (26, 27).
An increased understanding of the interac¬
tion between the transplanted nucleus and
the host cytoplasm and the relation between
the early embryo and the maternal environ¬
ment, together with improved culture sys¬
tems, should increase the success of embryo
production and manipulation in vitro.
The use of somatic cell donors for nucle¬
ar transfer in livestock offers many advan¬
tages over pronuclear microinjection. Since
1989, PPL Therapeutics has generated a
substantial number of transgenic sheep by
pronuclear microinjection. A total of 51.4
animals are required to produce one trans¬
genic lamb by pronuclear microinjection,
compared with 20.8 animals in the present
study by nuclear transfer, values that differ
by a factor of ~2.5 (Table 3). The most
important difference is that no recipients
are wasted gestating nontransgenic lambs in
the nuclear transfer technique.
Gestation of large numbers of nontrans¬
genic embryos represents a major source of
inefficiency (28). Several schemes have
been devised to identify transgenic embryos
before embryo transfer, either by detection
of the transgene in embryo biopsies by PCR
(29) or by co-expression of a marker gene
(30, 31). However, these methods, with the
possible exception of that of Takada et al.
(30), are restricted by the persistence of
Table 3. Comparison of the production of transgenic sheep by nuclear transfer or pronuclear micro¬
injection.
Pronuclear Nuclear transfer
Parameter microinjection of PDFF2
(1989-1996) transfectants
Oocyte donors 982 68
Intermediate recipients* Not 14
applicable
Final recipients 1895 22
Total number of sheep used 2877 104
Established pregnancies (% of final recipients) 912 (48%) 9 (41 %)
Lambs born 1286 6
Viable transgenic lambs bornt 56 5
Percentage of offspring transgenic 4.35% 100%
Sheep required for production of one transgenic lamb 51.4 20.8
"After nuclear transfer, intermediate recipients are used to allow development of reconstructed embryos to blastocyst
stage. tDefined as those alive at 1 week of age.
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unintegrated DNA during the short time
that embryos can be cultured before embryo
transfer. In contrast, cells transfected in
vitro can be analyzed extensively before
effort is devoted to large animals. This ad¬
vantage will be particularly important in
instances in which microinjection is ineffi¬
cient; for example, with large constructs
such as yeast artificial chromosomes.
Delayed integration of microinjected
DNA into the embryo genome often results
in mosaic founder animals. The reduced
rate of transgene transmission resulting
from germline mosaicism can hinder or pre¬
vent the establishment of transgenic lines
from potentially valuable founder animals.
In contrast, animals produced by nuclear
transfer are entirely transgenic.
Nuclear transfer allows the sex of trans¬
genic animals to be predetermined and thus
offers a further twofold increase in efficiency
relative to pronuclear microinjection when
the sex of the transgenic founder animal is
critical. If, for example, the primary interest
is the expression of human proteins in milk,
the founder generation can be all females.
Sheep with different random integrations of
the transgene can be produced by nuclear
transfer from independent cell clones and
the milk analyzed. After a suitable clone has
been identified, the corresponding stock of
cells can be used to generate an "instant
flock" by further nuclear transfer. Such a
flock could be superior to those produced by
conventional breeding as a source of proteins
for human therapy because genetic identity
would contribute to the consistency of the
medicinal product.
The procedures of transfection, drug se¬
lection, and growth from single-cell clones
described here are essentially the same as
those required for gene targeting. The real¬
istic prospect of targeted genetic manipula¬
tion in a livestock species should open a
vast range of new applications and research
possibilities.
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The Lamb That Roared
A lamb cloned from a single cell of an adult sheep demonstrated the power of cloning technology,
surprising both researchers and the public, and igniting a fierce debate about ethics
A year ago, few researchers would have
guessed that science's most stunning achieve¬
ment in 1997 would come from a barn. But in
late February, a bleating, white-nosed lamb
swept into the public eye: 7-month-old Dolly,
the first animal cloned from an adult cell. She
electrified both the research community and
the general public, for although animals had
been cloned before, creating a sheep from a
single cell of a 6-year-old ewe was a
stunning technological feat that
many had thought impossible.
Cloning is of practical import, as
it can be used to quickly create herds
of identical animals that churn out
medically useful proteins; the first
such animals—a handful of trans¬
genic sheep clones—are described
on page 2130 of this issue. But the
implications of cloning technology
go much further, opening up new
avenues of research in cancer, de¬
velopment, and even aging. In¬
deed, Dolly forces a reexamination
of what it means to grow old, for
although she is now 18 months old,
her DNA, taken from the donor cell, may be
almost 8 years old.
According to conventional wisdom, adult
cells cannot give rise to new, mature organ¬
isms. So after Dolly's debut, researchers
scrambled to understand how she was created.
Scientific societies convened their own im¬
promptu meetings to discuss both the scien¬
tific and ethical implications of the work, and
companies specializing in transgenic animals
saw their stock value jump overnight.
But despite Dolly's soft brown eyes, some
feared that she was a wolf in sheep's clothing,
come to steal humankind's individuality and
autonomy. She sparked calls for a ban on hu¬
man cloning in theUnited States, Switzerland,
China, and other nations, and to some, she
raised the sci-fi specter of cookie-cutter clones
grown for spare parts. But whetherwelcomed or
feared, cloning in 1997 forced scientists and the
public alike to rethink their basic ideas about
life, and to confront the implications of our
growing ability to manipulate life's blueprint.
As is true formany breakthroughs, cloning
represents the convergence of advances in
several disciplines over several decades. Pains¬
taking progress in sheep reproductive biology,
genetic manipulation, and cell culture all
paved the way for Dolly. But the critical tech¬
nique is nuclear transfer, in which the intact
nucleus of one cell is absorbed into an egg
whose own nucleus has been removed.
Researchers seeking to unlock the secrets of
embryonic development had been working to
perfect this technique for 40 years, startingwith
experiments in frogs in 1952. They transferred
the nuclei of embryonic or tadpole cells into
frog eggs and succeeded in raising cloned tad¬
poles and even adult frogs. But the older the
frog cell donating the DNA, the less likely was
the resulting clone to develop normally. When
donor cells from an adult were used, no frog
clone ever developed beyond the tadpole stage.
And in mice, the typical mammalian model
organism, results were even more discouraging.
At the time, researchers couldn't get viable
young from anything but nuclei taken from
very early embryos—the two- to four-cell stage.
So most biologists came to accept that mature
cells could not give rise to entire organisms,
especially in mice. Only an egg cell possessed
that mysterious power, called totipotency.
But those working with cows and sheep
were not quite persuaded. A team of re¬
searchers at the Roslin Institute outside
Edinburgh, Scotland, for example, suspected
that previous failures were caused by donor
DNA that was in a different stage of the cell
cycle than the recipient egg cell. They used
nuclear transfer to clone sheep from embry¬
onic cells, and in 1996 announced the birth
of two cloned lambs. Next, they cloned
sheep from fetal fibroblast cells. And in part¬
nership with a local biotechnology company,
they attempted what everyone had said was
impossible: to clone a sheep from adult cells.
To do this, the team used cultured udder
cells, taken from a 6-year-old ewe, and then
starved them, forcing most of their genes to
enter an inactive phase that the researchers
hoped would match the cell-cycle stage of the
recipient eggs. Once the udder-cell nuclei
were transferred into the eggs, still-unknown
factors coaxed that "inactivated" 6-year-old
DNA to go back in time, so to speak, and
apparently become totipotent once more, di¬
recting the eggs to develop into lambs. Out of
277 such eggs, only one produced a healthy
living animal: Dolly.
To a startled public, Dolly made the hor¬
rors of science fiction clones seem all too
possible. If she could be cloned from an udder
cell, people wondered, then why not a dicta¬
tor from his nose, as was attempted in the
movie Sleeper, or a spare self as a reservoir of
replacement body parts? Such things are
safely in the realm of fiction, of course, but
many people, scientists included, became
concerned that cloning people would dehu¬
manize our species and spoke out against it.
Yet upon reflection it's clear that just as
identical twins grow up to be individuals,
clones would never be truly identical. Even
Dolly is not an exact replica of the ewe used
to clone her, because she did not develop in
that ewe's uterus nor receive its genes in the
cellular organelles called mitochondria.
For now, Dolly stands alone. No one, not
even the Roslin team, has made a second ani¬
mal from an adult cell. Of course, most bio¬
medical researchers work with mice—and
mouse nuclear transfer results are still dismal.
So attention is focused on the handful of labs
worldwide working on cloning in livestock.
Most are starting with fetal cells, whose DNA
can more easily be made totipotent. So far,
several firms say they too have cloned either
sheep or cows from fetal cells, and one group
has cloned monkeys from embryonic cells.
Nuclear transfer experiments are under
way in other species too, ranging from zebra-
fish to rabbits. Among basic researchers, the
Scottish group's success has inspired new ex¬
periments looking at how DNA changes as
a cell matures. Clarifying the nature of totipo¬
tency may spark insight into what makes cells
and organisms age, and how cell growth can
go awry, as in cancer. Researchers are watch¬
ing Dolly closely, for although so far she seems
the 18-month-old she's supposed to be, her
DNA may make her age prematurely.
Cloning experts point out that the true
identity of Dolly's progenitor cell is not
known for sure—it's possible that it was a stem
cell, known to be able to develop into several
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kinds of tissues. Even if that's true, the ability
to restore totipotency to easily harvested adult
cells would offer a potentially simple method
to replace lost or damaged cells.
Meanwhile, the Roslin team has taken the
next step toward making cloning economi¬
cally useful by cloning sheep carrying foreign
genes. Three sheep carry a marker gene, and
two have both the marker gene and the gene
for the human factor IX protein, which some
hemophiliacs take to aid blood clotting. These
sheep were cloned from transgenic fetal fibro¬
blast cells, not adult cells, so they are most
remarkable not as clones, but because they
developed successfully despite having under¬
gone genetic manipulation.
On the drawing board are flocks of sheep
that make factor IX and other useful proteins
in their milk. Other scientists are developing
nuclear transfer techniques to create other
types of genetically tailored livestock, open¬
ing the door to better animal models of ge¬
netic diseases, animals as organ donors, and
possibly leaner, faster growing livestock.
Indeed, as with all breakthroughs, it's not
possible yet to foretell exactly where cloning
will lead. Although initial reactions were
universally against all human cloning, there
have been whispers that such cloning may
one day have a place in giving infertile couples
genetic offspring. Whatever direction the re¬
search takes, however, the public is likely to
demand a say in how cloning is applied. Bi¬
ologists, ethicists, and others will be wres¬
tling with the implications of this birth in a
barn for years to come.
-Elizabeth Pennisi
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